JP2003517310A - Induction of a cellular immune response against MAGE2 / 3 using peptide and nucleic acid compositions - Google Patents

Abstract

  (57) [Summary] The present invention uses our knowledge of the mechanism by which antigens are recognized by T cells to identify MAGE2 / 3 (melanoma antigen gene) epitopes and to identify MAGE2 / 3 (melanoma antigen gene) epitopes. And develop an epitope-based vaccine directed against tumors carrying MAGE2 / 3 (melanoma antigen gene). More particularly, the present application conveys our findings on pharmaceutical compositions and our use in methods of preventing and treating cancer.

Description

Detailed Description of the Invention

I. Background of the Invention An increasing body of evidence suggests that cytotoxic T lymphocytes (CTLs) are important in the immune response to tumor cells. CTLs recognize peptide epitopes in the context of HLA class I molecules expressed on the surface of almost all nucleated cells. After intracellular processing of endogenously synthesized tumor antigens, antigen-derived peptide epitopes bind to class I HLA molecules in the endoplasmic reticulum and the resulting complex is then transported to the cell surface. CTLs recognize the peptide-HLA class I complex, which in turn destroys cells harboring the HLA-peptide complex directly by the CTL and / or activation of non-destructive mechanisms (eg, ,
It results in destruction via lymphokines that enhance the immune response and promote destruction of tumor cells, such as activation of tumor necrosis factor alpha (TNF-alpha) or interferon gamma (IFNγ).

Tumor-specific helper T lymphocytes HTL are also known to be important for maintaining effective anti-tumor immunity. Its role in anti-tumor immunity has been shown in animal models where these cells act not only to help induce CTLs and antibody responses, but also to provide effector functions, which are direct cell Contact mediated and lymphokines (eg, IFNγ and TNF
It is also mediated by the choice of -α).

A fundamental challenge in the development of effective tumor vaccines is the possible immunosuppression or tolerance. Therefore, there is a need to establish vaccine embodiments that elicit an immune response of sufficient extent and strength to prevent progression and / or eliminate tumors.

The epitope approach used in the present invention is that various antibodies from distinct regions of the target tumor associated antigen (TAA) and / or other regions of TAA,
A solution to this challenge is presented in that it allows the CTL and HTL epitopes to be incorporated into a single vaccine composition. Such compositions can simultaneously target multiple dominant and subdominant epitopes and can be used to achieve effective immunity in different populations.

MAGE (melanoma antigen gene) is a family of related proteins. This protein was first described in 1991. Van der Brugge
n and co-workers, after isolation of CTL from patients with sudden tumor regression, MA
The GE gene was identified. These CTLs recognized all melanoma cell lines expressing the same HLA-A1 restriction gene and tumor lines from other patients (van de
r Bruggen et al., Science 254: 1643-1647, 199.
1; Deplaen et al., Immunogenetics 40: 360-369.
, 1994). The MAGE gene is a metastatic melanoma (see, eg, Brasseur et al., Int. J. Cancer 63: 375-380, 1995), non-small lung (Weynants et al., Int. J Cancer 56.
: 826-829, 1994), stomach (Inoue et al., Gastroente.
logology 109: 1522-1525, 1995), hepatocytes (Chen)
Et al., Liver 19: 110-114, 1999), Kidney (Yamanaka).
Et al., Human Pathol. 24.1127-1134, 1998), colorectal (Mori et al., Ann. Surg. 224: 183-188, 19).
96), and the esophagus (Quillien et al., Anticancer Res.
17: 387-391, 1997) Cancer and tumors of head and neck (Lett et al., Acta Otolaryngol. 116: 633-6.
39, 1996), ovary (Gillespie et al., Br J. Cancer.
78: 816-821, 1998; Yamada et al., Int. J. Can
cer 64: 388-393, 1995), bladder, and osteosarcoma (Sudo).
Et al., J. Orthop. Res. 15: 128-132, 1997). Therefore, MAGE2 / 3 is an important target for cancer immunotherapy.

The information provided in this section is intended to disclose the state of the art currently understood as of the filing date of this application. Information obtained after the priority date of this application is included in this section. Therefore, the information in this section is not intended to be delineated by the priority date of the present invention in any way.

II. SUMMARY OF THE INVENTION The present invention applies our knowledge of the mechanism by which antigens are recognized by T cells, for example to develop epitope-based vaccines against TAA. More specifically, the present application conveys our findings on pharmaceutical compositions of specific epitopes and methods of use in the prevention and treatment of cancer.

With the development of suitable technology, the use of this epitope-based vaccine has several advantages over current vaccines, especially when compared to the use of whole antigens in vaccine compositions. For example, immunosuppressive epitopes that may be present throughout the antigen may be evaded by the use of epitope-based vaccines. Such immunosuppressive epitopes may, for example, correspond to immunodominant epitopes in the whole antigen, which can be avoided by selecting peptide epitopes from non-dominant regions (eg Disis et al., J. Immunol. 156: 315
1-3158, 1996).

A further advantage of the epitope-based vaccine approach is the ability to combine selected epitopes (CTL and HTL) and further modify the composition of these epitopes (eg to achieve enhanced immunogenicity). Ability.
Thus, the immune response can be modulated as appropriate for the target disease. Similar manipulations of this response are not possible with conventional approaches.

Another major advantage of epitope-based immunostimulatory vaccines is their safety. Infectious age that may have its own biological activity
potential pathological side effects caused by nt) or whole protein antigens are eliminated.

Epitope-based vaccines also provide the ability to direct and focus an immune response against multiple selected antigens from the same pathogen (the “pathogen” can be a pathogen or a tumor-associated molecule). . Thus, patient-to-patient variability in the immune response to a particular pathogen can be mitigated by including epitopes from multiple antigens from this pathogen in the vaccine composition.

Furthermore, epitope-based anti-tumor vaccines also offer the opportunity to combine epitopes from multiple tumor-associated molecules. Thus, this ability could address the problem of tumor-to-tumor variability that arises when developing broadly targeted anti-tumor vaccines for a given tumor type, and also the potential for tumor escape due to antigen loss. Can decrease. For example, melanoma in one patient may express a different target TAA than melanoma in another patient. Epitopes from multiple TAAs can be included in a polyepitope vaccine targeting both melanomas.

However, one of the most difficult barriers to the development of broadly effective epitope-based immunotherapeutics was the extreme polymorphism of the HLA molecule. To date, effective population coverage without non-genetic bias is a rather complex task; such coverage uses epitopes specific to HLA molecules corresponding to each individual HLA allele. Needed that. Therefore, to cover ethnically diverse groups,
It was impractical to use a large number of epitopes. Therefore, there was a need for peptide epitopes bound by multiple HLA antigen molecules for use in epitope-based vaccines. The greater the number of HLA antigen molecules bound, the greater the vaccine coverage of the population.

Furthermore, as described in more detail herein, a peptide binding property (eg, a peptide capable of binding multiple HLA antigens to multiple HLA antigens with an affinity that stimulates an immune response) is used. There was a need to regulate (to bind). Identification of epitopes that are bound by more than one HLA allele with an affinity that correlates with immunogenicity provides sufficient population coverage and in order to prevent or eliminate infection in various parts of the population. It is important in order to be able to elicit a sufficiently strong response. Such a response may also target a wide variety of epitopes. The technology disclosed herein provides such a favorable immune response.

In a preferred embodiment, epitopes for inclusion in a vaccine composition of the invention are selected by a process that evaluates the protein sequences of known antigens for the presence of motif-bearing or supermotif-bearing epitopes.
Peptides corresponding to the motif-bearing or supermotif-bearing epitopes are then synthesized and the peptides are tested for their ability to bind to HLA molecules that recognize the selected motif. Moderate or high affinity (ie, IC ₅₀ (or K _D value) for HLA class I molecules)
500nM or less, or for HLA class II _molecules, IC 50 1000n
These peptides that bind below M are further evaluated for their ability to induce a CTL or HTL response. Immunogenic peptide epitopes are selected for inclusion in the vaccine composition.

Supermotif-bearing peptides can be further tested for the ability to bind multiple alleles within the HLA supertype family. Furthermore, peptide epitopes can be analogized to modify binding affinity for multiple alleles within the HLA supertype and / or ability to bind to these multiple alleles.

The invention also encompasses embodiments that include methods for monitoring or assessing an immune response to TAA in a patient with a known HLA type. Such a method comprises the steps of incubating a sample of T lymphocytes from a patient with a peptide composition comprising a TAA epitope, and detecting for the presence of T lymphocytes that bind the peptide. Binds the product of at least one HLA allele present in that patient, Table XXIII
, XXIV, XXV, XXVI, XXVII, and having the amino acid sequences set forth in Table XXXI. CTL peptide epitopes can be used, for example, as a component of the tetramer complex for this type of analysis.

Alternative modes for defining peptide epitopes according to the present invention include physical properties (eg, long lengths) that are correlated with binding to a particular allele-specific HLA molecule or group of allele-specific HLA molecules. Primary structure; or charge). Additional modes for defining peptide epitopes describe physical properties of the HLA binding pocket or properties shared by several allele-specific HLA binding pockets (eg, pocket shape and charge distribution), and To describe that this peptide epitope fits and binds in the pocket (s).

Other methods and embodiments are also contemplated, as will be apparent from the discussion below.
Moreover, novel synthetic peptides produced by any of the methods herein are also part of this invention.

[0020]   (III. Brief Description of Drawings)   Not applicable.

IV. Detailed Description of the Invention The peptide epitopes and corresponding nucleic acid compositions of the invention are useful for stimulating an immune response against TAA by stimulating the production of a CTL or HTL response. . These peptide epitopes may be derived directly or indirectly from the native TAA protein amino acid sequence, bind HLA molecules and
It can stimulate an immune response to AA. The complete sequence of the TAA protein analyzed can be obtained from Genbank. As is apparent from the disclosure provided below,
Peptide epitopes and analogs thereof can also be readily determined from sequence information, which may be discovered in the future for previously unknown variants of specific TAAs.

A list of target TAAs includes, but is not limited to, the following antigens: MAGE1, MAGE2, MAGE3, MAGE-11, MAGE-A10.
, BAGE, GAGE, RAGE, MAGE-C1, LAGE-1, CAG-3
, DAM, MUC1, MUC2, MUC18, NY-ESO-1, MUM-1,
CDK4, BRCA1, NY-LU-1, NY-LU-7, NY-LU-12,
CASP8, RAS, KIAA-2-5, SCC, p53, p73, CEA, H
er2 / neu, Melan-A, gp100, tyrosinase, TRP2, gp
75 / TRP1, kallikrein, PSM, PAP, PSA, PT1-1, B-catenin, PRAME, telomerase, FAK, cyclin D1 protein, NO
EY2, EGF-R, SART-1, CAPB, HPVE7, p15, folate receptor CDC27, PAGE-1 and PAGE-4. The peptide epitopes of the present invention have been identified in a number of ways, as discussed below. It is also discussed in more detail that by modifying specific amino acid residues to create peptide analogs that exhibit altered immunogenicity, analog peptides are induced and the binding activity of HLA molecules is modulated. . Furthermore, the present invention may allow epitope-based vaccines capable of interacting with HLA molecules encoded by various alleles to provide broader population coverage than prior art vaccines,
Compositions and combinations of compositions are provided.

IV.A. Definitions The present invention may be better understood with reference to the following definitions, listed in alphabetical order.

A “computer” or “computer system” generally comprises: a processor; at least one information storage / retrieval device (eg, hard drive, disk drive or tape drive, etc.); at least one input device (eg, , Keyboard, mouse, touch screen, or microphone); and display structure. In addition, the computer may include a communication channel that communicates with the network. Such a computer may be more or less equipped with those listed above.

As used herein, “construct” generally refers to non-naturally occurring compositions. The constructs may be produced by synthetic techniques for nucleic acids or amino acids, such as recombinant DNA preparation and expression or chemical synthesis techniques. Constructs can also be produced by the addition or affiliation of one material to another such that its form is not found in nature.

“Cross-reactive bond” refers to the binding of more than one HLA molecule to a peptide; a synonym is a degenerate bond.

A “cryptic epitope” induces a response by immunization with an isolated peptide, but when the whole intact protein containing the epitope is used as an antigen, the response is in vitro. Not cross-reactive.

A “dominant epitope” is an epitope that induces an immune response upon immunization with whole native antigen (see, eg, Sercarz et al., Annu. Rev. Immunol. 11: 729-766, 1993). ). Such a response is cross-reactive with the isolated peptide epitope in vitro.

For a particular amino acid sequence, an “epitope” is the set of amino acid residues involved in recognition by a particular immunoglobulin, or, in the context of T cells,
T cell receptor protein and / or major histocompatibility complex (MHC
) Residues required for recognition by receptors. In the setting of the immune system in vivo or in vitro, the epitopes together form the collective features of the molecule (eg, primary peptide structure, secondary peptide structure and Tertiary peptide structure and charge). Throughout this disclosure, epitopes and peptides are often referred to as
Used interchangeably. However, it is clear that isolated or purified proteins or peptide molecules containing longer and epitopes of the invention are still within the scope of the invention.

It is to be understood that protein or peptide molecules comprising the epitope of the invention and additional amino acids are within the scope of the invention. In certain embodiments, there are restrictions on the length of the peptides of the invention, which are otherwise not constructs as defined herein. A length-limited embodiment occurs when the epitope-containing protein / peptide of the invention comprises a region (ie, a series of contiguous amino acids) with 100% identity to the native sequence.
For example, the length of any region with 100% identity to the native peptide sequence is limited in order to avoid defining open reading frame derived epitopes for the entire native molecule. Thus, for peptides containing (and otherwise not a construct) a region having 100% identity to the epitope and native peptide sequences of the invention, that region having 100% identity to the native sequence is generally 600 Amino acids or less, often 500 amino acids or less, often 400 amino acids or less, often 250 amino acids or less, often 100 amino acids or less, often 85 amino acids or less, often 75 amino acids or less, often 65 amino acids or less, and often 50 amino acids It has the following lengths: In certain embodiments, an “epitope” of the invention that is not a construct is less than 51 amino acids (any variation (50, 49, 48, 47, 46, 45, having 45% identity to the native peptide sequence. 44, 43, 42, 41, 40, 39
, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27
, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15
, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5) to 5 amino acids).

Specific peptide or protein sequences longer than 600 amino acids are within the scope of the invention. Such long sequences have the same sequence as the native peptide sequence.
It is within the scope of the invention as long as it does not include any contiguous sequence greater than 600 amino acids with 00% identity, or if longer than 600 amino acids, as long as they are constructs. For any peptide having 5 or fewer consecutive residues corresponding to the native sequence, there is no limitation on the maximum length of the peptide to be within the scope of the invention. It is presently preferred that the CTL epitopes of the present invention be 8 amino acid residues in length from any variation of less than 600 residues.

“Human lymphocyte antigen” or “HLA” is a human class I or class II major histocompatibility complex (MHC) protein (eg, Statuses et al., I.
mmunology, 8th edition, Lang Publishing, Los A
ltos, CA (1994)).

As used herein, “HLA supertype or family” describes a set of HLA molecules grouped based on shared peptide binding specificity. HLA class I molecules that share somewhat similar binding affinities for peptides bearing particular amino acid motifs are grouped into HLA supertypes. The terms HLA superfamily, HLA supertype family,
The HLA family and HLA xx-like molecules, where xx represents a particular HLA type, are synonymous.

Throughout this disclosure, results are referred to by the term “IC ₅₀ ”. The IC _50, 50% inhibition of binding of a reference peptide is observed, the concentration of the peptide in the binding assay. Considering the conditions under which the assay is performed (ie, rate-limiting HLA protein concentration and labeled peptide concentration), these values are close to the K _D values. Assays for measuring binding are described, for example, in PCT Publications WO94 / 20127 and WO9.
4/03205, described in detail. IC ₅₀ values are dependent on the assay conditions being changed, and depending on the particular reagents used (eg, HLA preparations, etc.)
It should be noted that (often dramatically) it can change. For example, an excess concentration of HLA molecules increases the apparent measured IC ₅₀ of a given ligand.

Alternatively, the binding is expressed in relation to the reference peptide. As a particular assay becomes more or less sensitive, the IC ₅₀ of the peptide tested may change somewhat, but the binding to the reference peptide does not change significantly. For example,
In an _{assay IC 50} of the reference peptide carries under conditions such that 10-fold increase, also to about 10 fold shift _{an IC 50} value of the test peptides. Therefore, in order to avoid ambiguity, an assessment of whether a peptide is a good, moderate, weak, or negative binding agent is generally standard. Based on the IC _{50 of the} peptide, relative to its IC ₅₀ .

Binding can also be measured using other assay systems, including assay systems using the following: living cells (eg Ceppelini et al., Nature 339).
: 392, 1989; Christnick et al., Nature 352: 67,
1991; Busch et al., Int. Immunol. 2: 443, 19990;
Hill et al. Immunol. 147: 189, 1991; del Gue.
rcio et al. Immunol. 154: 685, 1995), cell-free systems using detergent lysates (eg Cerundol et al., J. Immunol.
． 21: 2069, 1991), immobilized purified MHC (eg, Hill et al., J.
． Immunol. 152, 2890, 1994; Marshall et al. I
mmunol. 152: 4946, 1994), ELISA system (for example, Rea
y et al., EMBO J .; 11: 2829, 1992), surface plasmon resonance (eg, Khilko et al., J. Biol. Chem. 268: 15425, 1993).
); High flux soluble phase assay
se assay) (Hammer et al., J. Exp. Med. 180: 2353).
, 1994), and measurement of stabilization or assembly of class I MHC (eg, Ljunggren et al., Nature 346: 476, 1990; Sch.
umacher et al., Cell 62: 563, 1990; Townsend et al.
Cell 62: 285, 1990; Parker et al. Immunol. 1
49; 1896, 1992).

As used herein, “high affinity” for an HLA class I molecule is defined as binding with an IC ₅₀ or K _D value of ₅₀ nM or less; “moderate affinity”. Is the binding with an IC ₅₀ or K _D value of between about 50 nM and about 500 nM. "High affinity" for binding to HLA class II molecules means 100 nM
Defined below as binding at IC ₅₀ or K _D values; “moderate affinity” is binding at IC ₅₀ or K _D values of between about 100 nM and about 1000 nM.

The term “identical” or percent “identity” in the context of more than one peptide sequence.
Is the same or a certain percentage of identity when compared and aligned for maximum match over the comparison window, as measured using a sequence comparison algorithm or by manual alignment and visual inspection. Two or more sequences or partial sequences having amino acid residues.

“Immunogenic peptide” or “peptide epitope” means that the peptide is H
Peptides containing allele-specific motifs or supermotifs that bind LA molecules and induce CTL and / or HTL responses. Thus, the immunogenic peptides of the invention can bind to the appropriate HLA molecule and then induce a cytotoxic or helper T cell response to the antigen from which the immunogenic peptide is derived.

The phrases “isolated” or “biologically pure” refer to a material that is substantially or essentially free of the components normally associated with that material when found in its native state. Therefore, the isolated peptide according to the invention is preferably
It does not include substances that normally associate with the peptide under its in situ environment.

“Ligation” or “bond” refers to any method known in the art for functionally connecting peptides, including recombinant fusion, covalent bonds, disulfide bonds, ionic bonds, Examples include, but are not limited to, hydrogen bonds, and electrostatic bonds.

The “major histocompatibility gene complex” or “MHC” is a cluster of genes that play a role in the regulation of cellular interactions responsible for the physiological immune response. In humans, the MHC complex is also known as the HLA complex. For a detailed description of MHC and HLA complexes, see Paul, FUNDAMENTAL I.
MMUNOLOGY, 3rd Edition, Raven Press, New York, 1
See 993.

The term “motif” refers to a pattern of residues in a peptide of defined length. In general, peptides of about 8 to about 13 amino acids for class I HLA motifs and about 6 to about 25 amino acids for class II HLA motifs, which are recognized by specific HLA molecules. Peptide motifs typically differ for each protein encoded by each human HLA allele and differ in the pattern of primary and secondary anchor residues.

“Non-native” sequences or “non-native” “constructs” refer to sequences that are not found in nature (ie, “non-naturally occurring”). Such sequences include, for example, lipidated or otherwise modified peptides, and polyepitopic compositions containing epitopes that are not contiguous in the native protein sequence.

“Negative binding residue” or “deteriou
An "s) residue" is an amino acid that, when present at a particular position in a peptide epitope (typically not the primary anchor position), causes a reduction in the binding affinity of the peptide for the corresponding HLA molecule.

The term “peptide” is used herein interchangeably with “oligopeptide” (typically due to the peptide bond between the α-amino group and the carboxyl group of adjacent amino acids. ) A series of residues linked to each other (typically L-
Amino acid). Preferred CTL-derivatizing peptides of the invention are 13 or less residues in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues. Preferred HTL-derived oligopeptides are less than about 50 residues long and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25 residues. , And often between about 15 and 20 residues.

“Pharmaceutically acceptable” generally refers to non-toxic, inert, and / or pharmacologically compatible compositions.

“Pharmaceutical excipients” include substances such as adjuvants, carriers, pH adjusting agents and buffers, tonicity adjusting agents, wetting agents, preservatives and the like.

A “primary anchor residue” is an amino acid at a specific position along a peptide sequence that is understood to provide a point of contact between the immunogenic peptide and the HLA molecule. One to three (usually two) primary anchor residues within a peptide of defined length generally define a "motif" for the immunogenic peptide. It is understood that these residues fit in close contact with the peptide binding groove of the HLA molecule, which has these side chains buried in specific pockets of the binding groove itself. In one embodiment, for example, primary anchor residues are located at position 2 (from the amino terminal position) and the carboxyl terminal position of a 9 residue peptide epitope according to the present invention. The primary anchor positions for each motif and supermotif are shown in Table 1. For example, analog peptides can be made by altering the presence or absence of particular residues at these primary anchor positions. Such analogs are used to regulate the binding affinity of peptides containing particular motifs or supermotifs.

“Random recognition” is that different peptides are recognized by the same T cell clone in the context of different HLA molecules. Messy recognition or binding
Synonymous with cross-reactive bond.

“Protective immune response” or “therapeutic immune response” refers to a CTL and / or HTL response to an infectious agent or an antigen derived from a tumor antigen, which prevents the symptoms or progression of the disease or At least partially suppress. The immune response may also include an antibody response promoted by stimulation of helper T cells.

The term “residue” refers to an amino acid or amino acid mimetic that is incorporated into an oligopeptide by an amide bond or an amide bond mimetic.

A “secondary anchor residue” is an amino acid that can affect peptide binding at positions other than the primary anchor position in a peptide. Secondary anchor residues occur at a significantly higher frequency than expected due to the disordered distribution of amino acids at certain positions in the bound peptides. Secondary anchor residues are said to occur at "secondary anchor positions". Secondary anchor residues are associated with residues that occur more frequently in peptides that bind with high or moderate affinity, or that otherwise have high or moderate affinity binding. Can be identified as a residue. For example, analog peptides can be made by altering the presence or absence of particular residues at these secondary anchor positions. Such analogs are used to better regulate the binding affinity of peptides containing particular motifs or supermotifs.

A “subdominant epitope” is an epitope that causes little or no response upon immunization with the entire antigen containing the epitope, but which can be elicited by immunization with the isolated peptide. And (unlike the case of cryptic epitopes) this response uses the whole protein to recall the response in vitro or in vivo.
If it does, it will be detected.

A “supermotif” is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles. Preferably, the supermotif-bearing peptide is recognized by two or more HLA antigens with high or moderate affinity (as defined herein).

“Synthetic peptide” refers to a peptide made by a human using methods such as chemical synthesis or recombinant DNA technology.

As used herein, a “vaccine” is a composition that comprises one or more peptides of the invention. An embodiment of a vaccine according to the invention (eg by a cocktail of one or more peptides; one or more epitopes of the invention comprised by a polyepitopic peptide; or a nucleic acid encoding such a peptide or polypeptide (eg , Minigenes that encode polyepitopic peptides). "One or more peptides" means 1 to
Any of the entire 150 unit integers (eg, at least 2, 3, 4, 5, 6, 7
, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2
0, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 3,
2, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 6
0, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 1
15, 120, 125, 130, 135, 140, 145 or 150 or more) of the peptides of the invention. These peptides or polypeptides can be modified, if necessary, by, for example, lipidation, addition of targeting sequences or other sequences. The HLA class I-binding peptides of the invention can be mixed or linked with HLA class II-binding peptides to promote activation of both cytotoxic and helper T lymphocytes. The vaccine can also include antigen-presenting cells (eg, dendritic cells) pulsed with the peptide.

The nomenclature used to describe peptide compounds follows conventional practice,
Here, the amino group is shown on the left (N-terminal) and the carboxyl group on the right (C-terminal) of each amino acid residue. When amino acid residue positions are referred to in a peptide epitope, they are numbered in the amino to carboxyl direction by the position which is the position adjacent to the amino terminus of the epitope or peptide or protein which may be part. In the form showing selected specific embodiments of the invention, although not specifically shown, the amino and carboxyl end groups are the forms that would otherwise be taken at physiological pH values unless otherwise specified. In the amino acid structure format, each residue is generally indicated by the standard three-letter or one-letter code. Amino acid residues in the L-form are indicated by the uppercase one-letter or uppercase letter in the first letter of the three-letter code, and the D-form for those amino acids having the D-form is the lowercase one-letter or lowercase letters. It is indicated by a three letter symbol. Glycine has no asymmetric carbon atoms and is simply referred to as "Gly" or G. The amino acid sequences of the peptides shown herein are generally indicated using the standard one letter code (A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine. G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N
, Asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; and Y, tyrosine).
In addition to these symbols, the one-letter abbreviation “B” used herein refers to α-aminobutyric acid.

(IV.B. Stimulation of CTL and HTL Responses) The mechanism by which T cells recognize antigens has been described in the last decade. Based on our understanding of the immune system, we have developed effective peptide epitope vaccine compositions that can elicit a therapeutic or prophylactic immune response against TAA in a broad population. In order to understand the value and efficacy of the claimed composition, a brief review of immunology-related techniques is provided. This overview is
It is intended to disclose the current level of understanding in the art as of the filing date of this application. Information generated after the priority date of this application is included in this section. Therefore, the information in this section is not intended to describe a priority date for the present invention in any way.

The complex of HLA molecule and peptide antigen acts as a ligand recognized by HLA-restricted T cells (Buus, S. et al., Cell 47: 1071, 19).
86; Babbitt, B .; P. Et al., Nature 317: 359, 1985.
Townsend, A .; and Bodmer, H .; , Annu. Rev. I
mmunol. 7: 601, 1989; Germain, R .; N. , Annu.
Rev. Immunol. 11: 403, 1993). Studies of single amino acid substitution antigen analogs, as well as sequencing of endogenously linked naturally-processed peptides, identified key residues corresponding to the motif required to specifically bind to HLA antigen molecules. And described herein, Table I, Table II.
And shown in Table III (eg, Southwood et al., J. Immu).
nol. 160: 3363, 1998; Rammensee et al., Immunog.
enetics 41: 178, 1995; Rammensee et al., SYFPE.
ITHI, http://134.2.96.221/scripts. hla
server. dll / home. Access via the web at http; Set
te, A. and Sidney, J .; Curr. Opin. Immunol.
10: 478, 1998; Engelhard, V .; H. Curr. Opin
． Immunol. 6:13, 1994; Sette, A .; and Gray,
H. M. Curr. Opin. Immunol. 4:79, 1992; Sin
igaglia, F.M. and Hammer, J .; Curr. Biol. 6: 5
2, 1994; Ruppert et al., Cell 74: 929-937, 1993.
Kondo et al. Immunol. 155: 4307-4312, 1995
Sidney et al., J. Am. Immunol. 157: 3480-3490,199.
6; Sidney et al., Human Immunol. 45: 79-93, 199.
6; Sette, A .; and Sidney, J .; Immunogenetic
s 1999 Nov; 50 (3-4): 201-12, Review).

Further X-ray crystallographic analysis of the HLA-peptide complex revealed a pocket within the peptide-binding cleft of the HLA molecule that accommodates residues carried by the peptide ligand in an allele-specific manner. . These residues, in turn, determine the HLA binding capacity of the peptides in which they are present (eg Madden, DR,
Annu. Rev. Immunol. 13: 587, 1995; Smith et al.,
Immunity 4: 203, 1996; Fremont et al., Immunity.
y 8: 305, 1998; Stern et al., Structure 2: 245,
1994; Jones, E .; Y. Curr. Opin. Immunol. 9:
75, 1997; Brown, J .; H. Et al., Nature 364: 33, 19
93; Guo, H .; C. Et al., Proc. Natl. Acad. Sci. USA
90: 8053, 1993; Guo, H .; C. Et al., Nature 360: 36.
4, 1992; Silver, M .; L. Et al., Nature 360: 367, 1
992; Matsumura, M .; Et al., Science 257: 927, 19
92; Madden et al., Cell 70: 1035, 1992; Fremont.
, D. H. Et al., Science 257: 919, 1992;
A. Bjorkman, P .; J. and Wiley, D.M. C. J. Mol
． Biol. 219: 277, 1991).

Therefore, class I allele-specific HLA binding motifs and class II
Defining an allele-specific HLA binding motif, or defining a class I or class II supermotif, allows the identification of regions within a protein that have the potential to bind a particular HLA molecule.

The inventors have found that the correlation between binding affinity and immunogenicity disclosed herein is an important factor to consider when evaluating candidate peptides. Therefore, a combination of motif search and HLA-peptide binding assay identified candidates for epitope-based vaccines. After determining their binding affinities, further confirmation work can be performed to select among these vaccine candidates epitopes that have favorable characteristics with respect to population coverage, antigenicity and immunogenicity.

Various strategies can be utilized to assess immunogenicity. Examples of these are given below: 1) Evaluation of primary T cell cultures derived from normal individuals (eg Wentworth,
P. A. Et al., Mol. Immunol. 32: 603, 1995; Celis,
E. Et al., Proc. Natl. Acad. Sci. USA 91: 2105,1.
994; Tsai, V .; Et al., J. Immunol. 158: 1796, 1997
Kawashima, I .; Et al., Human Immunol. 59: 1, 19
98). These procedures involve stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells in vitro for a period of several weeks. T cells specific for this peptide are activated during this time and detected using, for example, a ⁵¹ Cr release assay encapsulating peptide-sensitized target cells.

2) Immunization of HLA transgenic mice (eg, Wentworth,
P. A. Et al., J. Immunol. 26:97, 1996; Wentworth.
, P .; A. Int. Immunol. 8: 651, 1996; Alexan.
der, J.D. Et al., J. Immunol. 159: 4753, 1997). In this method, peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. A few weeks after immunization, spleen cells are removed and cultured in vitro in the presence of test peptide for about 1 week. For example wrap and target cells expressing the peptide sensitized target cells and endogenously produced antigen, using ^{5 1 Cr} release assay, peptide-specific T cells are detected.

3) Demonstration of a recall T cell response from effectively vaccinated or tumor-bearing patients (eg Rehermann, B. et al., J.
． Exp. Med. 181: 1047, 1995; Doolan, D .; L. ,
Immunity 7:97, 1997; Bertoni, R .; Et al., J. Cli
n. Invest. 100: 503, 1997; Threlkeld, S .; C.
Et al., J. Immunol. 159: 1648, 1997; Diepolder,
H. M. Et al., J. Virol. 71: 6011, 1997; Tsang et al.
Natl. Cancer Inst. 87: 982-990, 1995; Dis.
is et al. Immunol. 156: 3151-3158, 1996). In applying this strategy, recall responses are detected by culturing PBLs from cancer patients who were "naturally" producing an immune response or from patients vaccinated with a tumor antigen vaccine. Subject-derived PBLs were cultured in vitro in the presence of test peptide and antigen presenting cells (APCs) for 1-2 weeks to enable activation of "memory" T cells when compared to "naive" T cells. To do. At the end of the culture period, T-activity was assayed using an assay for T-cell activity including ⁵¹ Cr release including peptide-sensitized target, T cell proliferation or lymphokine release.
Cell activity is detected.

[0067]   The peptide epitopes of the invention and corresponding nucleic acids are described below.

IV.C. Peptide Epitope Binding Affinity for HLA Molecules As shown herein, the large degree of HLA polymorphisms should be considered with respect to epitope-based approaches to vaccine development. It is an important factor. To address this factor, epitope selection, which involves the identification of peptides capable of binding to multiple HLA molecules with high or medium affinity, is preferably utilized, most preferably those epitopes with high affinity or It binds with moderate affinity to two or more allele-specific HLA molecules.

CTL-inducing peptides of interest for vaccine compositions include Class I H
Mention may be made of those having an IC ₅₀ or binding affinity value for the LA molecule, preferably of 500 nM or better (ie its value is less than or equal to 500 nM). HTL-inducing peptides include those having an IC ₅₀ or binding affinity for class II HLA molecules, preferably 1000 nM or better (ie, the value is 1000 nM or less).
For example, peptide binding is assessed by testing the ability of candidate peptides to bind to purified HLA molecules in vitro. Peptides showing high or medium affinity are then considered for further analysis. Selected peptides are tested against other members of the supertype family. In a preferred embodiment,
Peptides that exhibit cross-reactive binding are then used in cell screening assays or vaccines.

As disclosed herein, higher HLA binding affinity correlates with higher immunogenicity. Higher immunogenicity can be displayed in several different ways. Immunogenicity refers to whether any immune response is elicited, and the strength of any particular response,
And to the extent of the population in which the response is elicited. For example, peptides can elicit an immune response in a diverse group of populations, but do not produce a strong response. Higher binding affinity peptides elicit stronger immunogenic responses. As a result, less peptide is required to elicit similar biological effects when high or medium affinity binding peptides are used. Therefore, in a preferred embodiment of the invention, high affinity binding epitopes or medium affinity binding epitopes are particularly useful.

The relationship between the binding affinity for HLA class I molecules and the immunogenicity of separate peptide epitopes on the bound antigen was first determined in the art by the inventors. The correlation between binding affinity and immunogenicity was analyzed in two different experimental approaches (eg Sette et al., J. Immunol. 153: 5586-5592,
1994). In the first approach, 1 in HLA binding affinity
The immunogenicity of cryptic epitopes over the range of 10,000-fold has resulted in HLA-A ^* 020
One transgenic mouse was analyzed. In the second approach, all A ^* 0
About 100 different hepatitis B viruses (HBs) carrying the 201-binding motif
V) The antigenicity of the derived latent epitope was evaluated using PBL from acute hepatitis patients. According to these approaches, it was determined that an affinity threshold of about 500 nM (preferably 50 nM or less) determines the ability of the peptide epitope to elicit a CTL response. These data are correct for class I binding affinity measurements for naturally processed peptides as well as class I binding affinity measurements for synthetic T cell epitopes. These data also indicate an important role for determinant selection in determining T cell responses (eg, Schaeffer).
Et al., Proc. Natl. Acad. Sci. USA 86: 4649-465.
3, 1989).

Affinity thresholds associated with immunogenicity in the context of HLA class II DR molecules have also been described (eg Southwood et al., J. Immunology 16).
0: 3363-3373, 1998 and co-pending US patent application Ser. No. 09/0.
09,953 (filed January 21, 1998)). To define a biologically significant threshold for DR binding affinity, a database of binding affinities of 32DR restricted epitopes to their restricted elements (ie HLA molecules that bind the motif) was compiled. In about half of the cases (15 epitopes out of 32), DR constraint was associated with high binding affinities (ie, binding affinity values of 100 nM or less). In the other half of the cases (16 out of 32), DR constraint was associated with moderate affinity (binding affinity values in the 100-1000 nM range). 1 out of 32 cases
In the examples only, DR constraint was associated with an IC ₅₀ of 1000 nM or higher. Thus 1000 nM may be defined as the affinity threshold associated with immunogenicity in the context of DR molecules.

In the case of tumor-associated antigens, many CTL peptide epitopes that have been shown to induce CTLs that lyse peptide-pulsed target cells and tumor cell targets that endogenously express their epitopes have ≤200 nM shows the binding affinity or _{IC 5 0} value. In a study evaluating the association between binding affinity and immunogenicity of such TAA epitopes, 100% (10/10) of high binders (ie peptide epitopes that bind with an affinity of 50 nM or less) are immunogenic. Yes, 80% of them (
8/10) elicited CTLs that specifically recognize tumor cells. 51-200n
Very similar numbers were obtained in the M range. CTL induction positive for peptide and tumor cells was 86% (6/7) and 71% (5, respectively) of peptide.
/ 7) It was recognized. In the 201-500 nM range most peptides (4/5
Wild type) was positive for the induction of CTLs that recognize the wild type peptide,
No tumor recognition was detected.

The binding affinity of peptides for HLA molecules can be determined as described in Example 1 below.

IV.D. Peptide Epitope Binding Motif and Supermotif By study of single amino acid substitution antigen analogs and sequencing of endogenously linked naturally processed peptides, allele specificity with HLA molecules Critical residues required for dynamic binding have been identified. The presence of these residues indicates that HLA
Correlates with binding affinity for the molecule. The identification of motifs and / or supermotifs that correlate with high and medium affinity binding is an important issue with respect to the identification of immunogenic peptide epitopes for inclusion in vaccines. Kast et al. (J. Immunol. 152: 3904-3912, 1994), 9 of the epitopes whose motif-bearing peptides bind to allele-specific HLA class I molecules.
It was shown to occupy 0%. In this study, human papillomavirus type 16 E
All possible peptides (240 peptides), 9 amino acids long and overlapping 8 amino acids, covering the entire sequence of 6 and E7 proteins,
It was evaluated for binding to five allele-specific HLA molecules that are frequently expressed among different ethnic groups. This unbiased set of peptides allowed evaluation of the predictive value of HLA class I motifs. From the 240 peptide set, 22 peptides were identified as binding to allele-specific HLA molecules with high or medium affinity.
Of these 22 peptides, 20 (ie 91%) were motif-bearing. Therefore, this study demonstrates the value of motifs for the identification of peptide epitopes for inclusion in vaccines. Application of the motif-based identification technique identifies approximately 90% of potential epitopes in the target antigen protein sequence.

[0076]   Such peptide epitopes are identified in the table below.

The peptides of the invention also include epitopes that bind to MHC class II DR molecules. There is a greater degree of heterogeneity in class II peptide ligands in both the size of the motif and the binding frame position compared to the N- and C-termini of the peptide. This increased heterogeneity of HLA class II peptide ligands is due to the structure of the groove of the HLA class II molecule, which is open at both ends, unlike its class I counterpart. Crystallographic analysis of the HLA class II DRB ^* 0101 peptide complex showed that the main energy of binding was DRB ^* 010
It was shown to be due to peptide residues complexed with complementary pockets on one molecule. The key anchor residues mate with the deepest hydrophobic pocket (eg Madden, DR Ann. Rev. Immunol. 13: 587, 1).
995), referred to as position 1 (P1). P1 may represent the N-terminal residue of a class II binding peptide epitope, but more typically is flanked in the N-terminal direction by one or more residues. Other studies have also pointed out a key role for the peptide residue at the 6th position in the C-terminal direction relative to P1 for binding to various DR molecules.

Over the last few years, a number of HLA class I, each characterized by a nearly overlapping peptide binding repertoire as well as a consensus structure of the main peptide binding pocket.
Evidence has accumulated demonstrating that molecules and HLA class II molecules can be classified into a relatively small number of supertypes. Thus, the peptides of the present invention are characterized by any one of a number of HLA-specific amino acid motifs (see, eg, Tables I-III), or the presence of that motif results in some allele-specific HLA molecules. Supermotifs are identified when they correspond to their ability to bind. HL binding to a peptide having a specific amino acid supermotif
The A molecules are collectively referred to as the HLA “supertype”.

The peptide motifs and supermotifs described below and summarized in Tables I-III provide guidance regarding the identification and use of peptide epitopes according to the present invention.

Examples of respective supermotifs or peptide epitopes carrying motifs are included in the table given in the description of each motif or supermotif below. The table contains the binding affinity ratios listed for some of the peptide epitopes. The ratio can be converted into _{IC 50} using the following equation: _{IC 50} of _{IC 50} / ratio of the standard peptide = test peptide (i.e., peptide epitopes). The IC ₅₀ values of standard peptides used to determine binding affinity for Class I peptides are shown in Table IV. The IC ₅₀ values for standard peptides used to determine binding affinity for Class II peptides are shown in Table V. The peptides used as standards for the binding assays described herein are examples of standards. Alternative standard peptides can also be used when performing binding studies.

To obtain the peptide epitope sequences listed in each of Tables VII-XX, the amino acid sequences of MAGE2 and MAGE3 were evaluated for the presence of the designated supermotif or motif. Ie for the presence of primary anchor residues as described in Table I (for class I motifs) or Table III (for class II motifs) for each respective motif or supermotif,
The amino acid sequence was searched.

In the table, the amino acid sequence-carrying motif and / or supermotif is the following C
Position numbers and epitope lengths are indicated for EA sequences and numbering. The "pos" (position) column indicates the MA corresponding to the first amino acid residue of the epitope.
Amino acid positions in the GE2 and MAGE3 protein sequences are indicated. "Number of amino acids" indicates the number of residues in the epitope sequence and thus the length of the epitope. For example, the first peptide epitope listed in Table VIIA is a 9 residue long sequence beginning at position 154 of the MAGE2 amino acid sequence. Therefore, the amino acid sequence of this epitope is ASEYLQLVF.

The binding data shown in Tables VII-XX are expressed as relative binding ratios (above).

[0084]   (MAGE2 amino acid sequence)

[0085]

[Chemical 1] (MAGE3 amino acid sequence)

[0086]

[Chemical 2] HLA Class I Motif Showing CTL-Derived Peptide Epitopes The primary anchor residues of the HLA class I peptide epitope supermotif and HLA class I peptide epitope motif below are outlined in Table I. The HLA class I motifs described in Table I (a) are those most particularly relevant to the invention claimed herein. Primary anchor positions and secondary anchor positions are outlined in Table II. Allele-specific HLA molecules, including the HLA class I supertype family, are listed in Table VI. In some cases, peptide epitopes may be listed in both the motif and supermotif tables. The relationship between specific motifs and their respective supermotifs is indicated in the individual motif descriptions.

IV.D.1.HLA-A1 Supermotif The HLA-A1 supermotif is a small (2) position at this epitope (
Characterized by the presence in the peptide ligand of a (T or S) or hydrophobic (L, I, V or M) primary anchor residue as well as an aromatic (Y, F or W) primary anchor residue at the C-terminal position. Attached. HLA binding to A1 supermotif
This corresponding family of molecules (ie, HLA-A1 supertype)
At least: consisting of A ^* 0101, A ^* 2601, A ^* 2602, A ^* 2501 and A ^* 3201 (eg, DiBrino, M. et al., J. Immunol.
． 151: 5930, 1993; DiBrino, M .; Et al., J. Immunol
． 152: 620, 1994; Kondo, A .; Et al, Immunogeneti
cs 45: 249, 1997). Other allele-specific HLA molecules predicted to be members of this A1 superfamily are shown in Table VI. The peptides that bind to each of these individual HLA proteins are primary and / or
Alternatively, it may be regulated by substitution at the secondary anchor position, preferably by selecting each residue specified in this supermotif.

Representative MAGE2 and MAGE3 peptide epitopes containing the A1 supermotif are shown in Tables VII (A) and VII (B), respectively.

IV.D.2.HLA-A2 Supermotif Primary anchor specificity for allele-specific HLA-A2.1 molecules (eg, Falk et al., Nature 351: 290-296, 1991; Hunt et al., Science). 255: 1261-1263, 1992; Parker et al.,
J. Immunol. 149: 3580-3587, 1992; Ruppert.
Et al., Cell 74: 929-937, 1993), and HLA-A2.
And cross-reactive linkages between HLA-A28 molecules have been described (for a review of relevant data see, eg, Fruci et al., Human Immunol. 38:
187-192,1993; Tanigaki et al., Human Immunol.
39: 155-162, 1994; Del Guercio et al., J. Am. Immun
ol. 154: 685-693, 1995; Kast et al., J. Am. Immunol.
152: 39004-3912, 1994). These primary anchor residues define the HLA-A2 supermotif; its presence in the peptide ligand corresponds to its ability to bind several different HLA-A2 and HLA-A28 molecules. This HLA-A2 supermotif is L, I, V, M, A, T or Q as the second anchor anchor residue of this epitope and L, I as the first anchor residue of the C-terminal position of this epitope. Have V, M, A or T,
Contains a peptide ligand.

This corresponding family of HLA molecules (ie, the HLA-A2 supertypes that bind these peptides) has at least: A ^* 0201, A ^* 0202.
, A ^* 0203, A ^* 0204, A ^* 0205, A ^* 0206, A ^* 0207,
It consists of A ^* 0209, A ^* 0214, A ^* 6802 and A ^* 6901. Other allele-specific H predicted to be members of this A2 superfamily
LA molecules are shown in Table VI. As described in detail below, binding to each of these individual allele-specific HLA molecules results in substitutions at primary and / or secondary anchor positions (preferably specific to this supermotif). Each residue is selected).

Representative MAGE2 and MAGE3 peptide epitopes containing the A2 supermotif are shown in Tables VIII (A) and VIII (B), respectively. Primary anchor residue V, A, T or Q at position 2 and primary anchor residue L at C-terminal position,
These motifs, including I, V, A or T, are the motifs most particularly relevant to the invention claimed herein.

IV.D.3.HLA-A3 Supermotif The HLA-A3 supermotif is A, L, I, V, M, S or T and this epitope as the second anchor of this epitope. Is characterized by the presence in the peptide ligand of a positively charged residue R or K at the C-terminal position (eg, position 9 of the 9-mer) (eg, Sidney et al., Hum. Immunol. 4).
5:79, 1996). HL that binds to this A3 supermotif
Examples of members of this corresponding family of A molecules (ie, the HLA-A3 supertype) include at least: A ^* 0301, A ^* 1101, A ^* 310.
1, A ^* 3301 and A ^* 6801. Other allele-specific HLA molecules predicted to be members of this A3 supertype are shown in Table VI. As described in detail below, a peptide that binds to each of these individual allele-specific HLA proteins has a substitution of amino acids at the peptide's primary and / or secondary anchor positions (preferably this superposition). By selecting each residue specified in the motif).

Representative MAGE2 and MAGE3 peptide epitopes containing this A3 supermotif are shown in Tables IX (A) and IX (B), respectively.

IV.D.4.HLA-A24 Supermotif The HLA-A24 supermotif is an aromatic residue (F, W or Y) or hydrophobic aliphatic as the primary anchor at position 2 of this epitope. Residues (L, I, V,
M or T) and Y, F as the primary anchor of the C-terminal position of this epitope
, W, L, I or M in the peptide ligands (eg Sette and Sidney, Immunogenetics 199).
9 Nov; 50 (3-4): 201-12, Review). For this corresponding family of HLA molecules that bind to this A24 supermotif (ie, A24 supertype), at least: A ^* 2402, A ^* 3
001 and A ^* 2301. Other allele-specific HLA molecules predicted to be members of this A24 supertype are shown in Table VI. Peptides that bind to each of these allele-specific HLA molecules are regulated by substitutions at primary and / or secondary anchor positions (preferably selecting each residue specified in this supermotif). Can be done.

Representative MAGE2 and MAGE3 peptide epitopes containing this A24 supermotif are shown in Tables X (A) and X (B), respectively.

[0096]   (IV.D.5.HLA-B7 supermotif)   The HLA-B7 supermotif is the secondary anchor for this epitope.
Position as a primary anchor at proline as well as at the C-terminal position of this epitope
Possesses hydrophobic or aliphatic amino acids (L, I, V, M, A, F, W or Y)
Is characterized by a peptide. Bind to this B7 supermotif
This corresponding family of HLA molecules (ie, HLA-B7 supertype
) Is at least: B^*0702, B^*0703, B^*0704, B^*0705
, B^*1508, B^*3501, B^*3502, B^*3503, B^*3504,
B^*3505, B^*3506, B^*3507, B^*3508, B^*5101, B ^* 5102, B^*5103, B^*5104, B^*5105, B^*5301, B^* 5401, B^*5501, B^*5502, B^*5601, B^*5602, B^*6
701 and B^*At least 26 HLA-B proteins, including 7801
(See Sidney et al., J. Immu for a review of related data.
nol. 154: 247, 1995; Barber et al., Curr. Biol. 5
179, 1995; Hill et al., Nature 360: 434, 1992;
Rammensee et al., Immunogenetics 41: 178,199.
5). Others predicted to be members of this B7 supertype
Allele-specific HLA molecules are shown in Table VI. As explained in detail below
, A peptide that binds to each of these individual allele-specific HLA proteins
Is a substitution (preferably a substitution at primary and / or secondary anchor positions of this peptide
, By selecting each residue specified in the supermotif)
It

Representative MAGE2 and MAGE3 peptide epitopes containing this B7 supermotif are shown in Tables XI (A) and XI (B), respectively.

IV.D.6. HLA-B27 Supermotif The HLA-B27 supermotif is a positively charged (R, H or K) residue as a primary anchor at position 2 of this epitope and of this epitope. Characterized by the presence in the peptide ligand of a hydrophobic (F, Y, L, W, M, I, A or V) residue as the primary anchor at the C-terminal position (eg Sidney and Sette, J. et al. Immunogenetics 1999 Nov; 50 (
3-4): 201-12, Review)). Exemplary members of this corresponding family of HLA molecules that bind to this B27 supermotif (ie, the B27 supertype) are at least: B ^* 1401, B ^* 14.
02, B ^* 1509, B ^* 2702, B ^* 2703, B ^* 2704, B ^* 270.
5, B ^* 2706, B ^* 3801, B ^* 3901, B ^* 3902 and B ^* 73.
01 is mentioned. Other allele-specific HLA molecules predicted to be members of this B27 supertype are shown in Table VI. This allele-specific HLA
Peptides that bind to each of the molecules can be regulated by substitution at primary and / or secondary anchor positions (preferably selecting each residue specified in the supermotif).

Representative MAGE2 and MAGE3 peptide epitopes containing this B27 supermotif are shown in Tables XII (A) and XII (B), respectively.

IV.D.7.HLA-B44 Supermotif The HLA-B44 supermotif is a negatively charged (D or E) residue as the primary anchor at position 2 of this epitope and the C-terminus of this epitope. Characterized by the presence in the peptide ligand of a hydrophobic residue (F, W, Y, L, I, M, V or A) as the primary anchor at a position (eg Sidney et al., I.
mmunol. Today 17: 261, 1996). This B4
Exemplary members of this corresponding family of HLA molecules that bind the 4 supermotif (ie, the B44 supertype) include at least: B ^* 18.
01, B ^* 1802, B ^* 3701, B ^* 4001, B ^* 4002, B ^* 400
6, B ^* 4402, B ^* 4403 and B ^* 4404. Peptides that bind to each of these allele-specific HLA molecules are regulated by substitutions at primary and / or secondary anchor positions (preferably selecting each residue specified in this supermotif). Can be done.

IV.D.8.HLA-B58 Supermotif The HLA-B58 supermotif contains a small aliphatic residue (A, S or T) as the primary anchor residue at position 2 of this epitope and C of this epitope
Aromatic or hydrophobic residues (F, W, Y, as primary anchor residues at terminal positions)
L, I, V, M or A) are characterized by their presence in the peptide ligand (eg, Sidney and Sette, Immunogenetics).
1999 Nov; 50 (3-4): 201-12, Review). Exemplary members of this corresponding family of HLA molecules that bind to this B58 supermotif (ie, the B58 supertype) are at least: B ^* 1516, B ^* 1517, B ^* 5701, B ^* 5702 and B ^* 58.
01 is mentioned. Other allele-specific HLA molecules predicted to be members of this B58 supertype are shown in Table VI. These allele-specific H
The peptides that bind to each of the LA molecules can be regulated by substitution at primary and / or secondary anchor positions, preferably at each residue specified in this supermotif.

Representative MAGE2 and MAGE3 peptide epitopes containing this B58 supermotif are shown in Tables XIII (A) and XIII (B), respectively.

IV.D.9.HLA-B62 Supermotif The HLA-B62 supermotif is a polar aliphatic residue Q or a hydrophobic aliphatic residue (L) as the primary anchor at position 2 of this epitope. , V, M, I or P
) And a hydrophobic residue (F) as a primary anchor at the C-terminal position of this epitope.
, W, Y, M, I, V, L or A) in the peptide ligand (eg, Sidney and Sette, Immunogene).
tics 1999 Nov; 50 (3-4): 201-12, Review). Exemplary members of this corresponding family of HLA molecules that bind to this B62 supermotif (ie, the B62 supertype) are at least: B ^* 1501, B ^* 1502, B ^* 1513 and B ^* 5201.
Is mentioned. Other allele-specific HLA molecules predicted to be members of this B62 supertype are shown in Table VI. These allele-specific HLA
Peptides that bind to each of the molecules are substituted at primary and / or secondary anchor positions (preferably selecting each residue specified in this supermotif).
Can be adjusted by

Representative MAGE2 and MAGE3 peptide epitopes containing this B62 supermotif are shown in Tables XIV (A) and XIV (B), respectively.

IV.D.10.HLA-A1 Motif The HLA-A1 motif is T, S or M as the primary anchor residue at position 2 of this epitope and the primary at the C-terminal position of this epitope. It is characterized by the presence of Y as an anchor residue in this peptide ligand. The alternative allele-specific A1 motif is characterized by a primary anchor residue at position 3 rather than position 2. This motif is characterized by the presence of D, E, A or S as the primary anchor residue at position 3 of this epitope and Y as the primary anchor residue at the C-terminal position of this epitope (related data). See, eg, DiBrino et al., J. Immunol., 1
52: 620, 1994; Kondo et al., Immunogenetics 45.
: 249, 1997; and Kubo et al., J. Am. Immunol. 152: 391
3, 1994). Peptides that bind to HLA-A1 can be regulated by substitution at primary and / or secondary anchor positions (preferably selecting each residue specified for this motif).

Representative peptide epitopes containing either A1 motif are shown in Tables XV (A and B) (MAGE2 and MAGE3), respectively. Epitopes containing T, S or M at position 2 and Y at the C-terminal position are also HL listed in Table VII because these residues are a subset of the A1 supermotif primary anchor.
Included in the list of A-A1 supermotif-bearing peptide epitopes.

IV.D.11.HLA-A ^* 0201 Motif The HLA-A2 ^* 0201 motif is the L or M as the primary anchor residue at position 2 of the 9 residue peptide and of the 9 residue peptide. It was determined to be characterized by the presence in the peptide ligand of L or V as the primary anchor residue at the C-terminal position (eg, Falk et al., Nature 351: 290-296).
, 1991), and in addition, it was found to contain I or A at the I and C-terminal positions at position 2 of the 9 amino acid peptide (eg, Hunt et al., S.
science 255: 1261-1263, March 6, 1992; Pa.
rker, et al. Immunol. 149: 3580-3587, 1992). This A ^* 0201 allele-specific motif is V, A, T or Q and C of this epitope as the primary anchor residue at position 2 of this epitope.
It was defined by the present inventors to further include M or T as a primary anchor residue at the terminal position (eg, Kast et al., J. Immunol. 152: 39.
04-3912, 1994). Therefore, the HLA-A ^* 0201 motif is L, I, V, M, A as the primary anchor residue at position 2 of this epitope.
, T or Q and L as the primary anchor residue at the C-terminal position of this epitope,
Peptide ligands having I, V, M, A or T are included. These preferred and tolerated residues that characterize the primary anchor position of this HLA-A ^* 0201 motif are identical to those that describe the A2 supermotif (for a review of related data see, eg, Del Guercio et al. , J. Immunol.
154: 685-693, 1995; Ruppert et al., Cell 74:92.
9-937, 1993; Sidney et al., Immunol. Today 17:
261-266, 1996; Sette and Sidney, Curr. Opi
n. in Immunol. 10: 478-482, 1998).
Secondary anchor residues that characterize this A ^* 0201 motif have been further defined (eg, Ruppert et al., Cell 74: 929-937, 1993).
checking). These are shown in Table II. Peptides that bind to the HLA-A ^* 0201 molecule can be regulated by substitution at primary and / or secondary anchor positions, preferably selecting each residue specified in this motif.

Representative peptide epitopes containing the A ^* 0201 motif are shown in Table VIII (A
And B) (MAGE2 and MAGE3) respectively. Primary anchor residues V, A, T or Q at position 2 and primary anchor residues L, I, V at the C-terminal position.
A ^* 0201 motifs, including A or T, are the motifs most particularly relevant to the invention claimed herein.

IV.D.12.HLA-A3 Motif The HLA-A3 motif is L, M, V, I, S, A, T, F as the primary anchor residue at position 2 of this epitope. , C, G or D and K, sY, R, H, F or A as the primary anchor residue at the C-terminal position of this epitope, is characterized by the presence in the peptide ligand (eg DiBrino et al.,
Proc. Natl. Acad. Sci. USA 90: 1508, 1993;
And Kubo et al. Immunol. 152: 3913-3924,199
4). Peptides that bind to HLA-A3 can be regulated by substitution at primary and / or secondary anchor positions, preferably selecting each residue specified in this motif.

Representative peptide epitopes containing this A3 motif are shown in Tables XVI (A and B) (MAGE2 and MAGE3), respectively. Peptide epitopes also containing this A3 supermotif are also listed in Table IX. This A3 supermotif primary anchor residue comprises a subset of A3- and A11-allele-specific motif primary anchor residues.

IV.D.13.HLA-A11 Motif The HLA-A11 motif is V, T, M, L, I, S, A, G as the primary anchor residue at position 2 of this epitope. , N, C, D or F and K, R, Y or H as primary anchor residues at the C-terminal position of this epitope are characterized by their presence in the peptide ligand (eg Zhang et al., Pr.
oc. Natl. Acad. Sci. USA 90: 2217-2221,1.
993; and Kubo et al. Immunol. 152: 3913-392
4, 1994). Peptides that bind to HLA-A11 can be regulated by substitution at primary and / or secondary anchor positions, preferably selecting each residue specified in this motif.

Representative peptide epitopes containing this A11 motif are shown in Table XVII (A and B) (MAGE2 and MAGE3), respectively. Peptide epitopes containing the A3 allele-specific motif are also shown in this table due to the extensive overlap between the A3 motif primary anchor specificity and the A11 motif primary anchor specificity. In addition, peptide epitopes containing the A3 supermotif are also shown in Table IX.
Are listed in.

IV.D.14.HLA-A24 Motif The HLA-A24 motif is located at Y, F, W or M as the primary anchor residue at position 2 of this epitope and at the C-terminal position of this epitope. Is characterized by the presence in the peptide ligand of F, L, I or W as the primary anchor residue of (eg, Kondo et al., J. Immunol. 155: 4307).
-4312, 1995; and Kubo et al., J. Am. Immunol. 152: 39
13-3924, 1994). Peptides that bind to the HLA-A24 molecule can be regulated by substitution at primary and / or secondary anchor positions, preferably selecting each residue specified in this motif.

Representative peptide epitopes containing this A24 motif are shown in Table XVIII (A
And B) (MAGE2 and MAGE3) respectively. These epitopes have the primary anchor residues that characterize this A24 allele-specific motif
Since it contains a subset of the A24 supermotif primary anchor residues, Table X (HL
A-A24-supermotif-bearing peptide epitope is shown).

Motif Showing Class II HTL-Induced Peptide Epitopes The primary and secondary anchor residues of the HLA class II peptide epitope supermotifs and HLA class II peptide epitope motifs described below are summarized in Table III.

[0116]   (IV.D.15.HLA DR-1-4-7 supermotif)   Three common HLA class II allele-specific HLA molecules: HLA DRB1 ^* 0401, DRB1^*0101 and DRB1^*Peptide that binds to 0701
Also, motifs have been identified (eg, Southwood et al., J. I.
See review by mmunology 160: 3363-3373, 1998.
). Collectively, the common residues from these motifs are HLA DR-1-4-
7 Describe the super motif. Peptides that bind to these DR molecules have a position
Large aromatic or hydrophobic residues (Y, F, W as primary anchor residues in 1
, L, I, V or M), and the primary anchor at position 6 of the 9-mer core region.
-By a small uncharged residue (S, T, C, A, P, V, I, L or M) as a residue
Possesses a supermotif that is characterized by Allele-specific secondary effects and
And secondary anchors for each of these HLA types have also been identified (South
wood et al. ,the above). These are listed in Table III. HL
A-DRB1^*0401, DRB1^*0101 and / or DRB1^*070
Peptides that bind to 1 can be substituted by substitution at primary and / or secondary anchor positions.
Each of which can be tuned and is preferably specific for the supermotif
Select residues.

Possible epitope 9-mer core regions containing the DR-1-4-7 supermotif, where position 1 of the supermotif is at position 1 of the 9-residue core, are listed in Table XIX. Examples of respective 15 amino acid residue long peptide epitopes, each containing a 9 residue core, are also shown in the table, along with cross-reactive binding data for examples of 15 residue supermotif-bearing peptides.

IV.D.16.HLA DR3 Motif Two alternative motifs (ie, submotifs) characterize peptide epitopes that bind to HLA-DR3 molecules (eg, Geluk et al., J. Immu).
nol. 152: 5742, 1994). First motif (submotif D
In R3a) a large hydrophobic residue (L, I, V, M, F or Y) is present at anchor position 1 of the 9-mer core and D is towards the carboxyl terminus of the epitope,
Exists as an anchor at position 4. As with other class II motifs, core position 1 may or may not occupy the peptide N-terminal position.

The alternative DR3 submotif is at position 6 towards the carboxyl terminus of the epitope.
The presence of a positive charge at anchors provides for the lack of a large hydrophobic residue at anchor position 1 and / or the absence of a negatively charged or amide-like anchor residue at position 4. Thus for the alternative allele-specific DR3 motif (submotif DR3b):
L, I, V, M, F, Y, A or Y is present at anchor position 1; D, N, Q,
E, S or T is at anchor position 4; and K, R or H is at anchor position 6. Peptides that bind to HLA-DR3 can be tuned by substitution at primary and / or secondary anchor positions, preferably selecting each residue that is specific for its supermotif.

Possible peptide epitope 9-mer core regions corresponding to a 9 residue sequence containing the DR3a submotif (position 1 of the motif is position 1 of the 9 residue core) are listed in Table X.
Xa. Examples of respective 15-amino acid residue long peptide epitopes, each containing a 9-residue core, are also shown in Table XXa, along with binding data for representative DR3 submotif-bearing peptides.

A possible peptide epitope 9-mercore region comprising a DR3b submotif,
And each representative 15-mer peptide containing the DR3 submotif-b epitope is listed in Table XXb, along with binding data for representative DR3 submotif-b bearing peptides.

Each of the HLA class I or class II peptide epitopes listed in the tables herein is considered merely an aspect of the invention of this application. Furthermore, it is also an aspect of the present invention that each peptide epitope can be used in combination with any other peptide epitope.

IV. E. Vaccine Enhanced Population Coverage Vaccines with broad population coverage are preferred because they are more commercially viable and generally applicable to most people. Broad population coverage is considered by considering peptides of the invention (as well as the nucleic acid composition encoding such peptides), by selecting peptide epitopes that, when considered globally, bind to HLA alleles present in most populations. It is obtained by using Table XXI is
Global frequency of HLA class I supertypes in different ethnic groups (Table XXIa)
And the combined population coverage achieved by the A2-, A3- and B7-supertypes (Table XXIb) is listed. The A2-, A3-, and B7 supertypes are each present on average over 40% in each of these five major ethnic groups.
An excess coverage of 80% is achieved with a combination of these supermotifs. These results suggest that effective and ethnically unbiased population coverage is achieved with the use of a limited number of cross-reactive peptides. The population coverage achieved by these three major peptide specificities is high, but when using additional supermotif or allele specific motif bearing peptides, population coverage of 95% and above is reached, and The scope can be extended to more easily achieve multispecific responses.

The B44-supertype, A1-supertype and A24-supertype are each present in these major ethnic groups on average ranging from 25% to 40% (
Table XXIa). Overall low dissemination but B27-, B58- and B
Each of the 62 supertypes is present at a frequency of greater than 25% in at least one major ethnic group (Table XXIa). Table XXIb outlines the disseminated estimates of HLA supertype combinations identified in the five major ethnic groups. A2, A3 and B7
The coverage increments obtained by inclusion of A1 supertypes, A24 supertypes and B44 supertypes in coverage, as well as the coverage obtained using all supertypes described herein are shown. ing.

The data presented here together with the conventional definitions of A2-, A3- and B7 supertypes show that all antigens (with the possible exception of A29, B8 and B46) were 9 It shows that it can be classified into HLA supertypes. By including epitopes from the 6 most frequent supertypes, an average population coverage of 99% is obtained for the 5 major ethnic groups.

IV. I. Immune Response Stimulating Peptide Analogs (Analogs, Analogs) In general, CTL and HTL responses are not directed against all possible epitopes. Rather, they are a few "tumor antigen" determinants (im
It is bound to the mudominant detergent (Zink)
ernagel, et al., Adv. Immunol. 27: 5159, 1979; B
ennik, et al. Exp. Med. 168: 1935-1939, 1988
Rawle, et al. Immunol. 146: 3977-3984,199
1). Immunodominant (Benacerr
af, et al., Science 175: 273-279, 1972), a specific H
Selective binding of LA proteins (determinant selection theory) (Vitiello,
Et al., J. Immunol. 131: 1635, 1983; Rosenthal et al., Nature 267: 156-158, 1997) or the existing TCR (T.
Selective recognition by cell receptor) specificity (repertoire theory) (Klei
n, J. , IMMUNOLOGY, THE SCIENCE OF SELF /
NONSELF DISCRIMINATION, John Wiley &
Sons, New York, pp. 270-310, 1982) may be explained by any of the capabilities of a given epitope. It can be said that additional factors that are primarily linked to processing events may also play important roles in directing that a number of possible determinants exist as major antigenic determinants, beyond strict immunogenicity. Proven (Sercarz, et al., Annu. Rev. Immun.
ol. 11: 729-766, 1993).

Tissue-specific and developmental TAAs are expressed on normal tissues at at least some time points, or at at least some locations in the body, so that T cells, especially dominant epitopes, against them are It can be expected to be eliminated and tolerance induced during immune surveillance. However, CTL responses to tumor epitopes have been detected in both normal donors and cancer patients, which may indicate incomplete tolerance (eg, Kawashima et al., Hum.
Immunol. 59: 1, 1998; Tsang, J .; Natl. Cancel
r Inst. 87: 82-90, 1995; Rongoon et al., J. Am. Immu
nol. 163: 1037, 1999). Therefore, immune tolerance is a high affinity HL
It does not completely eliminate or inactivate CTL precursors that can recognize A class I binding peptides.

Yet another strategy to overcome tolerance is to use analog (analog) peptides. Not intended to be bound by theory, but dominant (do
minant) T-cells against the epitope are clonally deleted,
It is believed that the selection of subdominant epitopes requires pre-existing T cells, which in turn result in a therapeutic or prophylactic response.
However, HLA with subdominant epitopes
The binding of molecules is often less virulent than the binding of dominant epitopes. Therefore, one or more HLAs
The binding affinity of a particular immunogenic epitope for a molecule may be adjusted, thereby modulating the immune response elicited by the peptide, eg, to prepare an analog (analog) peptide that elicits a stronger response. There is a need.

The screening procedure described above has identified peptides with appropriate cross-reactivity between all alleles of the superfamily, but the cross-reactivity is not always as complete as possible and in some cases For that, techniques for increasing the cross-reactivity of peptides may be useful. Moreover, such techniques can also be used to modify other properties of peptides such as binding affinity or peptide stability. If a general principle governing peptide cross-reactivity to HLA alleles within a given motif or supermotif is established, it will be more extensive (
Alternatively, in order to achieve the otherwise modified HLA binding capacity, structural modifications (ie analogues) of the particular peptide of interest may be carried out. More specifically, peptides exhibiting the broadest cross-reactivity pattern can be produced according to the teachings herein. The concept of the present invention relating to analog (analog) generation is described in detail in US copending application Ser. No. 09 / 226,775 (filed Jan. 6, 1999).

In summary, the strategy used utilizes a motif or supermotif that correlates with binding to certain HLA molecules. A motif or supermotif is defined by having a primary anchor, often a secondary anchor.
Analog (analog) peptides can be made by substituting amino acid residues at the primary anchor, the secondary anchor, or at the primary and secondary anchor positions. Generally analogs are made to peptides that already carry the motif or supermotif. The supermotif and the preferred secondary anchor residues of the motif that were defined for the HLA class I and class II binding peptides are shown in Tables II and III, respectively.

With respect to a number of motifs or supermotifs of the present invention, allele-specific HLA molecules, or HLs that bind the respective motifs or supermotifs
Residues that are detrimental to binding members of the A supertype are defined (Tables II and III). Thus, the removal of such residues that are detrimental to binding can be performed according to the present invention. For example, in the case of the A3 supertype, when all peptides with such deleterious residues were removed from the population of peptides used in the analysis, the incidence of cross-reactivity increased from 22% to 37%. (Eg Sidn
ey, J.E. Hu. Immunol. 45:79, 1996). Therefore,
One strategy for improving cross-reactivity of peptides within a given supermotif is:
Simply by deleting one or more deleterious residues present in the peptide, small "neutral" residues,
For example, replacing Ala, which cannot affect T cell recognition of peptides. The association of high affinity binding with allele-specific HLA molecules or with multiple HLA molecules within the superfamily, along with elimination of deleterious residues within peptides.
The potential for enhanced cross-reactivity is expected when a "favorable" residue is inserted.

When the analog (analog) peptide is used as a vaccine, it actually elicits a CTL response against native epitopes in vivo (or in the case of class II epitopes, a helper that cross-reacts with the wild-type peptide). To induce T cells), the analog (analog) peptide
It can be used to immunize T cells in vitro from an individual with the appropriate HLA allele. The ability of the immunized cells to induce lysis of wild-type peptide-sensitized target cells is then assessed. It is a cell that has been infected or transfected with the appropriate gene to determine whether the endogenously produced antigen is also recognized by the associated T cells, or is only a class II epitope. In some cases, it may be desirable to use as an antigen presenting cell which is any cell that has been pulsed with the whole protein antigen.

Another embodiment of the invention is to make analogs of weakly binding peptides, thereby ensuring the proper number of cross-reactive cell binding agents. 500-500
Class I binding peptides that exhibit 0 nM binding affinity and are tolerable, but which carry a suboptimal primary anchor residue in one or both positions replace the preferred anchor residue according to their respective supertypes. Can be "fixed". The analog peptide can then be tested for cross-binding activity.

Another embodiment for generating effective peptide analogs (analogs) involves substitution of residues that adversely affect peptide stability or solubility, eg, in a liquid environment. This substitution can occur at any position of the peptide epitope. For example, cysteine can be substituted by selecting alpha aminobutyric acid (the one-letter abbreviation "B" for the peptide sequences listed herein). Due to its chemical nature, cysteine has a tendency to form disulfide bridges and structurally alters the peptide sufficiently to reduce its binding capacity. Substitution of α-aminobutyric acid for cysteine not only ameliorates this problem, but in some cases does improve binding and cross-linking capacity (eg Sette et al., In: Persistent Vi).
ral Informations, Eds. R. Ahmed and I.D. Che
n, John Wiley & Sons, England, 1999).

Representative analog (analog) peptides are listed in Tables XXII-XXVII. The table shows the length and sequence of the analog (analog) peptides and, where appropriate, the motif or supermotif. The "Source" column indicates the residue substituted with the position number supported for each analog (analog).

IV.G. Computer Screening of Protein Sequences from Disease-Associated Antigens for Supermotif-bearing Peptides or Motif-bearing Peptides Native protein sequences for identifying supermotif-bearing peptides or motif-bearing peptides in target antigens , Sequences associated with, for example, tumor-associated antigens, or infectious organisms, or donor tissues for transplantation, provide a means for intelligent computing or computing, such as to determine the presence of supermotifs or motifs within a sequence. Used to be screened. The information obtained from the analysis of native peptides can be used directly to assess the status of native peptides, or can subsequently be used to generate peptide epitopes.

Included in the present invention are computer programs that allow rapid screening of protein sequences for the occurrence of the subject supermotif or motif, as well as programs that allow the production of analog (analog) peptides. These programs are run to analyze any identified amino acid sequence, or to work on unknown sequences, at the same time confirming the sequence and identifying its motif-bearing epitopes. Analogues can be determined simultaneously as well. Commonly identified sequences are from pathogenic organisms or tumor associated peptides. For example, target TAA molecules include CEA, MAGE, p53 and ber2 / neu.
But is not limited to these.

It is important that the selection criteria utilized for prediction of peptide binding be as accurate as possible in order to most efficiently correlate with actual binding. The prediction of peptides that bind, for example, HLA-A ^* 0201 based on the presence of a suitable primary anchor is promising at a rate of approximately 30% (eg, Ruppert, J. et al., Cell.
74: 929, 1993). However, by extensive analysis of the peptide-HLA binding data disclosed herein, data in related patent applications and data in the art, we have determined the presence of the primary anchor residue alone. A number of allele-specific polynomial algorithms have been developed that dramatically increase the predictive value over the underlying identification. These algorithms take into account the presence or absence of primary anchors as well as the positive or deleterious presence of secondary anchor residues (to account for the effects of different amino acids at different positions). The algorithm is essentially based on the assumption that the total affinity (or ΔG) of peptide-HLA interactions can be estimated as a first order polynomial function of the form: ΔG = a _1i xa _2i xa _3i ... Xa _ni , where a _1i is a coefficient representing the effect of the presence of a given amino acid (j) at a given position (i) along the sequence of a peptide of n amino acids). An important assumption of this method is that the effects at each location are essentially independent of each other. This hypothesis is justified by studies demonstrating that the peptide is bound to the HLA molecule and is essentially recognized by T cells in the extended conformation. Derivation of specific algorithm coefficients is described, for example, in Gulukota, K .; Et al., J. Mol. Biol. 267:
1258, 1997.

Yet another method for identifying preferred peptide sequences that also use specific motifs includes the use of neural networks and molecular modeling programs (eg, Milik et al., Nature Biotechno).
logy 16: 753, 1998; Altuvia et al., Hum. Immuno
l. 58: 1, 1997; Altuvia et al. Mol. Biol. 249:
244, 1995; Buus, S .; Curr. Opin. Immunol. 11
: 209-213, 1999; Brusic, V .; Et al., Bioinformation
ics 14: 121-130, 1998; Parker et al., J. Am. Immuno
l. 152: 163, 1993; Meister et al., Vaccine 13: 5.
81, 1995; Hammer et al. Exp. Med. 180: 2353, 1
994; Turniolo et al., Nature Biotechnol. 17:
555, 1999).

For example, A ^* 0201 containing at least one preferred secondary anchor residue.
In the set of motif-bearing peptides, 69% of the peptides bind A ^* 0201, while avoiding the presence of any deleterious secondary anchor residues, with an IC ₅₀ of 500.
It has been shown to be less than nM (Ruppert, J. et al., Cel.
74: 929, 1993). These algorithms are also flexible in that the cutoff scores can be adjusted to select peptide sets with larger or lower predicted binding properties, if desired.

When utilizing computer screens to identify peptide epitopes, protein or translation sequences are labeled with software developed to search for motifs, such as the "FINDPATERNS" program (Devere).
ux, et al., Nucl. Acids Res. 12: 387-395, 1984).
, Or the MotifSearch 1.4 software program (D. Brown) to identify potential peptide sequences containing the appropriate HLA binding motif.
, San Diego, CA). The identified peptides can be scored using a customized polynomial algorithm to predict their ability to bind specific HLA class I or class II alleles. As will be appreciated by one of skill in the art, to evaluate known or unknown peptide sequences (eg, to identify epitopes, to identify epitope concentration per peptide length, or to generate analogs (analogs). For example, but not limited to, large arrays of computer programming software and hardware options are available in the relevant industries that may be used to implement the motifs of the invention.

Following the procedure described above, HLA supertypes or allele-specific HLA
MAGE2 / 3 peptide epitopes and their analogs (analogs) capable of binding molecules have been identified (Tables VII-XX, Tables XXII-XXXI).
).

Preparation of IV.H. Peptide Epitopes Peptides according to the present invention may be synthesized synthetically by recombinant DNA technology or chemical synthesis,
Alternatively it may be prepared from natural sources such as native tumors or pathogenic organisms. Peptide epitopes may be synthesized separately or as polyepitope peptides. The peptide is preferably substantially free of other naturally occurring host cell proteins and fragments thereof, although in some embodiments,
The peptide may be synthetically linked to the native fragment or particle.

The peptides according to the invention can be of various lengths and can be in their neutral (uncharged) form or in salt form. The peptides according to the invention do not contain modifications such as glycosylation, side chain oxidation or phosphorylation, or they are provided that the modifications do not destroy the biological activity of the peptides as described herein. , Containing these modifications.

When possible, a length of about 8 to about 13, often 8 to 11, preferably 9 to 10 amino acid residues, so that the HLA of the invention can be used in a polyepitope construct. It is desirable to optimize class I binding epitopes. The HLA class II binding peptide epitopes of the present invention may be optimized for lengths of about 6 to about 30 amino acids in length, preferably about 13 to about 20 residues. Preferably, the peptide epitope is comparable in size to an endogenously processed pathogen-derived peptide or tumor cell peptide bound to a related HLA molecule, although the identification and preparation of peptides containing the epitope of the invention is also herein described. Can be performed using the techniques described in.

In an alternative embodiment, the epitopes of the invention may be linked as a polyepitope peptide, or a minigene encoding a polyepitope peptide.

In another embodiment, it is preferred to identify native peptide regions that contain high concentrations of class I and / or class II epitopes. Such a sequence is generally selected on the basis that it contains the maximum number of epitopes per amino acid length. Epitopes exist in a nested or overlapping fashion, eg, a 10 amino acid long peptide may contain two 9 amino acid long epitopes and one 10 amino acid long epitope, and each epitope may be exposed during intracellular processing. It should be understood that when administered, it may be bound by HLA molecules. This larger, preferably multi-epitope peptide, can be produced synthetically, recombinantly, or by cleavage from its native source.

The peptides of the invention can be prepared in a wide variety of ways. For the preferred relatively short size, the peptides may be synthesized in solution or on a solid support according to conventional techniques. Various automatic synthesizers are commercially available and can be used according to known protocols (eg, Stewart & Young, SOLI.
D PHASE PEPTIDE SYNTHESIS, 2D, ED. , Pie
rc Chemical Co. , 1984). Further, individual peptide epitopes can be linked using chemical ligation to produce large peptides, which are also within the scope of this invention.

Alternatively, the nucleotide sequence encoding the immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into a suitable host cell and cultured under conditions suitable for expression. Recombinant DNA technology can be used. These techniques are described in Sambrook et al., MOLECULAR CLONIN.
G, A LABORATORY MANUAL, Cold Spring Ha
rbor Press, Cold Spring Harbor New Yo
It is generally known in the art, as described in rk (1989). Thus, recombinant polypeptides comprising one or more peptide sequences of the invention can be used to present the appropriate T cell epitope.

Nucleotides encoding sequences for peptide epitopes of preferred lengths contemplated herein can be prepared by chemical techniques, eg, by the techniques of Matteucci et al., J.
． Am. Chem. Soc. 103: 3185 (1981). Peptide analogs can be made by simply substituting the appropriate and desired nucleobase (s) in place of those encoding the native peptide sequence. Typical nucleic acid substitutions are those encoding the amino acids defined by the motifs / supermotifs herein. The coding sequence is then provided with a suitable linker and ligated into an expression vector commonly available in the art, as well as the vector used to transform a suitable host, to produce the desired fusion protein. obtain. Large numbers of such vectors and suitable host systems are currently available. For expression of fusion proteins, a coding sequence is provided with start and stop codons operably linked, promoter and terminator regions, and usually a replication system to provide an expression vector for expression in the desired cellular host. I will provide a. For example, promoter sequences compatible with bacterial hosts are provided in plasmids that contain convenient restriction sites for insertion of the desired coding sequence. The resulting expression vector is transformed into a suitable bacterial host. Of course, yeast, insect or mammalian cell hosts can also be used with appropriate vectors and control sequences.

IV.I. Assays for Detecting T Cell Responses Once HLA binding peptides have been identified, they can be tested for their ability to elicit a T cell response. Preparation and evaluation of motif-bearing peptides was performed using PCT
It is described in International Publication Nos. 94/20127 and 94/03205. In short, peptides containing epitopes from specific antigens are synthesized and tested for their ability to bind the appropriate HLA protein. These assays involve assessing the binding of the peptides of the invention to purified HLA class I molecules for the binding of radioiodinated reference peptides. Alternatively, cells expressing empty class I molecules (ie lacking the peptide therein) can be evaluated for peptide binding by immunofluorescent staining and flow microfluorescence measurements. Other assays that can be used to assess peptide binding include peptide-dependent class I assembly assays and / or inhibition of CTL recognition by peptide competition. Peptides that bind class I molecules, with an affinity of typically 500 nM or less, react with selected target cells in relation to their ability to serve as targets for CTL from infected or immunized individuals, as well as with disease-associated target cells. It is further evaluated for their ability to induce a primary in vitro or in vivo CTL response that can give rise to the resulting CTL population.

The corresponding assay is used for the evaluation of HLA class II binding peptides. HLA class II motif-bearing peptides, which have been shown to typically bind with an affinity of 1000 nM or less, are further evaluated for their ability to stimulate HTL responses.

Conventional assays utilized to detect T cell responses include proliferation assays, lymphokine secretion assays, direct cytotoxicity assays and limiting dilution assays. For example, antigen presenting cells incubated with peptides can be assayed for their ability to induce a CTL response in a responder cell population.
Antigen presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells. Alternatively, a mutant non-human mammalian cell line lacking the ability to load a class I molecule with an internally processed peptide and transfected with an appropriate human class I gene was tested for the ability of the peptide to induce a primary CTL response in vitro. Can be used to

Peripheral blood mononuclear cells (PBMCs) can be used as a source of responder cells for CTL precursors. Appropriate antigen presenting cells are incubated with the peptide and then peptide loaded antigen presenting cells are incubated with the responder cell population under optimized culture conditions. Positive CTL activation involves assaying the cultures for the presence of CTL that kill the radiolabeled target cells, the bispecific peptide pulsed target, as well as the target cells expressing the endogenously processed form of the antigen from which the peptide sequence is derived. Can be determined by

More recently, a method has been devised that allows direct quantification of antigen-specific T cells by staining with a fluorescein-labeled HLA tetramer complex (Altman, J.
． D. et al. , Proc. Natl. Acad. Sci. USA 90:
10330, 1993; Altman, J .; D. et al. , Science
274: 94, 1996). Other relatively recent technological developments include staining for intracellular lymphokines and interferon release assay or ELISP.
An OT assay is included. Tetramer staining, intracellular lymphokine staining and E
All LISPOT assays appear to be at least 10 times more sensitive than the more conventional assays (Lalvani, A. et al., J. Exp. Med. 1).
86: 859, 1997; Dunbar, P .; R. et al. Curr. B
iol. 8: 413, 1998; Murali-Krishna, K .; et a
l. , Immunity 8: 177, 1998).

HTL activation can also be assessed using techniques known to those of skill in the art, such as T cell proliferation and secretion of lymphokines such as IL-2 (see, eg, Alexandar et al., Immunity 1: 751-761, 1994). ).

Alternatively, immunization of HLA transgenic mice can be used to establish the immunogenicity of peptide epitopes. Several transgenic mouse models have been characterized, including mice with the human A2.1, A11 (which can additionally be used to analyze HLA-A3 epitopes) and B7 alleles, and others (eg, Transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed. Still other transgenic mouse models with other HLA alleles can be generated if needed. Mice are immunized with peptides emulsified in incomplete Freund's adjuvant and the resulting T cells are tested for their ability to recognize peptide-pulsed target cells and target cells transfected with the appropriate gene. . CTL responses can be analyzed using the cytotoxicity assay described above. Similarly, HTL responses can be analyzed using assays such as T cell proliferation or lymphokine secretion.

IV.J. Use of Peptide Epitopes as Diagnostic Agents and for Assessing Immune Responses In one embodiment of the invention, HLA class I and class II binding peptides as described herein. Is used as a reagent to assess the immune response.
The immune response to be assessed is the use of any agent as an immunogen that recognizes the peptide epitope (s) to be used as a reagent and can result in the production of antigen-specific CTLs or HTLs that bind to it. Induced by. Peptide reagents need not be used as immunogens. Assay systems used for such analysis include relatively recent technological developments such as tetramers, staining for intracellular lymphokines and interferon release assays or ELISPOT assays.

For example, the peptides of the invention can be used in a tetramer staining assay to assess peripheral blood mononuclear cells for the presence of antigen-specific CTL after exposure to tumor cell antigens or immunogens. The HLA-tetramer complex can be used to directly visualize antigen-specific CTL (eg, Ogg et al., Science 279: 2103-21).
06, 1998, and Altman et al., Science 174: 94-96.
, 1996), and to determine the frequency of antigen-specific CTL populations in peripheral blood mononuclear cell samples. Tetramer reagents using the peptides of the invention can be generated as follows: peptides that bind to HLA molecules are the corresponding HL
It is refolded in the presence of A heavy chain and β ₂ -microglobulin to form a trimolecular complex. The complex is biotinylated at the carboxyl terminus of the heavy chain at sites previously engineered into the protein. The addition of streptavidin then induces tetramer formation. With the fluorescently labeled streptavidin, tetramers are used to stain antigen-specific cells. The cells can then be identified by, for example, flow cytometry. Such analyzes can be used for diagnostic or prognostic applications.

The peptides of the invention can also be used as reagents to assess immune recall responses (eg, Bertoni et al., J. Clin. Invest. 100: 5).
03-513, 1997 and Penna et al., J. Am. Exp. Med. 174: 1
565-1570, 1991). For example, patient PBM from an individual with cancer
C samples can be analyzed for the presence of antigen-specific CTL or HTL with specific peptides. Blood samples containing mononuclear cells were cultured with PBMC,
It can be evaluated by stimulating cells with the peptides of the invention. After an appropriate culture time, the expanded cell population can be analyzed, eg, for CTL or for HTL activity.

Peptides can also be used as reagents to assess the efficacy of vaccines. PBMCs obtained from patients vaccinated with the immunogen are analyzed using, for example, any of the methods described above. Patients are HLA typed and peptide epitope reagents that recognize allele-specific molecules present in the patient are selected for analysis.
The immunogenicity of the vaccine depends on the epitope-specific CTL and / or PBMC samples in the sample.
Or indicated by the presence of HTL.

The peptides of the invention can also be used to raise antibodies using techniques well known in the art (eg, CURRENT PROTOCOLS IN IMMUNO).
LOGY, Willey / Greene, NY, and Antibodies
A Laboratory Manual, Harlow and Lane,
Cold Spring Harbor Laboratory Press,
1989), which may be useful as a reagent for diagnosing or monitoring cancer. Such antibodies may include those that recognize peptides in the context of HLA molecules, ie antibodies that bind to the peptide-MHC complex.

IV.K. Vaccine Compositions Vaccines containing immunogenicly effective amounts of one or more peptides as described herein and methods of preparing vaccines are further provided by the present invention. It is an embodiment. Once the appropriate immunogenic epitopes have been defined, they are classified and delivered by various means and are referred to herein as "vaccine" compositions.
Such vaccine compositions include, for example, lipopeptides (eg, Vitie
Ilo, A .; et al. J. Clin. Invest. 95: 341, 19
95), a peptide composition encapsulated in poly (DL-lactide coglycolide) (“PLG”) microspheres (eg, Eldridge et al., Molec. Immunol).
． 28: 287-294, 1991; Alonso et al., Vaccine 12:
299-306, 1994; Jones et al., Vaccine 13: 675-6.
81, 1995), a peptide composition contained in an immune stimulating complex (ISCOMS) (eg, Takahashi et al., Nature 344: 873-8).
75, 1990; Hu et al., Clin Exp Immunol. 113: 235
-243, 1998), multi-antigen peptide systems (MAPs) (eg Tam,
J. P. , Proc. Natl. Acad. Sci. USA. 85: 5409-
5413, 1988; Tam, J .; P. J. Immunol. Methods
196: 17-32, 1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, ME et al .: Concepts in vac
cine development, Kaufmann, S .; H. E. , Volume, p
． 379, 1996; Chakrabarti, S .; Et al, Nature 320
: 535, 1986; Hu, S .; L. Et al., Nature 320: 537, 19
86; Kieny, M .; P. Et al., AIDS Bio / Technology 4
: 790, 1986; Top, F .; H. Et al., J. Infect. Dis. 124
: 148, 1971; Chanda, P .; K. Et al., Virology 175:
535, 1990), particles of viral or synthetic origin (eg Kofler,
N. Et al., J. Immunol. Methods. 192: 25, 1996; El
bridge, J.D. H. Et al., Sem. Hematol. 30:16, 1993;
Falo, L .; D. , Jr. Et al., Nature Med. 7: 649, 1995
), Adjuvants (Warren, HS, Vogel, FR, and C).
hedid, L .; A. , Annu. Rev. Immunol. 4: 369, 19
86; Gupta, R .; K. Vaccine 11: 293, 1993),
Liposomes (Reddy, R. et al., J. Immumol. 148: 1585, 1
992; Rock, K .; L. , Immunol. Today 17: 131,1
996), or naked or particle-absorbed cDNA (Ulmer, JB et al., Sc
ience 259: 1745, 1993; Robinson, H .; L. , Hu
nt, L.N. A. , And Webster, R .; G. , Vaccine 11: 9
57, 1993; Shiver, J .; W. Et al: Concepts in vac
cine development, Kaufmann, S .; H. E. , Volume, p
． 423, 1996; Cease, K .; B. , And Berzofsky, J .;
A. , Annu. Rev. Immunol. 12: 923, 1994, and E.
ldridge, J .; H. Et al., Sem. Hematol. 30:16, 1993
) May be mentioned. Toxin-targeted delivery techniques, also known as receptor-mediated targeting, such as Avant Immunotherapeutics, In.
c. (Needham, Massachusetts) may also be used.

Vaccines of the invention include nucleic acid-mediated modalities. DNA or RNA encoding one or more peptides of the invention can also be administered to a patient. This approach is described, for example, by Wolff et al., Science 247: 1465.
(1990) and US Pat. Nos. 5,580,859 and 5,589,46.
No. 6, No. 5,804,566, No. 5,739,118, No. 5,736.
, 524, 5,679,647, WO 98/04720, and below in more detail. Examples of DNA-based delivery technologies include "naked DNA" facilitated (bupivacaine, polymer, peptide mediated) delivery, cationic lipid complexes, and particle mediated ("gene gun") or pressure mediated delivery. (See, for example, US Pat. No. 5,922,687).

For therapeutic or prophylactic immunization applications, the peptides of this invention may also be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts such as vaccinia or foulpox. As an example of this approach, vaccinia virus is used as a vector to express nucleotide sequences encoding the peptides of the invention. Upon introduction into a tumor-bearing host, the recombinant vaccinia virus expresses an immunogenic peptide,
Thereby eliciting a host CTL and / or HTL response. Vaccinia vectors and methods useful in immunization protocols are described, for example, in US Pat. No. 4,722,8.
48. Another vector is BCG (Bacille Calm).
Ette Guerin). BCG vectors are described by Stover et al., Nat.
ure 351: 456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, such as adeno and adeno-associated viral vectors, retroviral vectors, Salmone.
The lla typhi vector, detoxified anthrax toxin vector, etc. will be apparent to those of skill in the art from the description herein.

In addition, vaccines according to the present invention include compositions of one or more claimed peptides. The peptides can be individually linked to their own carriers; or the peptides can be present as homopolymers or heteropolymers of active peptide units. Polymers have the advantage of increased immunological response, and different antigenic determinations of pathogenic organisms or tumor-associated peptides targeted for immune response when different peptide epitopes are used to produce the polymer. It has the additional ability to induce antibodies and / or CTLs that react with the agent. This composition
It may be a naturally occurring region of the antigen or it may be prepared, eg recombinantly or by chemical synthesis.

Carriers that can be used with the vaccines of the present invention are well known in the art of interest,
Eg thyroglobulin, albumin such as human serum albumin, tetanus toxin,
Examples thereof include poly L-lysine, poly amino acids such as poly L-glutamic acid, influenza, hepatitis B virus core protein and the like. The vaccine may contain a physiologically tolerable (ie, acceptable) diluent such as water or saline, preferably phosphate buffered saline. Vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide or alum are examples of substances well known in the art of interest. Moreover, as disclosed herein, CTL responses, e.g. tripalmitoyl -S- glyceryl Resid cysteinyl glycerylcysteinlyseryl - primed by conjugating peptides of the present invention to lipids, such as serine (P 3 _CSS) obtain.

Upon immunization with a peptide composition according to the present invention via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal or other suitable route, the host's immune system is Respond to the vaccine by producing large amounts of CTLs and / or HTLs specific for the antigens of As a result, the host becomes at least partially immune to subsequent infection, or at least partially resistant to the development of an ongoing chronic infection, or the antigen is tumor associated. If
It elicits at least some therapeutic benefit.

In some embodiments, it may be desirable to combine the class I peptide component with a component that induces or facilitates a neutralizing antibody and / or a helper T cell response against the target antigen of interest. Preferred embodiments of such compositions include class I and class II epitopes according to the invention. An alternative embodiment of such a composition provides a class I and / or class II epitope according to the invention with an HLA class II cross-reactive binding molecule such as PADRE ^™ (Epimumu).
ne, San Diego, CA) with molecules (eg, US Pat.
36, 142).

Vaccines of the invention may also include antigen presenting cells (APC) (eg dendritic cells (DC)).
) As a vehicle for presenting the peptides of the invention. The vaccine composition may be made in vitro after dendritic cell recruitment and harvesting, whereby dendritic cell packing occurs in vitro. For example, dendritic cells are transfected, eg with the minigene according to the invention, or pulsed with peptides. The dendritic cells can then be administered to a patient to elicit an immune response in vivo.

Vaccine compositions, either DNA- or peptide-based, can also be administered in vivo in combination with dendritic cell recruitment, whereby dendritic cell packing occurs in vivo.

Antigenic peptides are also used to elicit CTL and / or HTL responses ex vivo. The resulting CTL or HTL cells can be used to treat tumors in patients who do not respond to other conventional forms of therapy or to the therapeutic vaccine peptides or nucleic acids according to the present invention. Ex vivo CTL or HTL responses to specific tumor-associated antigens indicate that the patient's or genetically compatible CTL or HTL progenitor cells are associated with a source of antigen presenting cells such as dendritic cells, and appropriate immunogenic peptides Induced by incubating in tissue culture together. After a suitable incubation time (typically about 7-28 days) in which the progenitor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they can target their specific target cells (infection). Cells or tumor cells) (CTL) or promote destruction (HTL). Transfected dendritic cells can also be used as antigen presenting cells.

The vaccine compositions of the present invention may also be used in combination with other therapies used for cancer, in combination with immunological adjuvants such as IL-2, IL-12, GM-CSF and the like. obtain.

Preferably, when selecting an array of epitopes for inclusion in a polyepitope composition for use in a vaccine, or alternatively, included in a vaccine and / or encoded by a nucleic acid such as a minigene. The following principles are utilized to select the different epitopes that are targeted. Typical epitopes that can be utilized in vaccines to treat or prevent cancer are listed in Tables XXIII-XXVII and X.
XXI. To make the selection, each of the following principles is preferably balanced. Multiple epitopes incorporated into a given vaccine composition include
The epitope may, but need not be, contiguous in the sequence in the native antigen from which it is derived.

1. 3.) Upon administration, an epitope is selected that mimics the immune response observed to correlate with tumor clearance. For HLA class I, this includes 3-4 epitopes that are from at least one TAA. HLA class II
For, a similar rationale is used, again with 3-4 epitopes selected from at least one TAA (eg, Rosenberg et al.
． , Science 278: 1447-1450). Epitopes from one TAA can be used in combination with epitopes from one or more additional TAAs to target tumors with different expression patterns of frequently expressed TAA, eg, as described in Example 15. Vaccine can be produced. M selected as inclusion
The AGE2 / 3 epitope is preferably maintained between the two proteins.

2. 3.) An epitope is selected that has the requisite binding affinity established to correlate with immunogenicity. For HLA class I, the IC ₅₀ is 500 nM or less and for class II the IC ₅₀ is 1000 nM or less.

3. 3.) Sufficient supermotif-bearing peptides, or sufficient arrays of allele-specific motif-bearing peptides, to give broad population coverage are selected.
For example, it is preferable to have a population coverage of at least 80%. Monte Carlo analysis, a statistical evaluation known in the field of interest, can be used to assess the breadth or severity of population coverage.

4. 2.) When selecting epitopes from cancer-associated antigens, it is often useful to select analogs because patients may develop tolerance to the natural epitopes. When selecting an epitope relating to an infectious disease-related antigen, it is preferable to select a natural or similar epitope.

5. ) Of particular relevance are epitopes called "nested epitopes". Nested epitopes occur when at least two epitopes overlap in a given peptide sequence. Nested peptide sequences can include both HLA class I and HLA class II epitopes. When providing nested epitopes, the general purpose is to provide the maximum number of epitopes per sequence. Thus one aspect is to avoid providing peptides that are arbitrarily long than the amino terminus of the amino terminal epitope in the peptide and the carboxyl terminus of the carboxyl terminal epitope. When providing a multi-epitope sequence, such as a nested epitope, it is generally important to screen the sequence to ensure that it does not have pathological or other deleterious biological properties. is there.

6. 2.) When a polyepitopic protein is made or a minigene is produced, one objective is to produce the smallest peptide that encompasses the epitope of interest. This principle is similar if not similar to that used when selecting peptides containing nested peptides. However, with artificial polyepitope peptides, the goal of size minimization is balanced against the need to incorporate optional spacer sequences between the epitopes in the polyepitope protein. Spacer amino acid residues are used, for example, to avoid junctional epitopes (epitope that are recognized by the immune system, are not present in the target antigen, and are created only by artificial juxtaposition of the epitopes) or make cleavage between epitopes. Can be introduced to facilitate and thereby enhance epitope presentation. Binding epitopes are generally avoided. This is because the recipient can mount an immune response against the unnatural peptide. Of particular importance is the "dominant"
t) an epitope "which is a binding epitope. Dominant
3.) Epitopes can provoke a frenetic response in which immune responses to other epitopes are diminished or suppressed.

IV.K.1. Minigene Vaccine A number of different approaches are available that allow for the simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in the minigene are preferably selected according to the guidelines described in the previous section. A preferred means of administering a nucleic acid encoding a peptide of the invention uses a minigene construct encoding a peptide containing one or multiple epitopes of the invention.

The use of multi-epitope minigenes is described below, as well as in US copending application Ser. No. 09 / 311,784, Ishioka et al., J. Am. Immunol. 162:
3915-3925, 1999, An, L. et al. and Whitton, J.M. L.
J. Virol. 71: 2292, 1997, Thomson, S .; A. et
al. J. Immunol. 157: 822, 1996, Whitton,
J. L. et al. J. Virol. 67: 348, 1993, Hanke.
R.K. et al. , Vaccine 16: 426, 1998. For example, a supermotif and / or motif-bearing MAGE2 / 3 epitope derived from multiple regions of MAGE2 / 3, universal.
) A helper T cell epitope (eg PADRE ^™ (or a multi-HTL epitope from MAGE2 / 3)) and a multi-epitope DNA plasmid encoding an endoplasmic reticulum translation signal sequence can be engineered. In addition to the MAGE2 / 3 epitope, the vaccine also contains other TAA-derived epitopes.

The immunogenicity of the multi-epitope minigene is dependent on the CTL against the epitope being tested.
It can be tested in transgenic mice to assess the magnitude of the induced response. Furthermore, the in vivo immunogenicity of DNA-encoding epitopes can be correlated with the in vitro response of specific CTL lines to target cells transfected with DNA plasmids. Thus, these experiments may show that the minigene both 1) produces a CTL response and 2) induced CTLs serve to recognize cells expressing the encoded epitope.

For example, the amino acid sequence of an epitope may be reverse translated to produce a DNA sequence (minigene) encoding the selected epitope for expression in human cells. The human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences can be directly flanked when translated so that a contiguous polypeptide sequence is created. Additional elements can be incorporated into the minigene design to optimize expression and / or immunogenicity. Examples of amino acid sequences that can be back-translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, ubiquitin binding signal sequences and / or endoplasmic reticulum targeting signals. In addition, HLA presentation of CTL and HTL epitopes results in CTL or HT
It can be improved by the inclusion of synthetic (eg polyalanine) or naturally occurring flanking sequences flanking the L epitope. These large peptides containing the epitope (s) are within the scope of the invention.

Minigene sequences can be converted to DNA by assembling oligonucleotides encoding the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized under suitable conditions using well known techniques,
It can be phosphorylated, purified, and annealed. The ends of the oligonucleotides are ligated, for example using T4 DNA ligase. This synthetic minigene encoding the epitope polypeptide can then be cloned into the desired expression vector.

Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cell. Several vector elements are desirable, including: promoters with downstream cloning sites for minigene insertions, polyadenylation signals for efficient transcription termination, the E. coli origin of replication, and E. coli selectable markers (eg ampicillin or kanamycin resistance). ). For this purpose, a number of promoters may be used, such as the human cytomegalovirus (hCMV) promoter. For other suitable promoter sequences, see, eg, US Pat. Nos. 5,580,859 and 5,589,466.

Further vector modifications may be desirable to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression and one or more synthetic or naturally occurring introns may be incorporated into the transcribed region of the minigene. Inclusion of mRNA stabilizing and replicating sequences in mammalian cells can also be considered for increased minigene expression.

Once the expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate E. coli strain and DNA is prepared using standard techniques. Minigene orientation and D
The NA sequence, and all other elements contained in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells carrying the correct plasmid can be stored as a master cell bank and a working cell bank.

Furthermore, immunostimulatory sequences (ISS or CpG) appear to play a role in the immunogenicity of DNA vaccines. These sequences can be included in a vector outside the minigene coding sequence if it is desired to enhance immunogenicity.

In some embodiments, a 2-cistron expression vector that enables the production of both the minigene-encoded epitope and a second protein (included to enhance or reduce immunogenicity) is provided. Can be used. Examples of proteins or polypeptides that may beneficially enhance the immune response when co-expressed include cytokines (eg IL-2, IL-12, GM-CSF), cytokine inducing molecules (eg LeIF), costimulation. For molecular or HTL response, pan DR
(Pan-DR) binding protein (PADRE ^™ , Epimmune, San
Diego, CA). The helper (HTL) epitope is linked to the intracellular targeting signal and is expressed separately from the expressed CTL. This allows the induction of HTL epitopes in a different cell compartment than that of CTL epitopes. If required, this may facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. HTL or CTL
In contrast to induction, specific reduction of the immune response by co-expression of immunosuppressive molecules (eg TGF-β) may be beneficial in certain diseases.

A therapeutic amount of plasmid DNA is described in, for example, E. It can be produced by fermentation in E. coli followed by purification. Aliquots from the working cell bank are used to inoculate growth medium and grown to saturation in shake flasks or bioreactors according to well known techniques. Plasmid DNA may be prepared using standard bioseparation techniques (eg QIAG).
EN, Inc. (Solid phase anion exchange resin supplied by Valencia, California). If necessary, gel electrophoresis or other methods can be used to isolate supercoiled DNA from the open and linear forms.

Purified plasmid DNA can be prepared for injection with various formulations. The simplest of these is the reconstitution of lyophilized DNA in sterile phosphate buffered saline (PBS). This approach, known as "naked DNA", is commonly used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effect of minigene DNA vaccine, purified plasmid DNA
An alternative method for prescribing a can be desirable. Various methods have been described and new techniques may be available. Cationic lipids, glycolipids and fusogenic liposomes may also be used in the formulation (eg WO 93/24640; Mannino & Gould-Fogerite).
, Bio Technologies 6 (7): 682 (1988), U.S. Pat. No. 5,279,833, WO 91/06309 and Felgner, e.
t al. Pro. Natl. Acad. Sci. USA 84: 7413 (
(1987)). Furthermore, they are collectively referred to as protective, interactive, non-condensed compounds (PI
Peptides and compounds called NC) can also be complexed with purified plasmid DNA to affect variables (variables) such as stability, intramuscular dispersion or transport to specific organs or cell types.

Target cell sensitization can be used as a functional assay for the expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, plasmid DNA
Is introduced into a mammalian cell line suitable as a target for a standard CTL chromium release assay. The transfection method used will depend on the final formulation. Electroporation is used for "naked" DNA, while
Cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) is co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 ( ⁵¹ Cr) labeled and used as target cells for the epitope-specific CTL line. Cytolysis detected by ⁵¹ Cr release indicates both production of minigene-encoded CTL epitopes and HLA presentation. Expression of HTL epitopes can be assessed in a similar manner using assays to assess HTL activity.

In vivo immunogenicity is the second approach for functional testing of minigene DNA formulations. Transgenic mice expressing the appropriate human HLA protein are immunized with the DNA product. The dose and route of administration are formulation dependent (eg IM for DNA in PBS, intraperitoneal (IP) for lipid complexed DNA). Twenty-one days after immunization, spleen cells were harvested and restimulated for 1 week in the presence of peptides encoding each epitope tested. Then, for CTL effector cells, the assay was performed using standard techniques to peptide loaded ⁵¹ Cr.
Performed on cytolysis of labeled target cells. Lysis of HLA-sensitized target cells loaded with peptide epitopes corresponding to the minigene-coded epitopes demonstrates DNA vaccine function for in vivo induction of CTL. The immunogenicity of HTL epitopes is evaluated in transgenic mice in a similar manner.

Alternatively, the nucleic acid can be administered using ballistic delivery, for example as described in US Pat. No. 5,204,253. Using this technique, particles composed of DNA alone are administered. In a further alternative embodiment, the DNA is attached to particles, eg gold particles.

The minigene can also be delivered using other bacterial or viral delivery systems well known in the art of interest. For example, an expression construct encoding an epitope of the invention can be incorporated into a viral vector such as vaccinia.

Combination of IV.K.2.CTL Peptide with Helper Peptide A vaccine composition comprising a peptide of the present invention or an analog thereof has immunostimulatory activity and possesses desired attributes, such as serum half-life. It may be modified to provide improvements or to increase immunogenicity.

For example, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence containing at least one epitope capable of inducing a T helper cell response. The use of T helper epitopes with CTL epitopes to enhance immunogenicity is described, for example, in US copending application 08 / 820,360, No. 0.
8 / 197,484 and 08 / 464,234.

The CTL peptide can be linked directly to the T helper peptide, but often the CTL epitope / HTL epitope conjugate is linked by a spacer molecule. Spacers are typically composed of relatively small neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacer is typically selected from, for example, Ala, Gly, or other neutral spacers of non-polar amino acids or neutral polar amino acids. It is understood that the optional spacers need not be composed of identical residues and thus may be hetero- or homo-oligomers. When present, the spacer will typically be at least 1 or 2 residues, more usually 3-6 residues, and in some cases 10 or more residues. The CTL peptide epitope can be linked to the T helper peptide epitope at the amino or carboxy terminus of the CTL peptide, either directly or via a spacer. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated.

In certain embodiments, the T helper peptide is a T helper peptide that is present in the majority population.
It is recognized by helper cells. This can be accomplished by selecting amino acid sequences that bind to many, most, or all HLA class II molecules. These are known as "loosely HLA-restricted" or "blunt" T helper sequences. Examples of chaotic peptides include positions 830-
Tetanus toxin at position 843 (QYIKANSKFIGITE), positions 378-398.
Plasmodium at (DIEKKLAKMEKASSVFNVVNS)
falciparum (plasmodium falciparum) sporozoite perimeter (CS) protein and Strep at position 116 (GAVDSILGGVATYGAA)
Sequences from antigens such as the Tococcus 18 kD protein are included. Other examples are DR1-4-7 supermotif, or DR
Peptides that carry any of the three motifs are included.

Alternatively, non-naturally occurring amino acid sequences can be used to prepare synthetic peptides capable of stimulating T helper lymphocytes in a loosely HLA-restricted manner (eg WO 95/95). No. 07707). Pan-DR binding epitopes (eg PADRE ™, Epimmune, Inc., San Die).
These synthetic compounds called go, CA) are most preferably most HL
Designed to bind A-DR (human HLA class II) molecules. For example, a pan-DR binding epitope peptide having the formula: aKXVAAWTLKAAa, where "X" is cyclohexylalanine, phenylalanine or tyrosine and "a" is D-alanine or L-alanine, is most HLA- DR
T from most individuals, which bind to alleles and are independent of their HLA type
It was found to stimulate the response of helper lymphocytes. Alternatives to pan-DR binding epitopes can be provided in the form of nucleic acids encoding the epitope, including all "L" type natural amino acids.

HTL peptide epitopes may also be modified to alter their biological properties. For example, they may be modified to include their D-amino acids in order to increase their resistance to proteases and thus prolong their serum half-life, or they may increase their biological activity. It may be associated with other molecules such as lipids, proteins, carbohydrates and the like. For example, the T helper peptide can be attached at the amino or carboxyl terminus to one or more palmitic acid chains.

IV.K.3. Combination of CTL Peptide with a T Cell Priming Agent In some embodiments, at least one component that primes cytotoxic T lymphocytes is a pharmaceutical composition of the invention. It is desirable to include it inside. Lipids have been identified as agents capable of priming CTLs in vivo against viral antigens. For example, a palmitic acid residue is attached to the ε and α-amino groups of a lysine residue, and then one or more linking residues such as Gly, Gly-Gly.
-, Ser, Ser-Ser and the like are linked to the immunogenic peptide. The lipidated peptide can then be administered directly into micelles or particles, incorporated into liposomes, or emulsified in an adjuvant such as Freund's incomplete adjuvant. A preferred immunogenic composition comprises palmitic acid linked to the ε- and α-amino groups of Lys, which is linked to the amino terminus of the immunogenic peptide via a bond (eg Ser-Ser). .

[0204]   As another example of lipid priming of CTL response, E. coli lipoprotein, eg
For example, tripalmitoyl-S-glyceryl cysteinyl ceryl-serine (P_ThreeCSS
) Primes virus-specific CTL when covalently linked to the appropriate peptide.
Can be used (eg, Deres et al., Nature 342:
561, 1989). The peptide of the present invention is, for example, a CTL for a target antigen.
P, a lipopeptide administered to an individual to specifically prime the response _Three It can be bound to CSS. In addition, the induction of neutral antibodies is_ThreeCSS binding epitope
Can be primed with. Two such compositions more efficiently
Can be combined to elicit a cell-mediated response.

CTL and / or HTL peptides facilitate coupling of peptides to each other, coupling to carrier supports or larger peptides, modification of physical or chemical properties of peptides or oligopeptides, etc. Can also be modified by adding amino acids to the end of the peptide. Amino acids such as tyrosine, cysteine, lysine, glutamic acid or aspartic acid can be introduced at the C or N-terminus of peptides or oligopeptides, especially class I peptides. However, modification of the carboxyl terminus of the CTL epitope results in
It should be noted that in some cases the binding properties of the peptide may be altered. Furthermore, the peptide or oligopeptide sequence may be modified by terminal NH ₂ acylation, for example by alkanoyl (C ₁ -C ₂₀ ) or thioglycolyl acetylation, terminal carboxylamidation, such as ammonia, methylamine, etc. Can be different from. In some cases, these modifications may provide sites for attachment to supports or other molecules.

(DCs pulsed with IV.K.4.CTL and / or HTL peptides
Vaccine Compositions Comprising an Embodiment An embodiment of a vaccine composition of the invention comprises administering a cocktail of epitope-bearing peptides ex vivo from patient blood to PBMCs or isolated DCs therefrom. Agents to facilitate collection of DCs, eg Progenipoietin
(Trademark) (Monsanto, St. Louis, MO) or GM-CSF /
IL-4 can be used. The peptide is used to wash the DC after pulsing the DC and prior to reinfusion into the patient to remove unbound peptide. In this embodiment, the vaccine comprises peptide-pulsed DCs that present on their surface pulsed peptide epitopes that complex with HLA molecules.

DCs can be pulsed ex vivo with a cocktail of peptides,
CTLs, some of which are directed against one or more antigens of interest such as MAGE polypeptides, Her2 / neu, p53, CEA, prostate cancer associated antigens, etc.
Stimulate the response. Optionally, a helper T cell peptide, such as PADRE ™
Family molecules can be included to enhance the CTL response.

Administration of Vaccines for Therapeutic or Prophylactic Uses The peptides and formulations of the present invention and vaccine compositions of the present invention can be administered to mammals (
It is particularly useful for administration to humans) to treat and / or prevent cancer.
Vaccine compositions containing the peptides of the invention may be administered to patients with cancer or to individuals susceptible to or otherwise at risk for developing an immune response to TAA. .

In therapeutic applications, the peptide and / or nucleic acid compositions are used to elicit an effective CTL and / or HTL response to tumor antigens and to cure or at least partially cure symptoms and / or complications. It is administered to the patient in an amount sufficient to cause rest or delay. A suitable amount to accomplish this is
Defined as "therapeutically effective dose". The amount effective for this use depends on, for example, the particular composition being administered, the method of administration, the stage and severity of the disease being treated, the weight and general health of the patient, and the judgment of the prescribing physician.

The vaccine composition of the invention may also be used purely as a prophylactic agent. In general, the dose for initial prophylactic immunization is lower at about 1, 5, 50, 5
00 or 1,000 μg, and the higher value is about 10,000, 20,000
There is a unit dose range of 30,000 or 50,000 μg. Dose values for humans typically range from about 500 μg to about 50,000 μg for a body weight of 70 kilograms. This is followed by about 1.0 μg to about 50 of the peptide administered at defined intervals of about 4 to 6 weeks after the initial vaccine administration.
Boost doses of between 1,000 μg. The immunogenicity of a vaccine can be assessed by measuring the specific activity of CTL and HTL obtained from the blood of the patient.

As described above, the peptides containing the CTL and / or HTL epitopes of the present invention, when presented by an HLA molecule and contacted with a CTL or HTL specific for the epitope constituted by the peptides, produce an immune response. Induce. Peptide is CT
The manner in which it is contacted with L or HTL is not critical to the invention. For example, the peptide can be contacted with CTL or HTL in vivo or in vitro. If the contact occurs in vivo, the peptide itself may be administered to the patient, or other vehicle, such as a DNA vector encoding one or more peptides, a viral vector encoding the peptide (s), liposomes. Etc. can be used as described herein.

When the peptide is contacted in vitro, the vaccine agent is derived by pulsing cells, eg, antigen presenting cells in vitro with the peptide,
It may comprise a population of peptide-pulsed dendritic cells or TAA-specific CTL. Thereafter, such cell population is administered to the patient in a therapeutically effective amount.

With regard to pharmaceutical compositions, the immunogenic peptides of the invention, or the DNA's encoding them, will generally be administered to an individual already diagnosed with cancer. The peptides or the DNA's encoding them can be administered separately or as a fusion of one or more peptide sequences.

For therapeutic use, administration should generally begin at the first diagnosis of cancer.
This is followed by boosting the dose, at least until the symptoms are substantially alleviated, and for a period thereafter. Embodiments of vaccine compositions that are delivered to a patient (ie, examples include, but are not limited to, for example, peptide cocktails, polyepitope polypeptides, minigenes or TAA-specific CTLs), the stage of the disease. It can change depending on For example, a vaccine comprising TAA-specific CTLs may be more effective in killing tumor cells in patients with advanced disease than alternative embodiments.

The vaccine composition of the present invention may also be used therapeutically in combination with treatments such as surgery. One example is a situation where a patient has surgery to remove a primary tumor and then uses a vaccine to delay or prevent recurrence and / or metastasis.

If susceptible individuals, such as those who may be diagnosed as inheriting a genetic predisposition to the development of a particular type of tumor, are identified prior to the diagnosis of cancer, the composition targets them, and It may minimize the need for administration to a larger population.

The dose for primary therapeutic immunization will generally be at a lower value of about 1, 5, 50,
500 or 1,000 μg, with higher values of about 10,000, 20,000
There is a unit dose range of 0, 30,000, or 50,000 μg. Dose values for humans are typically about 500 μg to about 5 per 70 kg patient.
It is in the range of 10,000 μg. A booster dose of about 1.0 μg to about 50,000 μg peptide according to a booster regimen over a period of weeks to months measures the patient's response and the specific activity of CTLs and HTLs obtained from the patient's blood. Can be administered depending on the conditions as determined by

Thus, for treatment of cancer, typical dosages are in the ranges disclosed above, ie, lower values of about 1, 5, 50, 500 or 1,000 μg,
Higher value is about 10,000, 20,000, 30,000, or 50000
0 μg, preferably from about 500 μg to about 50.0 per 70 kg patient.
It is in the range of 00 μg. Established intervals after initial dose (eg 4 weeks to 6 months)
A booster dose may be required (as long as possible to effectively immunize an individual). Administration should be continued for at least until clinical symptoms or laboratory tests show that the tumor has been cleared or tumor cell overload can be substantially reduced, and thereafter. Dosage amount, route of administration, and dosing schedule are adjusted according to methodologies known in the art.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, intrathecal or localized administration. Preferably the pharmaceutical composition is administered parenterally, eg intravenously, subcutaneously, intracutaneously or intramuscularly. The invention thus provides a composition for parenteral administration which comprises a solution of the immunogenic peptide dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. Various aqueous carriers can be used, such as water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like.
These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solution is either packaged for ready-to-use or lyophilized and the lyophilized preparation is combined with the sterile solution prior to administration. The composition comprises pharmaceutically acceptable auxiliary substances which are required to be physiologically similar, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, etc., such as sodium acetate, lactic acid. It may contain sodium, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate and the like.

The concentration of the peptides of the invention in the pharmaceutical formulation can vary over a wide range, ie, less than about 0.1%, usually at least about 2% by weight, and up to 20% to 50% by weight or more. , Mainly according to the fluid volume, viscosity, etc., according to the particular dosage form chosen.

Human unit dose forms of peptide compositions are typically included in pharmaceutical compositions that include a human unit dose of an acceptable carrier, preferably an aqueous carrier, and for humans such It is administered in a volume of fluid known to one of ordinary skill in the art to be used for administration of the composition (eg, Remington's Pharmac.
eutical Sciences, 17th edition, A. et al. Gennaro (ed) Ma
ck Publishing Co. , Easton, Pennsylvani
a, 1985).

The peptides of the present invention are useful for targeting the peptides to specific tissues, such as lymphoid tissues, or selectively to infected cells, as well as the half-life of the peptide composition. Can also be administered via liposomes, which help to increase the Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered, either as part of a liposome, alone or with a molecule that binds to a receptor widely present among lymphoid cells, such as monoclonal antibodies that bind to the CD45 antigen. ,
Alternatively it can be incorporated with other therapeutic or immunogenic compositions. Thus, liposomes loaded with or modified with the desired peptides of the invention are directed to the site of lymphoid cells, where they then deliver the peptide composition. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids, and sterols such as cholesterol. The choice of lipid is generally derived by considering, for example, liposome size, acid lability and stability of liposomes in the bloodstream. To prepare liposomes, see, for example, Szoka et al., Ann. R
ev. Biophys. Bioeng. 9: 467 (1980) and US Pat. Nos. 4,235,871, 4,501,728, 4,837,028 and 5,019,369. Is available.

Ligands incorporated into liposomes for targeting cells of the immune system include, for example, antibodies or fragments thereof specific for the cell surface determinants of the desired immune system cells. Liposomal suspensions containing peptides can be administered intravenously, locally, topically, etc., among other doses, depending on the mode of administration, the peptide delivered and the stage of the disease treated.

For solid compositions, conventional non-toxic solid carriers are used, examples of which include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate. Etc. For oral administration, a pharmaceutically acceptable non-toxic composition may be formulated with a conventional excipient such as any of the above carriers, generally 10-95% active ingredient, ie one of the invention or It is formed by incorporating more peptides, as well as more preferably at concentrations of 25% to 75%.

For aerosol administration, the immunogenic peptides may be supplied in finely divided form, preferably with a surfactant and propellant. Typical percentages of peptides are 0.01% -20% by weight, preferably 1% -10%. Surfactants, of course, are non-toxic and are preferably soluble in the propellant. Typical examples of such substances are fatty acids containing 6 to 22 carbon atoms, such as caproic acid, octanoic acid, lauric acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, olesteric acid. Of oleic acid,
It is an ester or partial ester with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides, can be used. Surfactants may make up 0.1% to 20% by weight of the composition, preferably 0.25% to 5%. The balance of the composition is usually a propellant. If desired, a carrier can also be included, such as lecithin for intranasal delivery.

IV.M.HLA Expression: Implications for T Cell-based Immunotherapy Disease progression in cancer and infectious disease Dynamic interactions exist between host and disease in the setting of cancer and infectious disease. It is well recognized to do. In the setting of infectious diseases, it is well established that pathogens evolve during the disease. The strains that predominate in HIV infection differ from those associated with AIDS and late disease stages (NS vs. S strains).
It has long been hypothesized that the pathogen forms that are effective in establishing infection may differ from the most effective in terms of replication and chronicity.

Similarly, it is widely recognized that the pathological process by which an individual succumbs to neoplastic disease is complex. During the course of the disease, numerous changes occur in cancer cells. Tumors are partially associated with dysregulation of growth and differentiation, but also with maximizing their proliferative capacity, accumulating mutations that escape drug therapy and / or the body's immune surveillance. Neoplastic diseases result in the accumulation of several different biochemical changes in cancer cells as a function of disease progression. It also results in significant levels of intra- and inter-cancer heterogeneity, especially in late metastatic stages.

Well-known examples of cellular alterations that affect treatment outcome include the development of radiation or chemotherapy resistant tumors during the course of treatment. These examples parallel the emergence of drug resistant virus strains as a result of aggressive chemotherapy, such as the emergence of chronic HBV and HIV infections, and the current revival of drug resistant organisms that cause tuberculosis and malaria. Significant heterogeneity of response is due to other approaches to cancer therapy,
For example, it is also relevant to anti-angiogenic agents, passive antibody immunotherapy, and activated T cell-based immunotherapy. Thus, in view of such phenomena, epitopes from multiple disease associated antigens can be used in vaccines and therapeutics, thereby interfering with the ability of diseased cells to mutate and escape therapy.

Interaction between Disease and Immune System One of the major factors involved in dynamic interaction between host and disease is pathogen,
An immune response raised against infected or malignant cells. In many conditions, such immune responses control the disease. Expected studies of natural infections in several animal model systems and humans suggest that immune responses to pathogens may control the pathogen, prevent progression to severe disease, and / or eliminate the pathogen. A common theme is the requirement for multispecific T cell responses, where narrow-focused responses appear to be less effective. These observations provide guidance to those of skill in the art regarding embodiments of methods and compositions of the present invention that provide a broad spectrum of immune responses.

In the case of cancer, several observations have been observed showing that the immune response can influence neoplastic growth: First, it is restricted by MHC class I in a number of different animal models. Evidence that anti-tumor T cells that are capable of preventing or treating tumors.

[0231]   Second, promising results have been obtained from immunotherapy trials.

Third, the observations made during the course of natural disease correlated the type and composition of T cell infiltration within tumors with positive clinical outcome (Coulie PG et al., Antitumor).
immunity at work in a melanoma patie
nt In Advances in Cancer Research, 21
3-242, 1999).

Finally, tumors are generally capable of causing mutations, thereby altering their immunological recognition. For example, the presence of monospecific CTL also correlated with the control of tumor growth until antigen loss occurred (Riker A et al. Immune.
selection after antigen-specific im
munotherapy of melanoma Surgery, Aug;
126 (2): 112-20, 1999; Marchand M et al., Tumor.
regressions observed in patients wi
th metastatic melanoma treated with
an antigenic peptide encoded by gene
MAGE-3 and presented by HLA-A1 Int
． J. Cancer 80 (2): 219-30, Jan. 18, 1999).
Similarly, loss of β2 microglobulin was detected in the 5/13 strain established from melanoma patients after receiving immunotherapy with NCI (Restifo NP et al., Los.
so of functional Beta2-microglobulin
in metastatic melanomas from five pa
students receiving immunotherapy Journal
al of the National Cancer Institute,
Vol. 88 (2), 100-108, Jan. 1996). It has long been recognized that HLA class I is frequently altered in various tumor types. This has led to the hypothesis that this phenomenon may reflect the immune pressure exerted on the tumor by class I restricted CTL. The extent and extent of alterations in HLA class I expression appear to reflect past immune pressure and may also have prognostic value (van Du
inen SG et al., Level of HLA antigens in lo.
corregal metastases and clinical c
source of the disease in patients wit
h melanoma Cancer Research 48, 1019-1
025, Feb. 1988; Moller P et al., Fluence of.
major histocompatibility complex cla
ss I and II antigens on survival in
collective carcinoma Cancer Research
51, 729-736, Jan. 1991). Taken together, these observations provide the basis for immunotherapy of cancer and infectious diseases, and suggest that effective strategies should account for a series of complex pathological changes associated with disease. To do.

Changes in the Three Main Types of HLA Expression in Tumors and Their Functional Implications The levels and patterns of HLA class I antigen expression in tumors have been studied and studied in a number of different tumor types. Changes have been reported in all types of tumors. The molecular mechanisms underlying the HLA class I alterations proved to be totally foreign. They include alterations in the TAP / processing pathway, mutations in β2-microglobulin and specific HLA heavy chains, alterations in regulatory elements controlling class I expression, and loss of whole chromosomal compartments. There are several reviews on this subject (eg Garrido F, et al. Natural hist.
ory of HLA expression dur ing tumour
development Immunology Today 14 (10): 491
-499,1993; Kaklamanis L et al., Loss of HLA.
class-I alleles, heavy chains and β2-
microglobulin in collective cancer I
nt. J. Cancer, 51 (3): 379-85, May 28, 1992.
reference). There are three main types of HLA class I alterations (complete loss, allele-specific loss and reduced expression). The functional meaning of each change is considered separately.

Complete Loss of HLA Expression Complete loss of HLA expression may be due to a variety of different molecular mechanisms. They are reviewed in the following references (Algarra I et al., The HL.
A crossroad in tumor immunology Huma
n Immunology 61, 65-73, 2000; Browning.
M et al., Mechanisms of loss of HLA class I
expression on collective tumour cell
s Tissue Antigens 47: 364-371, 1996; Fe
rrone S et al., Loss of HLA class I antigen
s by melanoma cells: molecular mechan
isms, functional signature and cli
natural relevance Immunology Today, 16 (
10): 487-494, 1995; Garrido F et al., Natural.
history of HLA expression burning tum
our development Immunology Today 14 (
10): 491-499, 1993; Tait, BD, HLA Class I.
expression on human cancer cells: Im
applications for effective immunothera
py Hum Immunol 61, 158-165, 2000). With respect to function, this type of change has several important implications.

The complete absence of class I expression precludes CTL recognition of their tumor cells, whereas loss of HLA class I also sensitizes tumor cells to lysis from NK cells (Ohmnacht). , GA et al., Heterogeneity in
expression of human leukocyte antig
ens and melanoma-associated antigens
in advanced melanoma J Cellular Phy
s 182: 332-338, 2000; Liunggren HG et al., Hos.
t resistance directed selective ag
ainst H-2 deficient lymphoma variant
s: Analysis of the mechanism J.S. Exp. Me
d. , Dec 1: 162 (6): 1745-59, 1985; Mio M et al., Reduction in sustainability to nature.
ral killer cell-mediated lysis of hu
man FO-1 melanoma cells after induce
ion of HLA class I antigen expressio
n by transfection with B2m gene J. Cl
in. Invest. 88 (1): 282-9, Jul 1991: Schr.
ier PI et al., Relationship between myconc
gene activation and MHC class I exp
reaction Adv. Cancer Res. , 60: 181-246,1
993).

Complementary interactions between loss of HLA expression and acquisition of NK sensitivity were reported by Couli.
e and collaborators (Coulie, PG, et al.
y at work in a melanoma patient. In A
dvances in Cancer Research, 213-242, 1
999), a classical study describing the evolution of a patient's immune response over the course of several years. Due to the increased susceptibility to NK lysis, approaches that result in stimulation of innate immunity in general, and in particular NK activity, are expected to have particular significance. One example of such an approach is to use various hematopoietic growth factors such as Flt3.
Induction of large numbers of dendritic cells (DC) by ligand or ProGP. The rationale for this approach lies in the well-known fact that dendritic cells produce large amounts of IL-12, which is one of the most potent stimulators of innate immunity and especially NK activity. Alternatively, IL-12 is administered directly or as a nucleic acid encoding it. In this regard, it is interesting to note that Flt3 ligand treatment results in transient tumor regression in a class I-negative prostate murine cancer model (C
iavarra RP et al., Flt3-Ligand induces tran.
sient tumor regression in an ectopic
treatment model of major histocompa
stability complex-negative prostate c
cancer Cancer Res. 60: 2081-84, 2000). In this context, the specific anti-tumor vaccines of the present invention synergize with these types of hematopoietic growth factors to promote both CTL and NK cell responses, thereby producing mutations and thereby effective treatment. Clearly impair the ability of cells to escape. Thus, embodiments of the present invention include the compositions of the present invention together with methods or compositions that increase the functional activity or number of NK cells. Such embodiments can include protocols that provide the compositions of the invention subsequently in an NK-inducible manner or at the same time in an NK-inducible manner.

Second, although complete loss of HLA often occurs only in a fraction of tumor cells,
On the other hand, the rest of the tumor cells continue to show normal expression. In terms of function, tumors are still partially challenged directly from the CTL response, with HLA-deficient parts of the cell remaining N
Receive a K response. Even when only the CTL response is used, disruption of the tumor's HLA-expressing fraction dramatically affects survival time and quality of life.

It should also be noted that in the case of heterologous HLA expression, both normal HLA expression as well as defective cells are predicted to be susceptible to immune destruction based on the "bystander effect". Such effects have been demonstrated, for example, in studies by Rosendahl and coworkers who investigated the in vivo mechanism of action of antibody-targeted superantigens (Rosendahl A et al., Perforin and IFN-gamm.
a are involved in the entity effe
cts of antibody-targeted superantige
ns J. Immunol. 160 (11): 5309-13, June 1,
1998). It is understood that the bystander effect is mediated, for example, by CTL-derived cytokines that act on HLA-bearing target cells, whereby the cytokines are present in the environment of other diseased cells that are concomitantly killed.

Allele-Specific Loss One of the most common types of class I molecule alteration is the selective loss of certain alleles in individuals heterozygous for HLA. Allele-specific changes are immunodominant (immuno) restricted by a single HLA restriction element.
It may reflect tumor fit to the immune pressure exerted by the dominant) response. This type of alteration causes tumors to retain class I expression and thus escapes NK cell recognition, but is still susceptible to CTL-based vaccines of the present invention that contain epitopes corresponding to the remaining HLA types. Therefore, a practical solution for overcoming the possible hurdles of allele-specific loss relies on the induction of multiple specific responses. Inclusion of multiple disease-associated antigens in the vaccines of the present invention is just as likely to prevent multiple mutations that result in loss of specific disease antigens.
Targeting specificity and multiple disease-associated antigens simultaneously prevents disease escape by allele-specific loss.

Reduced expression (allele-specific or non-specific) The sensitivity of effector CTL has been documented for many years (Brwer, RC et al., Minimal requirements for peptide mede).
differentiated activation of CD8 + CTL Mol. Imm
unol. , 31: 1285-93, 1994; Chrisnick, ET.
Et al., Low numbers of MHC class I-peptide
complexes required to trigger a T c
ell response Nature 352: 67-70, 1991; S
Ykulev, Y et al., Evidence that a single pep
side-MHC complex on a target cell ca
n elicit cytolytic T cell response I
Mmunity, 4 (6): 565-71, June 1996). Even a single peptide / MHC complex can cause tumor cell lysis and release antitumor lymphokines. The biological implications of possible tumor escape from reduced HLA expression and immune recognition are:
I'm not completely sure. Nevertheless, it has been demonstrated that CTL recognition of as few as one MHC / peptide complex is sufficient to guide tumor cell lysis.

Furthermore, the expression of HLA is expressed in γI, which is commonly secreted by the effector CTL.
It is generally observed that it can be upregulated by FN. Further HLA
Class I expression can be induced in vivo by both α and βIFN (Ha
lloran et al., Local T cell responses induc.
e widespread MHC expression, J Immuno
l 148: 3837, 1992; Pestka, S. et al., Interferon.
s and their actions Annu. Rev. Biochem
． 56: 727-77, 1987). Conversely, reduced levels of HLA class I expression also make cells more sensitive to NK lysis.

Regarding γIFN, Torres et al. (Torres, MJ et al., Loss o.
f an HLA haplotype in pancreas cance
r issue and it's responding tumor
Derived cell line. Tissue Antigens 4
7: 372-81, 1996), unless there is an overall loss of halotypes.
It is noted that HLA expression is upregulated by γIFN in pancreatic cancer. Similarly, Rees and Mian noted that allelic deletions and losses can be at least partially restored by cytokines such as IFN-γ (Rees, R et al., Selective MHC express.
ion in tumours modulas adapt an
d innate antitumour response Cancer
Immunol Immunoother 48: 374-81, 1999).
It was also noted that IFN-γ treatment resulted in upregulation of class I molecules in the majority of cases studied (Browning M et al., Mechani.
sms of loss of HLA class I expressio
non on color tumor cells, Tissue A
ntigens 47: 364-371, 1996). Kaklamakis et al. Also suggested that adjuvant immunotherapy with IFN-γ may be beneficial in the case of HLA class I negative tumors (Kaklamanis L, Los.
s of transporter in antigen processi
ng 1 transport protein and major his
tocompatibility complexity class I mole
cures in metastatic versus primary b
east cancer, Cancer Research 55: 5191
-94, November 1995). IFN-γ production is induced and self-amplified by local inflammation / immunization (Halloran et al., Local T cel).
l responses induce widespread MHC ex
compression, J.P. It is important to emphasize that Immunol 148: 3837, 1992), results in a large increase in MHC expression even at sites remote from the site of inflammation.

Finally, studies have demonstrated that reducing HLA expression may render tumor cells more sensitive to NK lysis (Ohnmachit, GA et al., Hete.
rogeneity in expression of human leu
kocyte antigens and melanoma-associa
ted antigens in advanced melanoma J
Cellular Phys 182: 332-338, 2000; Lung.
gren HG et al., Host resistance directed se
lectivelygain H-2 defensive lymp
Homa variants: Analysis of the mechan
ism J. Exp. Med. , 162 (6): 1745-59, Decemb.
er 1, 1985; Malo M et al., Reduction in Sustain.
ptibility to natural killer cell-med
iated lysis of human FO-1 melanoma c
ells after induction of HLA class I
antigen expression by transfection w
ith β2m gene J. Clin. Invest. 88 (1): 282
-9, July 1991: Schlier PI et al., Relationship.
p between myconcogene activation an
d MHC class I expression Adv. Cancer
Res. , 60: 181-246, 1993). If HLA expression is reduced, CT
A minimum level of HLA expression that allows resistance to NK activity is selected if it benefits the tumor to promote L escape, but sensitizes the tumor to NK lysis (Garido F et al. Implications for i
mmunosurveillance of alternated HLA cla
ss phenotypes in human tumours Imm
unol Today 18 (2): 89-96, February 1997.
). Thus, the therapeutic compositions or methods of the present invention sensitize tumors to CTL destruction in conjunction with treatment to upregulate HLA expression and / or treatment with high affinity T cells.

Frequency of changes in HLA expression The frequency of changes in class I expression has been the subject of numerous studies (Algarr.
a I et al., The HLA crossroad in tumor immu.
topology Human Immunology 61,65-73,200
0). Rees and Mian estimate that allele loss occurs in 3-20% of tumors and allele loss occurs in 15-50% of tumors. 2 for each cell
It should be noted that there are two separate sets of class I genes, each of which carries one HLA-A and one HLA-B locus. Thus, a fully heterozygous individual has two different HLA-A molecules and two different HL.
It carries an AB molecule. Therefore, the actual frequency of loss for any specific allele can be as low as one-quarter of the total frequency. They also noted that, in general, a gradient of expression exists between normal cells, primary tumors and tumor metastases. Natali and collaborators (Natali PG et al., Selective
changes in expression of HLA class
I polymorphic detergents in human
solid tumors PNAS USA 86: 6719-6723, S.
In a study from Eptember 1989) solid tumors were examined with the W6 / 32 antibody for global HLA expression and for allele-specific expression of the A2 antigen as assessed by use of the BB7.2 antibody. . 1 tumor sample
Obtained from primary cancer or metastasis for 3 different tumor types, scored negative if less than 20%, reduced if in the range 30-80%, and normal if greater than 80% . All tumors, both primary and metastatic, were HL with W6 / 32.
It was A positive. Regarding A2 expression, a reduction was observed in 16.1% of cases,
2 was scored as undetected in 39.4% of cases. Garrido and collaborators (Garido F et al., Natural history of HLA
expression duration tour development
Immunol Today 14 (10): 491-99, 1993),
It was emphasized that HLA changes appear to occur at specific stages of progression from benign to most aggressive. Jiminez et al. (Jiminez P et al., Microsat
ellite instability analysis in tumor
s with different mechanisms for tota
l loss of HLA expression, Cancer Immu
Mol Immunother 48: 684-90, 2000) analyzed 118 different tumors (68 colorectal cancers, 34 laryngeal cancers and 16 melanomas).
. Frequencies reported for overall loss of HLA expression were colon cancer 11%, melanoma 1
8% and laryngeal cancer 13%. Thus HLA class I expression is altered in a significant fraction of tumor types, presumably as a reflection of immune pressure or merely as a reflection of the accumulation of pathological and diseased cell changes.

Immunotherapy in HLA Loss Conditions The majority of tumors express HLA class I and tend to find more severe changes in late stages and in poorly differentiated tumors. This pattern holds promise in the context of immunotherapy, especially as follows: 1) the relative insensitivity of immunohistochemical techniques may underestimate HLA expression in tumors; 2) class I. Expression can be induced in tumor cells as a result of local inflammation and lymphokine release; and 3) Class I negative cells are susceptible to lysis by NK cells.

Accordingly, various embodiments of the present invention are particularly useful in the context of neoplastic disease.
It can be selected in view of the fact that there may be some loss of A molecules. For example, a treating physician may assay a patient's tumor to establish if HLA is expressed. If a percentage of tumor cells do not express class I HLA, then embodiments of the invention that include methods or compositions that elicit an NK cell response can be used. As described herein, such NK induction methods or compositions may include FIt3 ligands or ProGPs that promote dendritic cell recruitment. The rationale is that dendritic cells produce large amounts of IL-12. I
L-12 can be administered directly in either amino acid or nucleic acid form. It should be noted that the compositions of the present invention can be administered concurrently with the NK cell-inducing composition, or these compositions can be administered sequentially.

In the context of allele-specific HLA loss, tumors retained class I expression and thus escaped NK cell recognition and were still susceptible to CTL-based vaccines of the invention containing epitopes corresponding to the rest of the HLA types. Can be. This concept here is similar to embodiments of the invention that include multiple disease antigens to protect against mutations that result in the loss of specific antigens. Therefore, multiple HLA specificities and multiple epitopes from multiple disease-associated antigens can be targeted simultaneously to prevent allele-specific loss, as well as tumor escape due to loss of disease-associated antigens.
Further, embodiments of the present invention may be combined with alternative therapeutic compositions and methods. Such alternative compositions and methods include, but are not limited to, compositions / methods that induce radiation, cytotoxic agents and / or humoral antibody responses.

Furthermore, the expression of HLA is expressed in γI, which is commonly secreted by the effector CTL.
What can be upregulated by FN, and HLA class I expression is α and βI
It was observed that it could be induced in vivo by both FNs. Thus, embodiments of the present invention include α, β and / or γI to facilitate upregulation of HLA.
It may also include FN.

IV.N. Grace period from side-effect inducing therapy: “planned treatment interruption or drug holiday”) Infected with a pathogen and initially treated with a therapeutic regimen that reduces the pathogen load Recent evidence has shown that patients were able to maintain a reduced pathogen burden even when they were out of the treatment regimen, ie during the "drug holiday" (Rosenberg.
, E. Et al., Immune control of HIV-1 aftere.
only treatment of acute injection Na
pure 407: 523-26, Sept. 28, 2000). As will be appreciated by those in the art, numerous therapeutic regimens for both pathogens and cancers have
Often has serious side effects. During drug holidays, the patient's immune system suppresses the disease. The methods for using the compositions of the invention are used in the pharmaceutical holiday context against cancer and pathogenic infections.

For the treatment of infections, the compositions of the invention are administered concurrently with standard therapy, unless the therapy is specifically immunosuppressive. During this period, the patient's immune system is directed to elicit a response to the epitope contained by the composition of the invention. Upon departure from treatment with side effects, patients are primed to respond to infectious agents when the pathogen load begins to increase. The compositions of the present invention may be provided during drug holidays as well.

For cancer patients, many therapies are immunosuppressive. Thus, if remission is achieved or a patient is identified as refractory to standard therapy and then falls off immunosuppressive therapy, the compositions of the invention are administered. Thus, as the patient's immune system reconstitutes, valuable immunogens are simultaneously directed at the cancer. The compositions of the invention may optionally be administered concurrently with an immunosuppressive regimen.

IV.0. Kits The peptide and nucleic acid compositions of the invention may be provided in the form of kits with instructions for vaccine administration. Typically, the kit comprises the desired peptide composition (preferably in unit dosage form) in a container and instructions for administration. An alternative kit comprises a minigene construct (preferably in unit dose form) containing the desired nucleic acid of the invention in a container, together with instructions for administration. Lymphokines such as IL-2 or IL-12 can also be included in the kit. Other kit components that may be desired include, for example, sterile syringes, booster medications, and other desired excipients.

IV.P. Overview Epitopes according to the present invention have been successfully used to induce an immune response.
Immune responses using these epitopes were induced by administering these epitopes in various forms. These epitopes were administered as peptides, as nucleic acids, and as viral vectors containing nucleic acids encoding the epitopes of the invention. In administration of peptide-based epitope forms, the immune response is through direct loading of the epitope on empty HLA molecules expressed on cells and through internalization of this epitope and processing through the HLA type I pathway. Induced; in each case, HLA molecules expressing this epitope could then interact and induce a CTL response. Peptides can be delivered directly or using agents such as liposomes. These are also provided by ballistic delivery.
), Where the peptide is typically in crystalline form.
When DNA is used to induce an immune response, the DNA may be naked DNA (generally a dosage range of about 1-5 μg) or via gun-type “gene gun” delivery (typically about Dosage range of 10-100 μg). DNA can be delivered in various conformations (eg, linear, circular, etc.). Various viral vectors containing a nucleic acid encoding an epitope according to the present invention have also been used successfully.

Thus, the composition according to the invention exists in several forms. Embodiments of each of these compositional forms according to the invention have been successfully used to induce an immune response.

One composition according to the invention comprises a plurality of peptides. The plurality of peptides or cocktails of peptides are generally mixed with one or more pharmaceutically acceptable excipients. The peptide cocktail may contain multiple copies of the same peptide,
Or it may comprise a mixture of peptides. Peptides can be analogs of naturally occurring epitopes. Peptides can include artificial amino acids and / or chemical modifications (eg, lipidation; addition of surface-active molecules such as acetylation, glycosylation, biotinylation, phosphorylation). The peptide can be a CTL epitope or an HTL epitope. In a preferred embodiment, the peptide cocktail comprises a plurality of different CTL epitopes and at least one HTL epitope. HTL
Epitopes may be natural or non-natural (eg, PADRE®, Epim).
mune Inc. , San Diego, CA). The number of different epitopes in embodiments of the invention is generally an integer from 1 to 200.
unit integer) (for example, 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80
, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92
, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 10
3, 104, 105, 106, 107, 108, 109, 110, 111, 11
2, 113, 114, 115, 116, 117, 118, 119, 120, 12
1, 122, 123, 124, 125, 126, 127, 128, 129, 13
0, 131, 132, 133, 134, 135, 136, 137, 138, 13
9, 140, 141, 142, 143, 144, 145, 146, 147, 14
8, 149, 150, 151, 152, 153, 154, 155, 156, 15
7, 158, 159, 160, 161, 162, 163, 164, 165, 16
6, 167, 168, 169, 170, 171, 172, 173, 174, 17
5, 176, 177, 178, 179, 180, 181, 182, 183, 18
4, 185, 186, 187, 188, 189, 190, 191, 192, 19
3, 194, 195, 196, 197, 198, 199, 200).

A further embodiment of the composition according to the invention comprises a polypeptide multi-epitope construct (ie a polyepitope peptide). Polyepitope peptides according to the present invention are prepared by use of techniques well known in the art. By using these known techniques, the epitopes according to the invention are linked to each other. Polyepitope peptides can be linear or non-linear (eg, multivalent). These polyepitope constructs may include artificial amino acids, spacing or spacer amino acids, flanking amino acids, or chemical modifications between flanking epitope units. Polyepitope constructs can be heteropolymers or homopolymers. Polyepitope constructs are generally any integer amount between 2 and 200 (eg, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 1
7, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 2
9, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 4
1, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 5
3, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 6
5, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 7
7, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 8
9, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 etc.). The polyepitope construct comprises CTL epitopes and / or
Or it may include an HTL epitope. One or more epitopes in the construct can be modified, eg, by the addition of a surfactant (eg, lipid), or chemically modified (eg, acetylated, etc.). Furthermore, the linkage in the multi-epitope construct may be other than a peptide bond (eg, covalent bond, ester or ether bond, disulfide bond, hydrogen bond, ionic bond, etc.).

Alternatively, the composition according to the invention has homology to the native sequence (
That is, a sequence, sequence, stretch (s) of corresponding (or contiguous) amino acids.
trech) is included. This stretch of amino acids is, according to the invention, HL when cleaved or isolated from a longer series of amino acids.
It comprises at least one subsequence of amino acids, which functions as an AI type epitope or an HLA type II epitope. In this embodiment, the peptide sequence is modified to be a construct as defined herein by using a number of techniques known or provided in the art. Polyepitope constructs are 70-100% (eg 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
96, 97, 98, 99, or 100%) may include homology to the native sequence in any integer increment.

A further embodiment of the composition according to the invention is an antigen presenting cell, which comprises one or more epitopes according to the invention. Antigen presenting cells can be "professional" antigen presenting cells (eg, dendritic cells). Antigen presenting cells may comprise an epitope of the invention by any means known in the art or determined by the art. Such means include, by nucleic acid administration, such as gun-based nucleic acid delivery, or other techniques for administration of nucleic acids (vector-based (
Pulsed dendritic cells with one or more individual epitopes or one or more peptides containing multiple epitopes.

A further embodiment of the composition according to the invention comprises a nucleic acid encoding one or more peptides according to the invention, or a nucleic acid encoding a polyepitope peptide according to the invention. As will be appreciated by those in the art, different nucleic acid compositions encode the same peptide due to the degeneracy of the genetic code. Each of these nucleic acid compositions is included within the scope of the invention. This embodiment of the invention comprises DNA or RNA, and in particular embodiments a combination of DNA and RNA. It is understood that any composition comprising a nucleic acid encoding a peptide according to the invention or any other peptide-based composition according to the invention is within the scope of the invention.

The peptide-based forms of the present invention (as well as the nucleic acids encoding them) include analogs of the epitopes of the present invention that are already known in the art or are made using principles that become known. It is understood to get. The principles of analogization are now known in the art and disclosed herein; further, the analogization principle (heteroclitic analogization) is a co-pending application filed January 6, 1999. Application serial number U. S. S. N. No. 09 / 226,775. Generally, the compositions of the invention are isolated or purified.

The invention will be described in more detail by means of specific examples. The following examples are provided for purposes of illustration and are not intended to limit the invention in any manner. Those of ordinary skill in the art will readily recognize a variety of non-critical parameters that may be changed or modified in order to obtain alternative embodiments in accordance with the present invention.

V. Examples The following examples illustrate the identification, selection, and use of immunogenic class I and class II peptide epitopes for inclusion in vaccine compositions.

Example 1. HLA Class I and Class II Binding Assays The following examples of peptides that bind to HLA molecules are HLA class I and class I.
3 shows quantification of binding affinity of I peptide. Binding assays can be performed with peptides with or without motifs.

HLA class I and class II binding assays using purified HLA molecules were performed using
It was performed according to the disclosed protocol (eg PCT Publication WO 94/20127;
Sidney et al., Current Protocols in Immunol.
Ogy 18.3.1 (1998); Sidney, et al., J. Am. Immunol.
154: 247 (1995); Sette, et al., Mol. Immunol. 31
: 813 (1994)). Briefly, purified MHC molecules (5-500 nM) were incubated with various unlabeled peptide inhibitors and 1-10 nM ¹²⁵ I radiolabeled probe peptide described above. After incubation, the MHC peptide complex was separated from free peptide by gel filtration and the fraction of bound peptide determined. Typically, in a preliminary experiment, each MHC preparation was
Titration was performed in the presence of a fixed amount of radiolabeled peptide to determine the concentration of HLA required to bind 10-20% of total radioactivity. All subsequent inhibition and direct binding assays were performed with these HLA concentrations.

Under these conditions of [label] <[HLA] and IC ₅₀ ≧ [HLA], the measured IC ₅₀ value is a good approximation of the true K _D value. Peptide inhibitors are typically tested at concentrations ranging from 120 μg / ml to 1.2 ng / ml and in 2-4 completely independent experiments. The IC ₅₀ of the positive control for inhibition was tested for each peptide tested (typically an unlabeled version of the radiolabeled probe peptide) to allow comparison of data from different experiments. By dividing by the IC ₅₀ of
Relative binding numbers were calculated for each peptide. Edit relative binding values for database purposes and comparisons between experiments. These values can then be converted to IC ₅₀ nM values by dividing the positive control IC ₅₀ nM for inhibition by the relative binding of the peptide of interest. This data compilation method proved to be the most accurate and consistent for comparing peptides tested on different days or different lots of purified MHC.

The binding assay outlined above can be used, for example, to analyze supermotif and / or motif-bearing epitopes as described in Example 2.

Example 2. Identification of HLA Supermotifs and CTL Candidate Epitopes Bearing Motif The vaccine composition of the present invention uses multiple H's to achieve broad population coverage.
Multiple epitopes can be included, including the LA supermotif or the HLA motif. This example illustrates the identification of supermotifs and motif-bearing epitopes for inclusion in such vaccine compositions. Population coverage calculations were performed using the strategy described below.

Computer Search and Algorithms for Identification of Supermotif and / or Motif-bearing Epitopes The searches performed to identify motif-bearing peptide sequences in Examples 2 and 5 were tumor-associated antigen MAGE2 / Protein sequence data for 3 was used.

A computer search for epitopes bearing HLA class I or class II supermotifs or motifs was performed as follows. All translated protein sequences are searched for in text strings.
search) software program (eg MotifSearch 1.
4 (D. Brown, Sna Diego)) and analyzed using the appropriate HL
A potential peptide sequence containing an A-binding motif was identified; an alternative program
It is readily made in accordance with the information in the art, taking into account the motifs / supermotifs disclosed herein. Moreover, such calculations can be done in mind. The identified A2, A3 and DR supermotif sequences were scored using a polynomial algorithm to predict their ability to bind to a particular HLA class I or class II molecule. These polynomial algorithms consider both extension and refinement motifs (ie, taking into account the effects of different amino acids at different positions), and the overall affinity of the peptide-HLA molecular interaction (ie, ΔG). Is essentially based on the fact that can be approximated as a linear polynomial function of the following type: “ΔG” = a _1i × a _2i × a _3i . ． ． ． ． ． _{Xa ni} Here, _aji is a predetermined position (i) along the sequence of a peptide of n amino acids.
Is a coefficient representing the effect of the presence of a given amino acid (j) in. An important assumption of this method is that the effects at each position are essentially independent of each other (ie, independent attachment of individual side chains). If residue j occurs at position i of the peptide, it is assumed that a certain amount of j _i contributes to the free energy of binding of this peptide regardless of the rest of the sequence of the peptide. This hypothesis is substantiated by studies from our laboratory demonstrating that the peptide binds to MHC and is recognized by T cells in a substantially extended conformation. Data omitted in the book).

A method of deriving a specific algorithm coefficient is described by Gulukota et al. Mol. B
iol. 267: 1258-126, 1997; (Sidne
y et al., Human Immunol. 45: 79-93, 1996; and So.
Uthwood et al. Immunol. 160: 3363-3373, 199
See also 8). Briefly, for all i positions, the geometric mean of the average relative binding (ARB) of all peptides bearing j as well as anchor and non-anchor was calculated for the rest of this group, and j _i Used as an estimate of. For Class II peptides, if multiple alignments are possible, only the highest scoring sequence is used, following the iterative procedure. To calculate the algorithm score for a given peptide in the test set, the ARB value corresponding to the sequence of that peptide is
To multiply. If the product exceeds the selected threshold, the peptide is predicted to bind. Appropriate thresholds are selected as a function of the desired degree of prediction stringency.

Selection of HLA-A2 Supertype Cross-Reactive Peptides The complete protein sequence from MAGE2 / 3 was scanned using motif identification software to find the 8-mer containing the HLA-A2 supermotif primary anchor specificity. The 9-mer, 10-mer and 11-mer sequences were identified.

A total of 285 HLA-A2 supermotif positive sequences were labeled with MAGE2 and / or
Or identified within the MAGE3 protein sequence. Of these, the corresponding 137
Peptides and synthesized in vitro purified HLA-A ^* 0201 molecule (H
LA-A ^* 0201 was tested for their ability to bind prototypical A2 supertype molecules). 19 of these peptides are 500
It bound to A ^* 0201 with an IC ₅₀ value of less than nM.

Subsequently, the 19 A ^* 0201 binding peptides were added to additional A2 supertype molecules (A ^* 0202, A ^* 0203, A ^* 0206, and A ^* 6802).
Were tested for their ability to bind to. As shown in Table XXII, 17 of the 19 peptides were found to be A2 supertype cross-reactive binders, which out of the 5 A2 supertype alleles tested. Bind at least three.

Selection of HLA-A3 Supermotif-Containing Epitopes The protein sequences scanned above were also analyzed for HLA-A3 using a method similar to that performed to identify HLA-A2 supermotif-bearing epitopes.
Test for the presence of peptides with supermotif primary anchors.

[0276]   Then, peptides corresponding to these supermotif-bearing sequences are synthesized, and H
LA-A^*0301 and HLA-A^*1101 molecules (the two most common A3
Test for binding to the supertype allele). Next, 500 nM or less
Was found to bind to one of these two alleles with a lower binding affinity
Peptides to other common A3 supertype alleles (A^*3101, A ^* 3301, and A^*6801) for cross-reactivity
Of at least 3 out of 5 tested HLA-A3 supertype molecules.
The peptides that can be combined are identified. HLA-A3 crosslinks identified according to this procedure
Examples of combined supermotif-bearing peptides are provided in Table XXIII.

Selection of HLA-B7 Supermotif-bearing Epitopes The same target antigen protein sequences are also analyzed to identify HLA-B7 supermotif-bearing sequences. These corresponding peptides are then synthesized and HL
Test for binding to AB ^* 0702, the most common B7 supertype allele (ie, the original B7 supertype allele). Then 5
These peptides, which bind to B ^* 0702 with an IC ₅₀ of less than 00 nM, were tested for binding to other common B7 supertype molecules (B ^* 3501, B ^* 5101, B ^* 5301 and B ^* 5401), Peptides capable of binding to more than two of the five B7 supertype alleles tested are identified. Examples of HLA-B7 cross-binding supermotif-bearing peptides identified according to this procedure are provided in Table XXIV.

Selection of Epitopes Bearing A1 and A24 Motif To further increase population coverage, HLA-A1 epitope and HL
The A-A24 epitope can also be incorporated into potent vaccine constructs. Analysis of protein sequence data from the target antigen utilized above was also performed to determine HLA-A1.
-Identify conserved sequences containing motifs and HLA-A24-conserved sequences containing motifs. This corresponding peptide sequence is then synthesized and the appropriate allele-specific HL
Test for binding to A molecule (HLA-A1 or HLA-24). 500
Peptides that bind to allele-specific HLA molecules with an IC ₅₀ of nM or less are identified. Examples of peptides identified according to this procedure are provided in Tables XXV and XXVI.

Example 3: Confirmation of Immunogenicity [0279] The motif analysis and binding studies described in Example 2 were based on MAGE2 and MA.
17 potential epitopes were identified for both GE3. However, the four epitopes are identical in MAGE2 and MAGE3 and therefore do not show unique epitopes. Peptides were selected for in vitro immunogenicity studies. The tests were carried out using the following methodology: (Target cell line for cellular screening) HLA-A2.1 gene, mutant human B lymphoid without HLA-A, HLA-B, HLA-C. Produced by transfer to the blastoid cell line 721.221. The 221A2.1 cell line was used as a peptide loaded target to
The activity of LA-A2.1 restricted CTL was measured. HLA type melanoma cell line (624
mel and 888 mel) to Y. Kawakami and S.M. Rosenb
erg, National Cancer Institute, Bethes
da, obtained from MD. Colon adenocarcinoma cell lines SW403 and HT-20, osteosarcoma line Saos-2 and breast tumor line BT540,
American Type Culture Collection (ATC
C) Obtained from (Rockville, MD). The cell line was grown in RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, non-essential amino acids and 10% (v / v) heat-inactivated FCS. Melanoma cells were treated with 100 U / ml IFNγ (Genzyme) for 48 hours at 37 ° C. prior to ⁵¹ Cr release and use as a target in the in situ IFNγ assay.

(Primary CTL-Induced Culture) Generation of Dendritic Cells (DC): PBMCs with R containing 30 μg / ml DNAse
Thaw in PMI, wash twice, and complete medium (RPMI-1640 and 5
% AB human serum, non-essential amino acids, sodium pyruvate, L-glutamine and penicillin / streptomycin). Monocytes were purified by plating 10 × 10 ⁶ PBMC per well in 6 well plates. After 2 hours at 37 ° C, non-adherent cells were removed by gently shaking the plate and aspirating the supernatant. Wells were washed a total of 3 times with 3 ml RPMI to remove most non-adherent and loose adherent cells. Then 50n
3 ml of complete medium containing g / ml GM-CSF and 1,000 U / ml IL-4 was added to each well. DC were used for CTL induced cultures after 7 days in culture.

[0281]   Induction of CTLs with DC and peptides: CD8 + T cells were
Epidemiological magnetic beads (Dynabeads® M-450) and detac
Isolated by positive selection with ha-bead® reagent. Generation
Tableically, about 200 to 250 x 10⁶24 × 10 by processing 1 PBMC ⁶ 8 CDs⁺T cells (sufficient for 48-well plate culture) were obtained. in brief
In short, PBMCs were thawed in RPMI containing 30 μg / ml DNAse,
Washed once with PBS containing% human AB serum and 20 x 10⁶Concentration of cells / ml
The cells were resuspended in PBS / 1% AB serum at different times. Magnetic beads with PBS / AB serum
Wash 3 times and add to cells (20 x 10⁶140 μl beads per cell),
And incubated for 1 hour at 4 ° C. with continuous mixing. This bead and
Cells were washed 4 times with PBS / AB serum to remove non-adherent cells and 100
μl / ml of detacha-bead® reagent and 30 μg / ml
PBS / AB serum containing DNAse of 100 x 10⁶Cells / ml (first
Resuspended (based on cell number). The mixture is mixed at room temperature with continuous mixing at room temperature.
Incubate for hours. Wash the beads again with PBS / AB / DNAse
The CD8 + T cells were collected. Collect DC, and 5 at 1300 rpm
Centrifuge for 7 minutes, wash once with PBS containing 1% BSA, count, and 20
Β at 3 μg / ml for 4 hours at ℃_Two-1-2 x 10 in the presence of microglobulin ⁶ Pulse with 40 μg / ml peptide at a cell concentration of / ml.
)did. The DC were then irradiated (4,200 rad) and washed once with medium.
, And counted again.

Induction culture setup: 0.25 ml of cytokine-producing DC (@ 1 × 1)
0 ⁵ cells / ml), in the presence of 10 ng / ml of IL-7, in each of the wells of 48-well plates and co-cultured with CD8 + T cells in 0.25ml (@ 2 × 10 ⁶ cells / ml). Recombinant human IL10 was added the next day at a final concentration of 10 ng / ml, and recombinant human IL2 was added at 10 IU / ml.
At 48 hours later.

Restimulation of induced cultures with peptide-pulsed adherent cells: 7 and 14 days after primary induction, cells were restimulated with peptide-pulsed adherent cells. PBM
C was thawed and washed twice with RPMI and DNAse. 5 cells
Resuspended at × 10 ⁶ cells / ml and irradiated at approximately 4200 rad. PBMC
Were plated at 2 × 10 ⁶ in 0.5 ml complete medium per well,
And it incubated at 37 degreeC for 2 hours. The plate was washed twice with RPMI by gently trapping the plate to remove non-adherent cells, and adherent cells were washed with 0.25 ml RPMI / 5% A per well.
In the presence of 3 μg / ml β ₂ microglobulin in B at 37 ° C. for 2 hours,
Pulsed with 10 μg / ml peptide. The peptide solution from each well was aspirated and the wells were washed once with RPMI. Most of the culture medium
CD8 + cells) and made up to 0.5 ml with fresh medium. These cells were then transferred to wells containing peptide-pulsed adherent cells. After 24 hours, recombinant human IL10 was added at a final concentration of 10 ng / ml, and recombinant human IL2 was added the next day, and again at 50 IU / ml 2-3 days later (T
Sai et al., Critical Reviews in Immunology.
18 (1-2): 65-75, 1998). After 7 days, the culture was assayed for CTL activity in a ⁵¹ Cr release assay. In some experiments, the cultures were assayed for peptide-specific recognition in an in situ IFNγ ELISA upon a second restimulation, followed by an assay for endogenous recognition 7 days later. After expansion, activity was measured in both assays for equilibrium comparison.

Measurement of CTL lytic activity by ⁵¹ Cr release Seven days after the second restimulation, cytotoxicity was determined by assaying individual wells with one E: T (5 hours). Determined in a ⁵¹ Cr release assay. Peptide-pulsed targets were prepared by incubating cells at 37 ° C. overnight with 10 μg / ml peptide.

Adherent target cells were removed from culture flasks with trypsin-EDTA.
Target cells were incubated at 37 ° C. for 1 hour with 200 μCi of ⁵¹ Cr sodium chromate (D
upt, Wilmington, DE). Labeled target cells
10 ⁶ / resuspended in ml, and diluted 1:10 with K562 cells at a concentration of 3.3 × ¹⁰ 6 / ml (NK sensitive erythroid cell carcinoma (Erythroblast
oma) cell lines were used to reduce non-specific lysis). Target cells (100μ
1) and 100 μl of effector were plated in 96 well round bottom plates and incubated at 37 ° C. for 5 hours. At this time, 100 μl of supernatant was collected from each well and percent lysis was determined according to the following formula: [(cpm of test sample-cpm of spontaneous ⁵¹ Cr releasing sample) /
(Maximum ⁵¹ Cr-release sample cpm- spontaneous a ⁵¹ Cr release sample cp
m)] × 100. Maximum release and spontaneous release are 1% Trito respectively
Determined by incubating labeled target with nX-100 and media alone. Positive media were> 10% specific lysis (sample-background) in the case of individual wells and at the two highest E: T ratios when assaying expanded cultures, It was defined as 15% or more.

In Situ Measurement of Human γIFN Production as an Indicator of Peptide-Specific and Endogenous Recognition Immunon 2 plates were incubated overnight at 4 ° C. with mouse anti-human IFNγ monoclonal antibody (4 μg / ml 0.1 M NaHCO ₃ , pH 8). .2). This plate is ^added to Ca ²⁺ and Mg ²⁺ free PBS / 0.05%
Wash with Tween 20 and block with PBS / 10% FCS for 2 hours, after which CTL (100 μl per well) and target (10 per well).
0 μl) was added to each well, leaving empty wells for standards and blanks (these contained medium only). Target cells (either peptide-pulsed or endogenous targets) were used at a concentration of 1 × 10 ⁶ cells / ml. The plate was incubated for 48 hours at 37 ° C. with 5% CO ₂ .

Recombinant human IFNγ, 400 pg / 100 μl / well or 1200 pg
/ 100 μl / well, and add the plate to standard wells,
Incubated at 37 ° C for 2 hours. The plate is washed and 100 μl
Biotinylated mouse anti-human IFNγ monoclonal antibody (PBS / 3% FCS /
4 μg / ml in 0.05% Tween 20) was added and incubated for 2 hours at room temperature. After washing again, 100 μl of HRP-streptavidin was added and incubated for 1 hour at room temperature. The plate was then washed 6 times with wash buffer and 100 μl of developing solution (TMB1 per well).
1) was added and the plate was developed for 5-15 minutes. The reaction was stopped with 50 μl of 1 MH ₃ PO ₄ per well and read at OD450. At least 50 pg IFN per well above background
Gamma was measured and cultures were considered positive if expression was twice background levels.

CTL expansion Cultures showing specific lytic activity against peptide-pulsed targets and / or tumor targets were expanded with anti-CD3 for more than 2 weeks. Briefly, 5 × 10 ⁴ CD8 + cells were added to a T25 flask containing: 10
% (V / v) human AB serum, non-essential amino acid, sodium pyruvate, 25 μM
Irradiation of 1 × 10 ⁶ irradiations / ml in RPMI-640 containing 2-mercaptoethanol, L-glutamine and penicillin / streptomycin (4
, 200 rad) PBMC (autologous or allogeneic), 2 × 10 ⁵ irradiated (8,000 rad) EBV-transformed cells per ml, and 30 per ml.
OKT3 (anti-CD3) in ng. Recombinant human IL2 was added 24 hours later at a final concentration of 200 IU / ml, followed by 50 IU / ml of fresh medium every 3 days. When the cell concentration exceeded 1 × 10 ⁶ / ml, the cells were detached and the cultures were incubated in the ⁵¹ Cr release assay with 3 same targets as before expansion.
E: T ratios of 0: 1, 10: 1, 3: 1 and 1: 1 or in situ IF
Assayed between days 13 and 15 at 1 × 10 ⁶ / ml in NΓ assay.

Immunogenicity of A2-Supermotif-bearing Peptides Cellular assay of A2-supermotif cross-reactive binding peptides selected for further evaluation for their ability to induce peptide-specific CTL in normal individuals. Tested in. In this analysis, peptides were identified as epitopes if at least two donors (unless otherwise noted) induced peptide-specific CTLs and these CTLs also recognized endogenously expressed peptides. Regarded Table XXVII identifies examples of peptides that were able to induce a peptide-specific CTL response in at least 2 normal donors.

Peptides screened in the cellular assay and shown to induce a response in PBMCs from at least 2 normal donors are listed in Table XXV.
Illustrated in II. CTLs for some of these peptides were also able to recognize the endogenously expressed peptides (Table XXVII). When two of these peptide sequences (MAGE 3.159 and MAGE 3.160), overlap, and both bind to 5 allele-specific HLA molecules, MAGE 3.160 shows high affinity among the 5 alleles. Connect to four. An IFNγ in situ ELISA of individual CTL cultures induced with MAGE 3.159 showed that cells from 5 wells recognized the peptide pulsed target, and 2 of these wells also recognized the appropriate tumor target. It was In addition, MAGE 3.160
Peptide-specific CTL responses were induced in 14 of 48 wells and 3 of these wells showed endogenous recognition in the IFNγ assay.

MAGE3.112, MAGE2.157 and MAGE3.271 were also identified as epitopes (eg Kawashima et al., Human Immm.
unol. 59: 1-14, 1998; Visseren, Int.
J Cancer 73: 125, 1997).

(A ^* 03 / A11 Immunogenicity Assessment) Cross-reactive binding peptides bearing the HLA-A3 supermotif were also labeled with H
Immunogenicity is assessed using a methodology similar to that used to assess the immunogenicity of the LA-A2 supermotif peptide. Examples of such peptides, which identify peptides that induce an immune response using this procedure, are listed in Table XXIII.
Shown in.

Evaluation of B7 immunogenicity The immunogenicity screen of the B7 supertype tolerance reaction binding peptides identified in Example 2 is evaluated in an analog fashion to the evaluation of peptide bearing A2 and A3 supermotifs. This procedure is used to identify peptides that induce an immune response. Examples of such peptides are shown in Table XXIV.

Evaluation of Immunogenicity of Peptides Bearing Motif / Supermotif Similar methodologies as understood by those of skill in the art have been utilized to identify HLA class I motifs and / or supermotifs described herein. Determine the immunogenicity of the carried peptide. Such a procedure is used to identify peptides that induce an immune response (see, eg, Table XXVI).

Example 4. Expanded Supermotif Implementations to Improve Binding Ability of Native Epitopes by Making Analogs HLA motifs and supermotifs (primary and / or secondary residues) Are useful for identifying and preparing highly cross-reactive native peptides, as described herein. Moreover, the definition of HLA motifs and supermotifs also allows the design of highly cross-reactive epitopes by identifying residues within the native peptide sequence. This native peptide sequence is analogized or "fixed" to give the peptide a specific property (eg, greater cross-reactivity within the HLA molecule population, including supertypes, and / or Greater binding affinity for some or all of these HLA molecules). Examples of analog peptides that exhibit regulated binding affinity are shown in this example and are provided in Tables XXII to XXVII.

Analogization at Primary Anchor Residues A peptide engineering strategy was implemented to further increase the cross-reactivity of the above identified epitopes. For example, related and co-pending U.S.P. S. S. N 09/2
Based on the data disclosed in No. To introduce.

Peptides that exhibit at least weak A ^* 0201 binding (IC _{50 of} 5000 nM or less) and carry suboptimal anchor residues at either the 2-position, the C-terminal position, or both are normative. It can be fixed by introducing substitutions (L at position 2 and V at the C-terminus). Then at least 3 in A ^* 0201 binding
These analogized peptides that showed a 2-fold increase and bound with an IC ₅₀ of 500 nM or less were tested for A2 cross-reactive binding in addition to their wild type (WT) counterparts. Analogized peptides that bind at least three of the five A2 supertype alleles were then selected for cellular screening analysis.

Furthermore, the selection of analogs for cellular screening analysis is such that the WT parent peptide binds at least weakly to three or more A2 supertype alleles (
That is, it was further limited by its ability to bind with an IC ₅₀ of 5000 nM or less. The rationale for this requirement is that the WT peptide must be endogenously present in sufficient quantity to be biologically relevant. Analogized peptides have been shown to have increased immunogenicity and cross-reactivity with T cells specific for WT epitopes (eg Parkhurst et al., J.I.
mmunol. 157: 2539, 1996; and Pogue et al., Proc.
Natl. Acad. Sci. USA 92: 8166, 1995).

In a cellular screen for these peptide analogs, demonstrating that the analog-specific CTLs may also recognize wild-type peptides and possibly tumor targets that endogenously express this epitope. is important.

Of the 19 MAGE2 / 3-derived A ^* 0201 binding peptides, 14 had the lowest anchor residues. Analogs of two peptide epitopes were synthesized and tested for binding to HLA-A2 supertype molecule. MAGE3.
The 112 analog showed increased A ^* 0201 binding affinity, but the parent peptide bound all five A2 supertype HLA molecules and did not achieve significant improvement. However, the MAGE3.220 analog did not show a 3-fold increase in A ^* 0201 binding affinity and improved cross-reactive binding (Table XXII).
.

In addition, 24 of the 26 weak A ^* 0201 binding peptides also met the criteria for analogization and can be analyzed to improve binding affinity as well.

These MAGE2 / 3 analogs that show improved binding compared to the wild-type peptide are evaluated in the cellular assay screen as described in Example 3.

[0303]   Using a methodology similar to that used to develop the HLA-A2 analog
Of the HLA-A3 and HLA-B7 supermotif-bearing epitopes.
I will make a group again. For example, less than three-fifths of A3 supertype molecules
Peptides that bind weakly together are engineered at the primary anchor residue and are preferred at the 2-position
It may have residues (V, S, M or A). This analog peptide is then labeled with A ^* 03 and A^*Connect 11 (prototype A3 supertype allele)
Test for ability to match. Then, those showing a binding capacity of less than 500 nM
Peptides are tested for A3 supertype cross-reactivity. HLA-A3
Examples of supermotif analog peptides are provided in Table XXIII.

A B7 supermotif-bearing peptide can be engineered, for example, to have a preferred residue (V, I, L or F) at the C-terminal primary anchor position (eg, Sid).
(see J. Immunol. 157: 3480-3490, 1996)). The analogized peptide is then tested for cross-reactive binding to the B7 supertype allele. Examples of B7 supermotif bearing analog peptides are provided in Table XXIV.

Similarly, can HLA-A1 and HLA-A24 motif-bearing peptides be engineered with primary anchor residues to improve binding to allele-specific HLA molecules?
Or it may improve cross-reactive binding. Analogized HLA-A1 and HLA-A
Examples of 24-motif bearing peptides are provided in Tables XXV and XXVI.

An analogized peptide that exhibits improved binding and / or cross-reactivity is labeled with HL
Immunogenicity is assessed using a methodology similar to that described for the analysis of AA2 supermotif-bearing peptides. Such procedures are used to identify peptides that induce an immune response.

(Analogization at Secondary Anchor Residues) In addition, the HLA supermotif is a highly cross-reactive peptide, and / or
Alternatively, it would be valuable in designing peptides that bind HLA molecules with increased affinity by identifying specific residues at secondary anchor positions associated with such properties. Examples of such analogized peptides are provided in Table XXIV.

For example, the binding ability of the B7 supermotif-bearing peptide, typical of a discreet single amino acid substitution at position 1, can be analyzed. For example, the peptide can be analogized to replace L for F at position 1 and subsequently evaluated for increased binding affinity and / or increased cross-reactivity. This procedure identifies analogized peptides with regulated binding affinity.

Analogized peptides that exhibit improved binding and / or cross-reactivity are labeled with HL
Immunogenicity is assessed using a methodology similar to that described for the analysis of AA2 supermotif-bearing peptides. Such procedures are used to identify peptides that induce an immune response.

An engineered analog with sufficiently improved binding capacity or tolerance anti-royalties,
Test for immunogenicity as above.

Other Analogization Strategies Another form of peptide analogization that is unrelated to the anchor position involves substitution of cysteine with α-aminobutyric acid. Due to its chemical nature, cysteine is
It has the property of structurally altering the peptide sufficiently to form disulfide bridges and reduce binding capacity. Substitution of cysteine with α-aminobutyric acid has been shown not only to alleviate this problem, but in some instances improve binding and cross-binding ability (eg, review by Sette et al., Persis.
tent Virtual Infections, R.M. Ahmed and I.D. Ch
En., John Wiley & Sons, England, 1999).

Analogized peptides that exhibit improved binding and / or cross-reactivity are labeled with HL
Immunogenicity is assessed using a methodology similar to that described for the analysis of AA2 supermotif-bearing peptides. Such procedures are used to identify peptides that induce an immune response.

Thus, this example demonstrates that by using even one amino acid substitution, HL
Demonstrate modulating binding affinity and / or cross-reactivity of peptide ligands for A supertype molecules.

Example 5. Identification of peptide epitope sequences with HLA-DR binding motifs HLA class II supermotifs or peptide epitopes bearing motifs were also labeled with methodologies similar to those described in Examples 1-3. Can be used to identify as outlined below.

Selection of HLA-DR Supermotif-bearing Epitopes To identify HLA class II HTL epitopes, MAGE2 / 3 protein sequences were analyzed for the presence of sequences bearing the HLA-DR or supermotifs. Specifically, it contains a DR supermotif that further comprises a 9-mer core, and a 3-residue N-terminal and C-terminal flanking region (total 1
A sequence of 15 amino acids) was selected.

Protocols have been developed for the prediction of peptides that bind to DR molecules (
Southwood et al. Immunol. 160: 3363-3373, 1
998). These protocols, specific to individual DR molecules, allow scoring and ranking of the 9-mer core region. Each protocol has the presence of the primary anchor of the DR supermotif within the 9-mer core (ie positions 1 and 6).
Not only score the peptide sequence, but also evaluate the sequence for the presence of secondary anchors. Allele-specific selection table (eg S
(See outhwood et al., ibid.), these protocols have been found to effectively select peptide sequences with a high probability of binding a particular DR molecule. Furthermore, these protocols (specifically, DR1, DR4w4
It has been found that the cross-reactive peptides of DR can be effectively selected by carrying out the above (protocol for DR and DR7) in tandem.

The MAGE2 / 3-derived peptides identified above were transformed into various common HLA-
It was tested for its ability to bind to DR molecules. All peptides were first tested for binding to DR molecules in the primary panel: DR1, DR4w4 and DR7. Peptides that bind at least two of these three DR molecules with IC ₅₀ values of 1000 nM or less were then treated with DR5 ^* 0101, DRB1 ^* 1.
501, DRB1 ^* 1101, DRB1 ^* 0802 and DRB1 ^* 1302 were tested. The peptide was tested for cross-reactivity with D when it bound to at least 5 of the 8 alleles tested with an IC ₅₀ value of 1000 nM or less.
It was regarded as an R supertype binder.

Following the strategy outlined above, 97 DR supermotif-bearing sequences were cloned into CEA.
Identified within the protein sequence. Twenty-four of these are three composites (combi
2) scored as positive in two of the DR147 algorithms. These peptides were synthesized and HLA-DRB1 ^* 0101, DR
Tested for binding to B1 ^* 0401, DRB1 ^* 0701. Tested 23
Seven of the peptides bound at least two of the three alleles (Table XXVIII).

These 7 peptides were then labeled with the secondary DR supertype allele: D
RB5 ^* 0101, DRB1 ^* 1501, DRB1 ^* 1101, DRB1 ^* 08
02 and DRB1 ^* 1302 for binding. At least 5 of the 8 alleles tested bound and 5 peptides generated in distinct non-overlapping regions were identified (Table XXIX).

DR3 Motif Peptide Selection Since HLA-DR3 is the predominant allele in the Caucasian, Black and Spanish populations, DR3 binding capacity is an important criterion in the selection of HTL epitopes. . However, previously generated data showed that only DR3 rarely cross-reacts with other DR alleles (Sidney et al., J.
． Immunol. 149: 2634-2640, 1992; Geluk et al., J.
． Immunol. 152: 5742-5748, 1994; Southwoo.
d et al. Immunol. 160: 3363-3373, 1998). This is not surprising in that the DR3 peptide binding motif appears to differ from the specificity of most other DR alleles. For maximum efficiency in the development of vaccine candidates, it is desirable for the DR3 motif to be closely clustered with the DR supermotif region. Thus, peptides shown to be candidates can also be assayed for their DR3 binding capacity. However, given the different binding specificities of the DR3 motif, peptides that bind only DR3 may also be considered candidates for inclusion in vaccine formulations.

In order to effectively identify peptides that bind DR3, the MAGE2 / 3 protein sequence was modified by Geluk et al. (J. Immunol. 152: 5742-5748).
, 1994) and two DR3-specific binding motifs (Table III).
Conserved sequences carrying one of the above were analyzed. Twenty-three motif positive peptides were identified. The corresponding peptide is then synthesized and 1000 nM
Or better (ie less than 1000 nM)
The ability to bind DR3 with (nM) affinity was tested. Two peptides were found that met this binding criterion (Table XXX), which resulted in HLA class II
Considered as a high affinity binder.

Two DR3 binding peptides were then tested for binding to DR supertype alleles (Table XXXI). Both DR3 binding peptides were 269 nM
DRB1 ^* 1302 with an IC ₅₀ of 1, both of which were DR supertype cross-reactive bindings. Conversely, DR supertype cross-reactive binding peptide
Although tested for 3 binding capacity, no observation of DR3 binding was measurable. .

In summary, five DR supertype cross-reactive binding peptides and three DR3 binding peptides were identified from the CEA protein sequence, one peptide shared between the two motifs.

As with HLA class I motif-bearing peptides, class II motif-bearing peptides can be analogized to improve affinity or cross-reactivity. For example, 9
Aspartic acid at position 4 of the marcoa sequence is the optimal residue for DR3 binding, and substitution for that residue may improve DR3 binding.

Example 6 HTL Epitope Immunogenicity This example determines immunogenic DR supermotif-bearing and DR3 motif-bearing epitopes among the epitopes identified using the methodology in Example 5. To do. The immunogenicity of HTL epitopes can be assessed by assessing their ability to stimulate HTL responses and / or by using a suitable transgenic mouse model.
The L epitope is evaluated in a similar fashion to the determination of immunogenicity. Immunogenicity is determined by screening for: 1.) In vitro primary induction with normal PBMC, or 2. ) PBMC-derived recall of cancer patients
response.

Example 7. HL in various racial backgrounds to determine breadth of population range
Calculation of Phenotypic Frequency of A Supertypes This example illustrates the evaluation of population coverage of vaccine compositions composed of multiple supermotifs and / or multiple epitopes containing motifs.

To analyze population coverage, gene frequencies of HLA alleles were determined. The gene frequency for each HLA allele is calculated by the binomial distribution equation gf = 1- (SQRT
(1-af)) was used to calculate from antigen frequency or allele frequency (eg, Sidney et al., Human Immunol. 45: 79-93, 199).
See 6). Calculate the cumulative gene frequency to get the overall phenotypic frequency,
The cumulative antigen frequency was then derived by using the inverse function formula [af = 1- (1-Cgf) ² ].

[0328]   If frequency data were not available at the level of DNA classification, serologically
A correspondence of defined antigen frequencies was assumed. Total potential supertype collective range
Do not assume linkage disequilibrium, and belong to each supertype
Only confirmed alleles were included (minimum estimate). Between positions (in
Estimating the total potential range achieved by the ter-loci) combination
Cover the forest with A, which can be expected to be covered by the B allele considered.
Created by adding the proportion of the population that is not lost to the A range (eg, total
= A + B^*(1-A)). The confirmed member of A3's super type is A3
, A11, A31, A^*3301 and A^*6801. Super A3
Ip also has A34, A66 and A^*7401, but these conflicts
Genes were not included in the total frequency calculation. Similarly, A2-like super type family
The confirmed member of Lee is A^*0201, A^*0202, A^*0203, A ^* 0204, A^*0205, A^*0206, A^*0207, A^*6802 and
A^*6901. Finally, a confirmed allele of the B7-like supertype
Is: B7, B^*3501-03, B51, B^*5301, B^*54
01, B^*5501-2, B^*5601, B^*6701 and B^*7801 (submarine
Locally, again B^*1401, B^*3504-06, B^*4201 and B^*5
602).

The population range achieved by combining the A2, A3 and B7 supertypes is approximately 86% in the five major racial groups.
(See Table XXI). The range can be extended by including peptides carrying the A1 and A24 motifs. On average, A1 is 5
It is present in 12% of the population across three different major racial groups (Caucasians, North American blacks, Chinese, Japanese and Spanish), and A24 is 29 of the population across these five different major racial groups. Exists in%. Together, these alleles are represented with an average frequency of 39% in these same racial populations. A1 and A24 are replaced by A
When combined with a range of 2 supertype alleles, A3 supertype alleles and B7 supertype alleles, the total range over the major ethnic background is over 95%. A similar approach can be used to approximate the population range achieved with a combination of class II motif-bearing epitopes.

Example 8. Recognition of endogenously processed antigens after priming This example is a native peptide epitope or analog identified and selected as described in Examples 1-6. It is determined that CTLs induced by modified peptide epitopes recognize endogenously synthesized (ie native) antigens using a transgenic mouse model.

Peptide epitopes (eg, Wentworth et al., Mol. Immuno)
l. 32: 603, 1995) and effector cells (eg, HLA-A2 supermotif-bearing epitope) isolated from transgenic mice immunized with peptide-coated stimulator.
r) Cells are used to re-stimulate in vitro. After 6 days, the effector cells were
Cells are assayed for cytotoxicity and cell lines containing peptide-specific cytotoxic activity are further restimulated. After a further 6 days, these cell lines were tested for cytotoxic activity against Jrkat-A2.1 / ^Kb target cells labeled with < ⁵¹ > Cr in the absence or presence of the peptide and also synthesized endogenously. ⁵¹ Cr labeled target cells carrying the selected antigen (ie cells that are stably transfected with the TAA expression vector) are tested.

The results demonstrate that the CTL line obtained from animals primed with the peptide epitope recognizes endogenously synthesized antigens. The choice of transgenic mouse model to be used for such analysis depends on the epitope being evaluated. In addition to HLA-A ^* 0201 / ^Kb transgenic mice, several other transgenic mouse models, including mice with human A11 (which can also be used to assess A3 epitopes) and B7 alleles. Several other transgenic mouse models have been characterized, including mice carrying the gene, and others (eg, HLA-A1 and A24
Transgenic mice) have been developed. The HLA-DR1 and HLA-DR3 mouse models have also been developed, which can be used to evaluate HTL epitopes.

Example 9 Activity of CTL-HTL Conjugate Epitopes in Transgenic Mice This example demonstrates induction of CTL and HTL in transgenic mice by use of the tumor associated antigen CTL / HTL peptide conjugate. However, the vaccine composition thereby comprises a peptide to be administered to a cancer patient. The peptide composition may include multiple CTL and / or HTL epitopes and may further include an epitope selected from multiple tumor associated antigens. This epitope is identified using the methodology as described in Examples 1-6. This analysis demonstrates the increased immunogenicity that can be achieved by the inclusion of one or more HTL epitopes in the vaccine composition. Such a peptide composition is preferred CTL
It may include an HTL epitope conjugated to an epitope, which CTL epitope includes, for example, at least one CTL epitope selected from Tables XXVII and XXIII-XXVII, or other analogs of this epitope. This H
TL epitopes are selected, for example, from Table XXXI. If desired, the peptide can be lipidated.

Immunization Procedure: Immunization of transgenic mice is performed as described (
Alexander et al. Immunol. 159: 4753-4761, 1
997). For example, A2 / ^Kb mice, which are transgenic for the human HLA A2.1 allele and are useful for assessing the immunogenicity of HLA-A ^* 0201 motif-bearing epitopes or HLA-A2 supermotif-bearing epitopes. Is) subcutaneously (base of tail) with 0.1 ml of the peptide conjugate formulated in saline or DMSO / saline. Seven days after prime, splenocytes obtained from these animals are restimulated with peptide-coated, syngenic irradiated LPS-activated lymphoblasts.

Target cells for the peptide-specific cytotoxicity assay were HLA-A2.1.
Jurkat cells transfected with the / ^Kb chimeric gene (eg, Vitiello et al., J. Exp. Med. 173: 1007, 1991).

In vitro CTL activation: One week after priming, splenocytes (30 × 10 ⁶ cells / flask) were coated with syngeneic irradiated (3000 rad), peptide in 10 ml culture medium / T25 flask. Lymphoblasts (10 x 1
Co-culture at 37 ° C. with 0. ⁶ cells / flask). After 6 days, effector cells are harvested and assayed for cytotoxic activity.

Assay for cytotoxic activity: Target cells (1.0-1.5 × 10 ⁶ ) are incubated at 37 ° C. in the presence of 200 μl of ⁵¹ Cr. After 60 minutes, cells are washed 3 times and resuspended in medium. Peptide was added, in this case 1
Required at a concentration of μg / ml. For the assay, 10 ^{4 51} Cr-labeled target cells are added to U-bottom 96-well plates at different concentrations of effector cells (final volume 200 μl). After 6 hours of incubation at 37 ° C, a 0.1 ml aliquot of the supernatant is removed from each well and the radioactivity is determined in a Micromedic automatic gamma counter. Percent specific lysis is determined by the following formula: percent specific release = 100 ×
(Experimental release-spontaneous release) / (maximum release-spontaneous release). % ⁵¹ Cr release data are expressed as lysis units / 10 ⁶ cells to facilitate comparison between separate CTL assays performed under the same conditions. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a 6 hour ⁵¹ Cr release assay. To obtain specific lytic units / 10 ^6, subtracting the lytic units / 10 ⁶ obtained in the absence of peptides, from the lytic units / 10 ⁶ obtained in the presence of peptide. For example, 30%
Release of ⁵¹ Cr was obtained in the absence of peptide at an effector (E): target (T) ratio of 50: 1 (ie 5 × 10 ⁵ effector cells for 10,000 targets). And in the presence of the peptide, a ratio of 5: 1 (ie 10
5,000 targets for 5 × 10 ⁴ effector cells)
This particular dissolution unit is: [(1 / 50,000)-(1/500,
000)] × 10 ⁶ = 18 LU.

The results are analyzed to assess the magnitude of the CTL response in animals injected with the immunogenic CTL / HTL conjugate vaccine preparation. The frequency and extent of CTL response can also be compared to the CTL response achieved using the CTL epitope itself. A similar analysis can be performed to analyze multiple CTL epitopes and / or multiple HTLs.
The immunogenicity of the peptide conjugate containing the epitope can be evaluated. It is found that following these procedures, a CTL response is induced, and concomitantly, a HTL response is induced upon administration of such a composition.

Example 10: CTL Epitope and HTL for Inclusion in Cancer Vaccines
Epitope Selection This example illustrates the procedure for selecting peptide epitopes for vaccine compositions of the invention. The peptides in the composition may be in the form of nucleic acid sequences, either alone or in one or more sequences encoding the peptide (ie minigene), and may be single and / or polyepitopic peptides. May be.

In selecting an array of epitopes for inclusion in a vaccine composition, the following principles are utilized. Each of the following principles are compared and considered for making the selection.

Upon administration, an epitope is selected that mimics the immune response found to correlate with tumor clearance. For example, the vaccine may include 3-4 epitopes from at least one TAA. For example, to prepare a vaccine that targets tumors with altered expression patterns of frequently expressed TAA, as described in Example 15, one TAA-derived epitope is added to one or more additional TAA. It may be used in combination with the derived epitope.

Preferably, epitopes are selected that have a binding affinity (IC50) for HLA class I molecules of 500 nM or less, often 200 nM or less, or a binding affinity for class II molecules of 1000 nM or less.

[0334] Peptides with sufficient supermotifs, or sufficient arrays of peptides with allele-specific motifs, are chosen to give broad population coverage. For example, epitopes are selected to provide a coverage of at least 80% of the population. Monte Carlo analysis, a statistical evaluation known in the art, can be used to assess the breadth or overlap of populations.

In selecting epitopes from cancer-associated antigens, it is often preferable to select analogs, as patients will become resistant to the native epitopes.

In preparing polyepitopic compositions such as minigenes, it is typical to prepare the smallest peptide capable of containing the epitope of interest, although spacers or other flanking sequences may also be incorporated. Desirable for. The principles used are often similar to those used in selecting peptides containing nested epitopes. However, in addition, in determining the nucleic acid sequence provided as a minigene, the peptide sequence encoded by that nucleic acid sequence is analyzed to determine if a binding epitope has occurred. The binding epitope is a potential HLA binding epitope, as expected, for example, by motif analysis. Binding epitopes should generally be avoided as the recipient may bind the HLA molecule and generate an immune response against that epitope that is not present in the native protein sequence.

A CTL epitope intended for inclusion in a vaccine composition may be, for example,
Select from those listed in Tables XXVII and XXIII-XXVI. Examples of HTL epitopes that can be derived in vaccine compositions are provided in Table XXXI. Vaccine compositions containing the selected peptides, when administered, are safe and efficacious, eliciting an immune response that causes tumor cell destruction and reduction in tumor size or mass.

Example 11: Construction of minigene multi-epitope DNA plasmids This example provides a general description for the construction of minigene expression plasmids. Of course, the minigene plasmid will contain various C genes as described herein.
It may include TL and / or HTL epitopes or epitope analogs. For example, the co-pending U.S. filed May 13, 1999. S. S. N. 09 /
Expression plasmids were constructed and evaluated as described in 311,784.

The minigene expression plasmid may contain multiple CTL and HTL peptide epitopes. In this example, HLA-A2, HLA-A3, HLA-B
Peptide epitope with 7 supermotifs and HLA-A1 and HL
Peptide epitopes with the A-A24 motif are used with epitopes with the DR supermotif and / or DR3 epitopes. Preferred epitopes are e.g. defined in Tables XXIII-XXVII and XXXI. Multiple supermotifs / to ensure wide coverage
Multiple HLA class I supermotifs from TAAs or peptide epitopes with motifs are selected so that the motifs are shown. Similarly, HLA class II epitopes are selected from multiple tumor antigens to provide broad population coverage, that is, epitopes with the HLA DR-1-4-7 supermotif and epitopes with the HLA DR-3 motif. Both are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into the minigene for expression in the expression vector.

This example describes the method used to construct an expression plasmid bearing such a minigene. Other expression vectors that can be used in minigene compositions are available and known to those of skill in the art.

The minigene DNA plasmid contains a consensus Skozak sequence and a consensus mouse kappa Ig-light chain signal sequence. This consensus mouse kappa Ig-light chain signal sequence is followed by CTL and / or HTL epitopes selected according to the principles disclosed herein. This sequence is pcDNA3.1
It encodes an open reading frame fused to the Myc and His antibody epitope tags encoded by the Myc-His vector.

Synthesized overlapping oligonucleotides, eg, 8 oligonucleotides with an average length of approximately 70 nucleotides and 15 nucleotide overlaps,
PLC purify. The oligonucleotides encode suitable linker nucleotides, Kozak sequences and signal sequences, and selected peptide epitopes. Extend overlapping oligonucleotides in 3 sets of reactions using PCR,
Assemble the final multi-epitope minigene. Perkin / Elmer
Perform a total of 30 cycles using the 9600 PCR machine and using the following conditions.
The conditions are: 95 ° C. for 15 seconds, annealing temperature (5 ° C. lower than the calculated lowest Tm value of each primer pair) for 30 seconds, and 72 ° C. for 1 minute.

For the first PCR reaction, 5 μg of each of the two oligonucleotides is annealed and extended. Oligonucleotides 1 + 2, 3 + 4, 5 + 6 and 7 + 8 were added to Pfu polymerase buffer (1 × = 10 mM KCl, 10 mM
(NH ₄ ) ₂ SO ₄ , 20 mM Tris-hydrochloric acid, pH 8.75, ₂ mM Mg
SO ₄ , 0.1% Triton X-100, 100 μg / ml BSA), 0
． 100 μl containing 25 mM of each dNTP and 2.5 U of Pfu polymerase
1 to the reaction system. The full-length dimer product is gel purified and the two reactions containing the 1 + 2 and 3 + 4 products and the 5 + 6 and 7 + 8 products are mixed and the annealing and extension reactions are performed for 10 cycles. Next, half of the two reaction systems are mixed, subjected to 5 cycles of annealing and extension, and then adjacent primers are added to carry out 25 cycles of reaction to amplify the full-length product. The full-length product is gel purified, cloned into pCR-blunt (Invitrogen) and individual clones screened by sequencing.

Example 12: Plasmid construct and the extent to which it induces immunogenicity. It is evaluated by in vivo injection into mice followed by measurement of CTL and HTL activity in vitro. For example, U.S.A. submitted on May 13, 1999. S. S. N 09 / 311,784, and Ale
CTL and H using cytotoxicity and proliferation analysis, respectively, as detailed in Xander et al., Immunity 1: 751-761, 1994, respectively.
TL activity is analyzed.

Alternatively, plasmid constructs may be evaluated by testing epitope presentation by APCs in vitro, following transduction or transfection of APCs with the epitope expressing nucleic acid constructs. By such a test, "antigenicity"
Is determined and the use of human APC is enabled. Epitope on cell surface-HLA
By quantifying class I complex density, the ability of the epitope to be presented by APC in the context of being recognized by T cells is determined from the assay.
By directly measuring the amount of peptide eluted from the APC (eg, Sijt
S., et al. Immunol. 156: 683-692, 1996; Demotz.
Et al., Nature 342: 682-684, 1989); or quantification of lysis or lymphokine release induced by infected target cells or transfected cells, followed by comparable levels of lysis or lymphokines. The number of peptide-HLA class I complexes can be estimated by determining the peptide concentration required to obtain release (eg, Kageyama et al., J. Am.
Immunol. 154: 567-576, 1995).

PMin minigene constructs that induce CTL in vivo (eg, US.
S. N. 09 / 311,784, the HLA-A11 / K ^b transgenic mice are immunized intramuscularly with 100 μg of naked cDNA. . cDNA
As a method of comparing CTL levels induced by the immunization of Escherichia coli, when multiple epitopes were encoded by a minigene, an actual peptide composition containing multiple epitopes synthesized as a single polypeptide was used to control groups. Animals will also immunize.

Spleen cells from immunized animals were stimulated twice with each separate composition (minigene-encoded peptide epitopes, or polyepitopic peptides) and subjected to peptide-specific cytotoxicity in a ⁵¹ Cr release assay. Assay for sexual activity. The results indicate the extent of the CTL response directed against the A3 restricted epitope and thus the in vivo immunogenicity of the minigene and polyepitopic vaccines. Therefore, it becomes clear that the minigene elicits an immune response directed against the HLA-A3 supermotif peptide epitope, just as a polyepitopic peptide vaccine elicits an immune response. Similar analyzes are also performed using other HLA-A2 and HLA-B7 transgenic mouse models to assess CTL induction by the HLA-A2 and HLA-B7 motifs, or supermotif epitopes.

To assess the ability of minigenes encoding class II epitopes to induce HTL in vivo, for example, in I-Ab-restricted mice, 100 μg intramuscularly was administered.
Immunize with the plasmid DNA of. As a method of comparing HTL levels induced by DNA immunization, control animals are also immunized with the actual peptide composition emulsified with complete Freund's adjuvant. CD4 + T cells, or H
TL are purified from spleen cells of immunized animals and stimulated with each separate composition (minigene encoded peptide). ³ H-thymidine incorporation growth assay (eg, Alexander et al., Immunity 1: 751-761,1).
(See 994) to measure HTL response. From the result, HTL
The magnitude of the response and thus the immunogenicity of the minigene in vivo is indicated.

A DNA minigene constructed as described in Example 11 can also be evaluated as a vaccine in combination with a boosting agent using the prime boost protocol. Boosting agents include recombinant proteins (eg, Barnett et al., Aids Res. And Human Retrovi).
russes 14, Addendum 3: S299-S309, 1998) or recombinant vaccinia (eg, minigene or DN encoding the complete protein of interest).
Expressing A) (eg, Hanke et al., Vaccine 16:
439-445, 1998; Sedegah et al., Proc. Natl. Acad
． Sci USA 95: 7648-53, 1998; Hanke and Mc.
Michael, Immunol. Letters 66: 177-181,1
999; and Robinson et al., Nature Med. 5: 526-34
, 1999).

For example, the efficacy of the DNA minigene in transgenic mice can be evaluated. In this example, A2.1 / ^Kb transgenic mice are immunized intramuscularly with 100 g of a DNA minigene encoding an immunogenic peptide. After the incubation period (range 3-9 weeks), DN
Mice are boosted with 10 ⁷ pfu / mouse of recombinant vaccinia virus expressing the same sequence encoded by the A minigene. Control mice are immunized with 100 μg of DNA or recombinant vaccinia without the minigene sequence or with the DNA encoding the minigene, but without a vaccinia boost. After an additional 2 weeks incubation period, splenocytes harvested from the mice are immediately assayed for peptide-specific activity by ELISPOT assay. In addition, spleen cells were stimulated in vivo with an A2-restricted peptide epitope encoded in the minigene and recombinant vaccinia, then
Peptide specific activity is assayed in IFNγ-ELISA. It can be seen that the minigene utilized in prime boost mode elicits a greater immune response to the HLA-A2 supermotif peptide than does DNA alone. To assess CTL induction by HLA-A3 and HLA-B7 motifs or supermotif epitopes, other HLA-A11 and HLA-B7
Such an analysis is also performed using the transgenic mouse model.

Example 13 Peptide Compositions for Prophylactic Use The vaccine composition of the present invention is used to prevent cancer in persons at risk of developing a tumor. For example, a polyepitopic peptide epitope composition (or nucleic acid containing the same) comprising multiple CTL and HTL epitopes as selected in Examples 9 and / or 10 that were also selected to target 80% or more of the population. ) Is administered to individuals at risk of cancer, eg melanoma. The composition is provided as a single polypeptide containing multiple epitopes. The vaccine is administered with an aqueous carrier containing Freund's incomplete adjuvant. The peptide dose for the primary immunization is about 1 to about 50,000 μg for a patient weighing 70 kg,
Generally, it is 100-5,000 μg. A booster dose is given 4 weeks after the initial administration of the vaccine, after which the magnitude of the patient's immune response is assessed by a technique that measures the presence of epitope-specific CTL populations in PBMC samples. Additional booster doses will be administered as needed. It is recognized that the present composition is both safe and effective as a preventive agent against cancer.

Alternatively, the polyepitopic peptide composition may be administered as a nucleic acid according to the methodology known in the art and disclosed herein.

Example 14 Polyepitopic Vaccine Compositions Derived from Native TAA Sequences Identifying “relatively short” polyprotein regions that contain multiple epitopes and are preferably shorter in length than the complete native antigen. To this end, preferably a native TAA polyprotein sequence is screened using a computer algorithm defined for each class I and / or class II supermotif or motif. This relatively short sequence containing multiple distinct yet overlapping epitopes is selected and used to prepare the minigene construct. The construct is constructed to express a peptide corresponding to the native protein sequence. "Relatively short" peptides are generally less than 100, 500, or 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids, and more preferably less than 50 amino acids. The protein sequence of the vaccine composition has a maximum number of epitopes contained in the protein sequence,
That is, because the epitope is present in high concentration, that protein sequence is selected. As mentioned herein, the epitope motifs can be nested or overlapping (ie, frameshifted relative to each other). For example, if there are overlapping epitopes that are frameshifted, two 9-mer epitopes and one 10-mer epitope may be present in the 10 amino acid peptide. Such vaccine compositions are administered for therapeutic or prophylactic purposes.

The vaccine composition preferably comprises, for example, three CTL epitopes from TAA and at least one HTL epitope. The polyepitopic native sequence is administered either as a peptide or as a nucleic acid sequence encoding the peptide. Alternatively, analogs are generated from this native sequence, whereby one or more epitopes contain substitutions that alter the cross-reactivity and / or binding affinity properties of the polyepitopic peptide.

Embodiments of this example apply aspects of immune system processing not previously discovered to native nested structural sequences, thereby providing an immune response-inducing vaccine composition for therapeutic or prophylactic purposes. The possibility of facilitating the preparation of Moreover, such an embodiment offers the possibility of motif-bearing epitopes for currently unknown HLA structures. Furthermore, this embodiment (no analogues) directs an immune response against multiple peptide sequences that are actually present in the native TAA and thus avoid the need to evaluate any binding epitopes. Finally, this embodiment provides economies of scale when preparing nucleic acid vaccine compositions.

In connection with this embodiment, a computer program can be derived according to the art's principle of identifying the maximum number of epitopes per sequence length in a target sequence.

Example 15: Polyepitopic Vaccine Compositions Against Diverse Tumors To prepare vaccine compositions useful in the treatment of various types of tumors, the MAGE2 / 3 peptide epitopes of the invention may be combined with other vaccine compositions. For use with peptide epitopes derived from the target tumor antigen. For example, a set of TAA epitopes may be selected to allow targeting of most common epithelial tumors (eg Kawa).
Shima et al., Hum. Immunol. 59: 1-14, 1998). Such compositions include CEA, HER-2 / neu, and MAGE2.
/ 3-derived epitopes, all of which are expressed to a considerable degree (20-60%) in common tumors such as lung, breast, and gastrointestinal tumors.

The composition may be provided as a single polypeptide incorporating multiple epitopes from various TAAs, or the composition may be administered as a composition comprising one or more distinct epitopes. Alternatively, the vaccine may be administered as a minigene construct or as dendritic cells loaded with peptide epitopes in vivo.

Targeting multiple tumor antigens is also important to provide a large percentage coverage of any particular type of tumor. One TAA is rarely expressed in most tumors of a given type. For example, approximately 50% of breast tumors express CEA, 20% express MAGE3 and 30% express HER-2 / neu. Thus, the use of only one antigen in immunotherapy is only shown in limited patient coverage. However, the combination of the three TAAs can address approximately 70% of breast tumors. Furthermore, by containing CTL epitopes from p53 that are overexpressed in approximately 50% of breast tumors, coverage can reach approximately 85% of all breast tumors. Vaccine compositions containing epitopes from multiple tumor antigens also reduce the likelihood of escape mutants due to lack of expression of individual tumor antigens.

Example 16: Use of Peptides to Evaluate Immune Responses Peptides of the invention can be used to analyze the immune response to the presence of specific CTL or HTL populations directed against TAA. For example, Ogg et al., Science.
279: 2103-2106, 1998 and Greten et al., Proc.
． Natl. Acad. Sci USA 95: 7568-7573, 1998.
Such an analysis may be performed using a multimeric complex as described by In the following examples the peptides according to the invention are used as reagents for diagnostic or predictive purposes, but not as immunogens.

In this example, for example, HLA-A * 0201 specific CTL frequencies from tumor-associated antigen HLA-A * 0201 positive patients after immunization with TAA peptides containing the A * 0201 motif at different disease stages or thereafter. The sensitive human leukocyte antigen tetramer complex ("tetramer") is used for the cross-sectional analysis of. As described (Mursey et al., N. Engl. J. Med. 337: 126.
7, 1997), a tetramer complex is synthesized. Briefly, the prokaryotic expression system purified HLA heavy chain (A * 0201 in this example) and β.
2-synthesize microglobulin. Transmembrane-loss of cytoplasmic tail and COOH
-Modifying the heavy chain by adding to the end a sequence containing the biotinylation site of the BirA enzyme. Heavy chains, β2-microglobulin, and peptides are refolded by dilution. The 45-kD refolded product was isolated by high performance protein liquid chromatography and then biotin (Sigma, St. Louis, Missouri).
), Biotinylation with BirA in the presence of adenosine 5'triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added at a molar ratio of 1: 4 and the tetramer product is concentrated to 1 mg / ml. The product obtained is called tetramer-phycoerythrin.

For analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300 g for 5 minutes and resuspended in 50 μl cold phosphate buffered saline. Anti-CD8-T
Tri-color analysis is performed using tetramer-phycoerythrin with ricolor and anti-CD38. PBMC are incubated with tetramer and antibody for 30-60 minutes on ice and washed twice before fixation with formaldehyde. Apply so that the gate contains> 99.98% control sample. Tetramer controls include both A * 0201-negative individuals and A * 0201-positive uninfected donors. The percentage of cells stained with the tetramer is then measured by flow cytometry. The results show the number of cells in PBMC samples containing epitope-restricted CTLs, which indicates the extent of the immune response to the TAA epitope, and thus the stage of tumor progression, or exposure to a vaccine that elicits a protective or therapeutic response. Is easily indicated.

Example 17: Use of Peptide Epitopes to Assess Recursive Responses Peptide epitopes of the invention are used as reagents to assess T cell responses such as acute or recursive responses in patients. Such an analysis can be performed on patients in remission, patients with tumors, or patients vaccinated with the TAA vaccine.

For example, the vaccinated person's class I-restricted CTL response may be analyzed. The vaccine can be any TAA vaccine. PBMC are recovered from vaccinated individuals and HLA type is detected. The appropriate peptide epitope of the invention, optionally with a supermotif conferring cross-reactivity with multiple HLA supertype family members, is then used to analyze samples from individuals with that HLA type.

PBMCs from vaccinated individuals were treated with Ficoll-Histopa.
que density gradient (Sigma Chemical Co., St. Louis,
MO), washed 3 times with HBSS (GIBCO Laboratories), containing 10% heat-inactivated human AB serum, L-glutamine (2 mM), penicillin (50 U / ml), streptomycin (50 μg / ml) and Hepe.
RPMI-1640 (GIBCO Laborato added with s (10 mM))
Res) (complete RPMI) and plate in microculture format. A synthetic peptide containing the epitope of the present invention was added to each well at 10 μg / ml, and HBV core 12 was added as a supplementary T cell source during the first week of stimulation.
8-140 epitope is added to each well at 1 μg / ml.

In a microculture format, 100 μl / well of complete RPMI was added 9
4X105 PBMCs are stimulated with peptides in 8 homotypic cultures in 6-well round bottom plates. 100 and 100 liters of complete RP in each well on days 3 and 10
Add MI and rIL-2 at a final concentration of 20 U / ml. On day 7, cultures were transferred to 96-well flat bottom plates and exposed to peptides, rIL-2 and irradiation (3,3).
Restimulate with 10 ⁵ autologous feeder cells at 000 rad). 1 of the culture
Testing is done on day 4 for cytotoxic activity. As previously described (R
ehermann et al., Nature Med. 2: 1104-1108, 199
6; Rehermann et al. Clin. Invest. 97: 1655-1
665, 1996; and Rehermann et al. Clin. Invest
． 98: 1432-1440, 1996) based on comparison with uninfected control subjects, as positive CTL responses, exhibiting> 10% specific ⁵¹ Cr release in 2 or more of the 8 homotypic cultures. is necessary.

The target cell line is the American Society for Histoco.
Mpatability and Immunogenetics (ASHI,
Boston, MA) or as described (Guil
hot et al. Viol. 66: 2670-2678, 1992), established from patient pools or either autologous and allogeneic EBV transformed B-LCL.

The cytotoxicity assay is performed in the following manner. Target cells were incubated overnight with 10 μM synthetic peptide epitopes of the invention to give 100 μCi of ⁵¹ C.
r (Amersham Corp., Arlington Heights, I.
L) for 1 hour, followed by 4 washes with HBSS followed by either allogeneic HLA-matched or autologous EBV-transformed B lymphoblast cell lines.

Cytolytic activity is determined in a standard 4-hour split-well ⁵¹ Cr release assay using U-bottom 96-well plates containing 3,000 target cells / well. On day 14, stimulated PBMCs are tested at an effector / target (E / T) ratio of 20-50: 1. Percent cytotoxicity is calculated from the formula: 100X [(experimental release-spontaneous release) / maximum release-spontaneous release)]. Surfactant (2% Triton X-100; Sigma Chemi
cal Co. , St. Maximum release is determined by targeted cell lysis with Louis, MO). Spontaneous release is less than 25% of maximum release for all experiments.

The results of such an analysis show that the HLA-restricted CTL population is TAA or TAA.
The degree of irritation from previous exposure to the vaccine is shown.

Class II restricted HTL responses can also be analyzed. Purified PBMCs were cultured in 96-well flat bottom plates at a density of 1.5 × 10 ⁵ cells / well and 10 μg / well.
Stimulate with ml synthetic peptide, complete antigen, or PHA. Cells are plated as usual in 4-6 well homotypic cultures for each condition. After 7 days of culture, the culture medium is removed and replaced with a fresh culture medium containing 10 U / ml of IL-2. Two
After one day, 1 μCi of ³ H-thymidine is added to each well and incubation is continued for another 18 hours. Next, intracellular DNA is taken out on a glass fiber mat and analyzed for ³ H-thymidine incorporation. ³ H in the absence of antigen
- calculating the antigen-specific T cell proliferation as a ratio of ³ H- thymidine uptake in the presence of antigen divided by thymidine uptake.

Example 18 Induction of Specific CTL Responses in Humans A human trial of an immunogenic composition comprising the CTL and HTL epitopes of the present invention will be initiated as an IND Phase I, dose escalation study. Such a clinical trial is designed as follows, for example.

A total of approximately 27 subjects will be enrolled and divided into 3 groups: First group: 3 subjects will be injected with placebo and 6 subjects will be injected with 5 μg of the peptide composition.

Second group: 3 subjects are injected with placebo and 6 subjects are injected with 50 μg of the peptide composition.

Third group: 3 subjects are injected with placebo and 6 subjects with 500 μg of the peptide composition.

Four weeks after the first injection, all subjects are boosted with the same dose. Further boosters may be given on the same schedule.

The measures measured in this test relate to the immunogenicity of the peptide composition as well as its safety and tolerability. The cellular immune response against the peptide composition is an indicator of the intrinsic activity of the peptide composition and thus can be considered as a measure of biological efficacy. Next, clinical and experimental data related to safety and efficacy items are summarized.

Safety: The incidence of adverse events will be monitored in placebo and drug treated groups and assessed for extent and reversibility.

Assessment of Vaccine Efficacy: Subjects will be bled before and after injection to assess the efficacy of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted into cryopreservation medium and stored frozen. Samples are analyzed for CTL and HTL activity.

[0389]   It is recognized that this vaccine is safe and effective.

Example 19: Therapeutic Use in Cancer Patients In order to confirm the efficacy of the CTL-HTL peptide composition in cancer patients, the vaccine composition is evaluated. The main objectives of this trial are to determine the effective dose and regimen to induce CTL in cancer patients, to establish the safety of inducing CTL and HTL responses in these patients, and to what extent CTL
To investigate whether activation improves the clinical status of cancer patients, as evidenced by a reduction in tumor cell numbers. Design such a trial, for example:

This study will be conducted in multiple facilities. The study design is an open-label, uncontrolled dose escalation protocol (open-label, uncontrolled, doses) in which the peptide composition is administered as a single dose and 6 weeks later with a single boost at the same dose.
calation protocol). Dosage is 5 per injection
0, 500 and 5000 micrograms. Record drug-related side effects (severity and reversibility).

Patients will be divided into 3 groups. The first group is injected with 50 μg of the peptide composition, and the second and third groups are injected with 500 and 5000 μg of the peptide composition, respectively. Patients in each group are 21-65 years old, including both men and women (unless the tumor is sex-specific, eg breast cancer, prostate cancer, etc.) and exhibit varying racial backgrounds.

Example 20: Induction of CTL Response Using Prime Boost Protocol With the protocol underlying it, the protocol used to assess DNA vaccine efficacy in the transgenic mice described in Example 12 A similar prime boost protocol can be used for vaccination of humans. Such vaccine regimens include, for example, an initial dose with naked DNA followed by a recombinant virus encoding the vaccine or a recombinant protein / polypeptide or peptide mixture administered in an adjuvant. Immunity can be included.

For example, a naked nucleic acid is administered IM (or SC or ID) in an amount of 0.5 to 5 mg at multiple sites, and a primary immunization is performed using the expression vector as constructed in Example 11. You can do it. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. After an incubation period of 3-4 weeks, a booster dose is given. The booster may be one in which the recombinant fowlpox virus is administered at a dose of 5 × 10 ⁷ to 5 × 10 ⁹ pfu. Other recombinant viruses such as MVA, canarypox virus, adenovirus, or adeno-associated virus may also be used for boosting, or a polyepitopic protein or peptide mixture may be administered. To assess the efficacy of the vaccine, patient blood samples are taken before immunization and at regular intervals after the first vaccination and after the booster dose of vaccination. Fico from fresh heparinized blood
Peripheral blood mononuclear cells are isolated by 11-Hypaque density gradient centrifugation, divided into aliquots in cryopreservation medium and cryopreserved. Samples are assayed for CTL and HTL activity.

Analysis of the results shows that a magnitude of response is sufficient to achieve protective immunity against cancer.

Example 21: Administration of Vaccine Compositions Using Dendritic Cells “Professional” such as antigen presenting cells (APC) or dendritic cells (DC)
“Sional)” APCs can be used to administer vaccines containing the peptide epitopes of the invention. In this example, peptide-pulsed DCs are administered to a patient to stimulate a CTL response in vivo. In this method, dendritic cells are isolated, expanded and pulsed with a vaccine containing the peptide CTL and HTL epitopes of the invention. Dendritic cells are infused back into the patient to elicit CTL and HTL responses in vivo. Then, the induced CTLs and HTLs destroy specific target tumor cells having a protein derived from the epitope in the vaccine (CTL
), Or promote destruction (HTL).

For example, a cocktail of epitope-bearing peptides is administered to PBMCs derived from patient blood ex vivo or to DCs isolated from patients. Agents that facilitate recovery of DC, such as Progenipoietin ^™ (Monsanto
, St. Louis, MO) or GM-CSF / IL-4. After pulsing the DC with the peptide and before reinjecting into the patient, the DC is washed to remove unbound peptide.

The number of dendritic cells reinjected into a patient can vary, as is clinically recognized and readily determined by one of the clinical outcome-based techniques (eg, Nature). Med. 4: 328, 1998; Nature Med. 2:
52, 1996 and Prostate 32: 272, 1997). Typically, 2-50 × 10 ⁶ dendritic cells are administered per patient,
More dendritic cells such as 10 ⁷ or 10 ⁸ can also be given. Such cell populations typically contain 50-90% dendritic cells.

In some embodiments, peptide-loaded PBMCs are infused into patients without DC purification. For example, PBMC containing DC generated after treatment with an agent such as Progenipoetin ^™ is injected into a patient without DC purification.
The total number of PBMCs administered often ranges from 10 ⁸ to 10 ¹⁰ . Generally, the dose of cells injected into a patient is based on the percentage of DC in the blood of each patient, as measured by immunofluorescence analysis with specific anti-DC antibodies, for example. Thus, for example, if 2% of DCs are recruited in the peripheral blood of a given patient by Progenipoietin ^™ and that patient receives 5 × 10 6 cells, that patient will receive 2.5 × 10 ⁸ peptide-loaded cells. Injected with PBMC. The percentage of DC mobilized by agents such as Progenipoietin ^™ is typically estimated to be between 2-10%, but can be varied as will be appreciated by those in the art.

Ex vivo CTL / HTL Response Activation Alternatively, in tissue culture, the patient's, or genetically compatible CTL or H
Incubation of TL progenitor cells with a source of antigen presenting cells (APCs) such as dendritic cells and an appropriate immunogenic peptide can induce an ex vivo CTL or HTL response to a particular tumor associated antigen. After a suitable incubation time (typically 7-28 days) so that the progenitor cells are activated and develop into effector cells, the cells are infused back into the patient. The returned cells then destroy (CTL) or promote (HTL) their specific target cells, tumor cells.

Example 22 Alternative Method of Identifying Motif Peptides Another method of identifying peptides with motifs is to extract them from cells with defined MHC molecules. For example, the EBV-transformed B cell line used for histotyping has been thoroughly characterized to determine which HLA molecule it expresses. In some cases, these cells are the only type of H
Express only LA molecules. These cells may be infected with a pathogenic organism, or they may be transfected with nucleic acids expressing the tumor antigen of interest. Subsequently, the peptide produced by endogenous antigen processing of the peptide produced as a result of infection (or as a result of transfection) is transferred to HLA in cells.
It binds to molecules and is carried and presented on the cell surface.

The peptide is then extracted from the HLA molecule by exposure to mildly acidic conditions, eg by mass spectrometry (eg Kubo et al., J. Immunol. 1).
52: 3913, 1994) its amino acid sequence is determined. Since most peptides that bind a particular HLA molecule as disclosed herein have a motif, this is a peptide with a motif that correlates with the particular HLA molecule expressed on the cell. Is an alternative aspect to earning.

Alternatively, a cell line that does not express any endogenous HLA molecule can be transfected with an expression construct encoding one HLA allele. These cells can then be used as described, i.e. they are infected with a pathogenic organism in order to isolate peptides corresponding to the pathogen or antigen of interest presented on the cell surface. Alternatively, a nucleic acid encoding the antigen of interest may be transfected. The peptides obtained from such an analysis have a motif that corresponds to the binding of one HLA allele expressed in the cell.

As will be appreciated by those in the art, a similar analysis can be performed in cells with more than one HLA allele, followed by determination of peptides specific for each HLA allele that is being expressed. Moreover, one of skill in the art will also recognize that means other than infection or transfection, such as loading with protein antigens, may be used to provide a source of antigen to the cells.

The above examples are provided to illustrate the invention, but not to limit its scope. For example, the human term for major histocompatibility complex, HLA, is used throughout this document. It is recognized that these principles can be extended to other species as well. Accordingly, other modifications of the invention will be readily apparent to those skilled in the art and are covered by the appended claims. All publications, patents and patent applications cited herein are hereby incorporated by reference for all purposes.

[0406]

[Table 1]

[0407]

[Table 2]

[0408]

[Table 3]

[0409]

[Table 4]

[0410]

[Table 5]

[0411]

[Table 6]

[0412]

[Table 7]

[0413]

[Table 8]

[0414]

[Table 9]

[0415]

[Table 10]

[0416]

[Table 11]

[0417]

[Table 12]

[0418]

[Table 13]

[0419]

[Table 14]

[0420]

[Table 15]

[0421]

[Table 16]

[0422]

[Table 17]

[0423]

[Table 18]

[0424]

[Table 19]

[0425]

[Table 20]

[0426]

[Table 21]

[0427]

[Table 22]

[0428]

[Table 23]

[0429]

[Table 24]

[0430]

[Table 25]

[0431]

[Table 26]

[0432]

[Table 27]

[0433]

[Table 28]

[0434]

[Table 29]

[0435]

[Table 30]

[0436]

[Table 31]

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) C07K 14/47 C12N 15/00 ZNAA (81) Designated country EP (AT, BE, CH, CY, DE, DK) , ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OA (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML) , MR, NE, SN, TD, TG), AP (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP , KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, R O, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW (72) Inventor Sydney, John United States California 92130, San Diego, Court De La Siena 4218 (72) Inventor Southwood, Scott United States California 92071, Santee, Strathmore Drive 10679 (72) Inventor Chestnut, Robert United States Caliph CALIFORNIA 92007, Cardiff - by - The - Sea, King scan cross-drive 1473 (72) inventor Celis, Esteban United States Minnesota 55902, Russia Chester, light load es. W. 3683 (72) Inventor Keog, Elissa California 92121, San Diego, Caminito del Diamante 4343 F-term (reference) 4B024 AA01 BA36 CA01 HA20 4C085 AA03 AA04 BB01 BB11 CC03 CC21 DD62 DD86 EE01 EE03 EE06 4H030 BAA11 A11 CA40 DA86 EA31

Claims (34)

[Claims] 1. An isolated, prepared MAGE2 / 3 epitope, comprising:
The epitopes are listed in Table XXIII, Table XXIV, Table XXV, Table XXVI, Table XXV.
II and an epitope consisting of a sequence selected from the group consisting of the sequences shown in Table XXXI. 2. The composition of claim 1, wherein the epitope is mixed with or bound to a CTL epitope. 3. The composition according to claim 2, wherein the CTL epitope is selected from the group shown in claim 1. 4. The composition of claim 1, wherein the epitope is mixed with or bound to an HTL epitope. 5. The composition of claim 4, wherein the HTL epitope is selected from the group set forth in claim 1. 6. The composition according to claim 4, wherein the HTL epitope is a pan-DR binding molecule. 7. The composition according to claim 1, comprising at least 3 epitopes selected from the group shown in claim 1. 8. The composition of claim 1, further comprising liposomes,
A composition wherein the epitope is on or within the liposome. 9. The composition of claim 1, wherein the epitope is lipid bound. 10. The composition of claim 1, wherein the epitope is attached to a linker. 11. The composition of claim 1, wherein the epitope is bound to a complex of HLA heavy chain, β2-microglobulin, and streptavidin, thereby forming a tetramer. 12. The composition of claim 1, further comprising antigen presenting cells, wherein the epitope is on or within the antigen presenting cells. 13. The composition according to claim 12, wherein the epitope is bound to an HLA molecule on the antigen-presenting cell, and is thereby bound to the HLA molecule. A composition wherein, if (CTL) is present, the receptor for said CTL binds to the complex of said HLA molecule and said epitope. 14. A clonal cytotoxic T lymphocyte (CTL), which is cultured in vitro and is in Table XXIII, Table XXIV, Table XXV.
CTL, which binds to a complex of epitopes selected from the group shown in Tables XXVI and XXVII, the complex being bound to an HLA molecule. 15. A peptide comprising at least a first epitope and a second epitope, wherein the first epitope is in Table XXIII, Table XXIV, Table X.
A peptide selected from the group consisting of the sequences set forth in XV, Table XXVI, Table XXVII and Table XXXI; wherein the peptide comprises less than 50 contiguous amino acids with 100% identity to the native peptide sequence. 16. The composition of claim 15, wherein the first epitope and the second epitope are selected from the group of claim 14. 17. The composition of claim 16, further comprising a third epitope selected from the group of claim 15. 18. The composition of claim 15, wherein the peptide is a heteropolymer. 19. The composition of claim 15, wherein the peptide is a homopolymer. 20. The composition of claim 15, wherein the second epitope is a CTL epitope. 21. The composition of claim 20, wherein the CTL epitope is derived from a tumor associated antigen that is not CEA. 22. The first epitope is a pan-DR binding molecule.
The composition according to 5. 23. The first epitope is linked to a linker sequence,
The composition of claim 1. 24. A vaccine composition comprising a unit dose of a peptide comprising less than 50 contiguous amino acids having 100% identity with the native peptide sequence of MAGE2 / 3; a pharmaceutical excipient; The peptides are listed in Tables XXIII, XXIV, XXV, XXVI, XXVI.
I and a vaccine composition comprising at least a first epitope selected from the group consisting of the sequences shown in Table XXXI. 25. The vaccine composition of claim 24, further comprising a second epitope. 26. The method of claim 2, wherein the second epitope is a pan-DR binding molecule.
The vaccine composition according to 4. 27. The vaccine composition of claim 24, wherein the pharmaceutical excipient comprises an adjuvant. 28. An isolated nucleic acid encoding a peptide, wherein the peptide is selected from the group consisting of the sequences shown in Table XXIII, Table XXIV, Table XXV, Table XXVI, Table XXVII and Table XXXXI. An isolated nucleic acid comprising an epitope consisting of a sequence. 29. An isolated nucleic acid encoding a peptide, the peptide comprising at least a first epitope and a second epitope, wherein the first epitope is in Table XXIII, Table XXIV, Table XXV. Table XXVI, Table XXVII
And a nucleic acid comprising less than 50 contiguous amino acids with 100% identity to the native peptide sequence. 30. The peptides according to Table XXIII, Table XXIV, Table XXV,
30. The isolated nucleic acid of claim 29, comprising at least two epitopes selected from the sequences shown in Table XXVI, Table XXVII and Table XXXI. 31. The peptides according to Table XXIII, Table XXIV, Table XXV,
31. The isolated nucleic acid of claim 30, comprising at least 3 epitopes selected from the sequences shown in Tables XXVI, XXVII and XXXXI. 32. The second peptide, wherein the second peptide is a CTL epitope.
9. The isolated nucleic acid according to 9. 33. The isolated nucleic acid of claim 32, wherein the CTL is derived from a tumor associated antigen that is not MAGE2 / 3. 34. The second peptide of claim 2, wherein the second peptide is an HTL epitope.
0. The isolated nucleic acid according to 0.